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Abstract  
In children, maintenance of longitudinal growth is a complex process regulated by 
numerous hormonal and genetic factors, environment and nutrition. Among these, 
sex steroids are of vital importance and the most obvious demonstration of their 
effect on growth is the initiation, maintenance and decline of the pubertal growth 
spurt. In both sexes it is now accepted that oestrogen is the critical hormone in 
controlling the acceleration of growth during puberty and fusion of the growth plate. 
Although abnormalities of growth during puberty are common, the exact 
mechanisms that control the beginning and cessation of pubertal growth at the 
growth plate are poorly understood. The aim of the first part of my thesis was to 
characterise the effects of oestradiol at the level of the growth plate chondrocyte. The 
ATDC5 cell line, a murine chondrocyte model which progresses through the 
maturational stages of chondrogenesis and differentiation was initially used to 
investigate the effects of oestradiol in vitro. Thereafter, more physiological models of 
murine growth, primary chondrocytes and organ cultures, were used in an attempt to 
gain a better understanding of oestradiol action at the growth plate. In the absence of 
readily available physiological models of human growth, the effects of oestradiol on 
the human C28/I2 chondrocyte cell line were studied. The classical oestrogen 
receptors, ERα and ERβ, were shown to be expressed in both murine and human 
chondrocyte cell lines. Oestradiol and related chemicals, which alter the function of 
the oestrogen receptors (ER), were exploited to tease out the different functions of 
each ER in the growth plate. In the absence of foetal bovine serum, oestradiol had no 
effect on proliferation, differentiation or apoptosis of chondrocyte cells in monolayer 
culture or on the growth of the foetal metatarsal culture system. In addition, 
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oestradiol did not convey a protective effect on chondrocytes exposed to the pro-
inflammatory cytokines, tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β) in monolayer culture.  However, endogenous oestrogen appears to play an 
important role in maintaining chondrocyte proliferation in monolayer culture and 
mineralisation in metatarsal culture as reflected by the inhibitory effects of Faslodex, 
the non-specific ER antagonist, on chondrocytes and metatarsals in culture. In the 
presence of methyl-piperidino-pyrazole (MPP), a selective ERα antagonist, and 
raloxifene, a selective oestrogen receptor modulator with higher ERβ binding 
affinity, a reduction in chondrocyte proliferation and increase in apoptosis was 
observed in murine and human chondrocytes. Similarly, a marked reduction in linear 
growth occurred when foetal murine metatarsals were exposed to MPP and 
raloxifene in combination. A less marked reduction in growth was observed in MPP-
treated metatarsals. These findings suggest that the oestrogen receptors may have 
opposing actions in the growth plate with ERβ acting like a brake on chondrocyte 
growth and ERα promoting growth. ERβ may regulate cell proliferation through 
control of cell cycle modulators affecting G1/S phase transition as MPP and 
raloxifene in combination reduced cyclin E and p53 levels on Western blot analysis.  
 
The aim of the second part of my thesis was to investigate the effect of oral 
oestrogen on linear growth in girls with primary ovarian insufficiency (POI). A 
retrospective review of girls with POI treated at a tertiary endocrinology clinic over 
an 11 year period was performed. As expected the majority of girls with POI had 
Turner syndrome (TS; 83.7%). Non-TS associated POI was rare and the leading 
cause was iatrogenic secondary to the effects of total body irradiation for bone 
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marrow transplantation (12.8%). A significant proportion of these girls developed 
POI after full pubertal development so few cases were available to investigate the 
effect of oestrogen on growth. The oral oestrogen regime followed in individual 
patients with TS was highly variable so it was not possible to assess the effects of 
dose on height velocity (HV). The second clinical study examined the effect of 
oestrogen on growth in TS girls who received a standardised course of oral 
ethinylestradiol (EE2) for pubertal induction and a standard dose of growth hormone 
(10 mg/m
2
/week). These girls participated in a prospective randomised double-blind 
placebo-controlled multi-centre study of growth promoting treatment in TS. The girls 
were initially randomised to oxandrolone or placebo at 9 years of age and further 
randomised to oral EE2 at 12 or 14 years of age. Oxandrolone and delaying pubertal 
induction to 14 years of age both improved final height but there was a negative 
interaction suggesting that the interventions are antagonistic. Low dose EE2 (2 
µg/day) maintained HV for 1 year when it was introduced at 12 years of age. 
Thereafter, the natural deceleration in TS girls was augmented with subsequent 
increases in EE2. In contrast, the same low dose EE2 commenced at 14 years of age 
led to a reduction in HV which increased further with subsequent EE2 dose 
increases. Therefore TS girls who received oral EE2 to induce pubertal development 
did not show growth acceleration. In contrast, girls who underwent spontaneous 
puberty did exhibit a growth spurt. These differences observed in pubertal growth 
may be attributable to a less severe skeletal dysplasia in girls with preserved ovarian 
function but this is less likely because the degree of short stature and dysmorphology 
scores at enrolment between TS girls with spontaneous puberty and POI were 
similar. Therefore spontaneous puberty may be more growth-enhancing during 
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puberty than artificial induction with oral EE2 but final height obtained is 
unchanged.  
 
The laboratory effects of oestradiol found in this thesis suggest that ERα may 
stimulate or maintain growth, and ERβ may inhibit growth. The obvious question is 
how these observations might be involved in the complex relationship between 
puberty, oestrogen and height velocity in humans. As affinity studies show that the 
half maximal effective concentration (EC50) of ERα is achieved at slightly lower 
concentrations of oestradiol than ERβ it is conceivable that the ERα effect could 
predominate at lower systemic oestradiol concentrations and that ERβ could become 
more important at higher concentrations for example in later puberty. Alternatively, 
it is possible that the expression of ERα reduces or ERβ increases in the growth plate 
after reaching peak height velocity. 
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Preface 
In children, maintenance of longitudinal growth is a complex process regulated by 
several hormonal and genetic factors, environment and nutrition. Among these, sex 
steroids are of crucial importance and the most obvious demonstration of their effect 
on human growth is the initiation, maintenance and decline of the pubertal growth 
spurt. This accelerated period of growth accounts for about 20% of final adult height. 
Although abnormalities of growth during puberty are very common, the underlying 
mechanisms that govern the beginning and cessation of pubertal growth at the level 
of the growth plate are poorly understood. The effect of sex steroids on growth can 
either be studied at the systemic level or at the local level of the epiphyseal growth 
plate. In both sexes it is now accepted that oestrogen is the critical hormone in 
controlling the acceleration of growth during puberty and fusion of the growth plate. 
 
1.1 Growth in puberty 
1.1.1 Height velocity and pubertal development    
There are at least three distinct phases of post-natal growth. The infantile phase is the 
first phase with rapid height velocity (HV) during foetal life followed by rapid 
deceleration up to 3 years of age. The childhood phase follows which has a slowly 
decelerating velocity until puberty. The pubertal phase shows acceleration in HV and 
reaches a peak on average 22 months after initiation. HV then rapidly decreases and 
ceases.
(1)
 This pubertal growth comprises 15-20% of final height (FH) and precedes 
fusion of the growth plates. Both the amplitude of the pubertal spurt and peak HV 
vary negatively with the age of onset of puberty.
(1-3) 
Concordance is shown between 
the pubertal growth spurt and clinical pubertal development.
(1;4;5) 
The tempo of 
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pubertal growth shows sexual dimorphism. In girls, growth acceleration is usually 
seen early with peak HV occurring at Tanner breast stage B2 in 40%, B3 in 30%, B4 
in 20% and B1 in 10%.
(1) 
In contrast, boys show an acceleration of growth usually 
during the second year of pubertal development with peak HV occurring at Tanner 
genital stage G3 in 60%, stage 4 G4 in 28%, stage 2 G2 in 8% and stage 5 G5 in 
4%.
(1)
 This dimorphic pattern may be related to the delay in boys reaching the level 
of oestrogen required from the aromatisation of testosterone. Aromatisation is 
mediated by aromatase (an enzyme of the cytochrome P450 group) whose function is 
to mediate the conversion of androgens to oestrogens. 
 
1.1.2 Oestrogen and the pubertal growth spurt 
The pubertal growth spurt is primarily due to increased secretion of the sex steroids, 
oestrogens and androgens. It has been widely accepted that oestrogen mediates 
pubertal bone growth in females, however it has only been recently established that 
oestrogen, and not testosterone, mediates the same function for males. The growth 
patterns observed in certain rare syndromes suggest that, in humans, oestrogen is 
responsible for the initiation of the pubertal growth spurt and closure of the growth 
plate in both sexes. Inactivating mutations in either the oestrogen receptor-α (ERα) 
gene or the aromatase gene in males have resulted in a lack of a pubertal growth 
spurt, absent epiphyseal closure with resultant tall stature (taller than predicted). The 
individual with a defective ERα is unique.
(6)
 He presented with tall stature, normal 
male sexual maturation, osteoporosis and open epiphyses. Treatment with oestrogen 
did not produce epiphyseal fusion nor improve his bone mineral density. A similar 
phenotype was described in a 24-year old man with congenital aromatase deficiency 
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who had tall stature, a bone age (BA) of 14 years and osteoporosis despite high 
testosterone levels.
(7)
 Treatment with conjugated oestrogens for 6 months led to 
fusion of the growth plates and increased bone mineral density.
(8) 
Aromatase 
deficiency has now been described in others and they all show persistent linear 
growth in adulthood with open epiphyseal growth plates.
(9;10)
 Although data are 
limited, individuals with aromatase deficiency seem to have an absent growth spurt 
and fusion of the growth plates is reported after treatment with exogenous oestrogen 
but not with testosterone.
(9)
 46,XY girls with complete androgen insensitivity 
syndrome (CAIS; gonads in situ) do have a pubertal growth spurt, which tends to 
occur at a similar age and of similar amplitude to unaffected girls, thus, 
demonstrating that oestrogen is able to increase HV in the absence of androgen 
action.
(11)
 
 
Pubertal growth is influenced by the amount of body fat. In a longitudinal study of 
normal children an additional body mass index (BMI) point (+1 kg) was reported to 
decrease the growth spurt by a mean of 0.5 cm and 0.9 cm, in girls and boys, 
respectively. However, FH was not affected due to the growth acceleration observed 
in childhood.
(12) 
 
1.1.3 Growth plate fusion 
It has been widely accepted that longitudinal growth ceases in late adolescence as a 
result of epiphyseal fusion, an abrupt event in which growth plate cartilage is 
replaced by bone tissue. However, careful observation suggests that growth ceases 
before fusion occurs
(13;14) 
which suggests that fusion is the result of growth 
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cessation.
(13;15) 
The deceleration in longitudinal growth was previously attributed to a 
systemic mechanism. However, recent evidence indicates that it is caused by a local 
mechanism within the growth plate. In growth plate transplantation studies, the 
growth rate of the transplanted growth plate depended on the age of the donor 
animal, not that of the recipient.
(16)
 This intrinsic mechanism has been referred to as 
“growth plate senescence”.
(17) 
The senescent decline in growth rate is mainly due to a 
decrease in the rate of chondrocyte proliferation in the growth plate.
(18)
 Young 
rabbits treated with systemic dexamethasone for a 5-week period showed a reduction 
in longitudinal bone growth.
(19)
 After recovery, their growth plates showed a delay in 
senescent decline in the growth rate, chondrocyte proliferation rate, growth plate 
height, proliferating zone and hypertrophic zone height.
(19)
 This programmed 
senescence appears to be a function of proliferation. Oestrogen is reported to 
accelerate the normal process of growth plate senescence, leading to earlier 
exhaustion of the growth plate, and as a consequence earlier fusion.
(13)
 Although, this 
hypothesis was not supported by a recent study of castrated male rabbits
(20)
 in which 
oestrogen was shown to decrease proliferation in the resting zone chondrocytes. This 
latter study examined younger, male rabbits which were treated for a shorter period 
of time (two weeks compared to eight weeks) and the plasma oestrogen levels 
achieved were much lower.  
 
1.2 Conditions affecting pubertal growth  
1.2.1 Early pubertal development 
Early pubertal development is traditionally defined by the onset of puberty before the 
age of 8 years in girls or 9 years in boys. The occurrence of menarche before the age 
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of 10 years also indicates sexual precocity. In the USA these criteria have been 
reconsidered due to a community-based study of 17,000 girls who showed a trend 
towards earlier breast development.
(21)
 However, age at menarche is unaltered, 
suggesting that the tempo of puberty in the early developers may be slower. It has 
been proposed that the age of 7 years for white girls and 6.5 years for the African 
American population should be used as a cut-off for defining early puberty.
(22)
 In 
boys, the cut-off is unchanged. In Europe, the original criteria are still valid as there 
is no evidence of a recent reduction in age at onset of puberty in either gender.
(23)
 
Precocious puberty can be classified as central precocious puberty (CPP) or 
gonadotrophin-independent precocious puberty (GIPP). CPP involves the premature 
activation of the hypothalamic-pituitary-gonadal (HPG) axis. In GIPP the presence of 
sex steroids is independent of pituitary gonadotrophin release.  
 
1.2.1.1 Central precocious puberty  
CPP has an incidence of 1 in 5-10 000 children with a female to male ratio of greater 
than 20:1.
(24)
 The spectrum of idiopathic CPP contains transient, alternating, slowly 
progressive and rapidly progressive forms.
(25)
 Ninety-five percent of girls with CPP 
have idiopathic CPP whereas over 50% of boys have an identifiable aetiology.
(26)
 
Acceleration of growth is almost invariable in CPP but these children will also show 
premature ossification and fusion of the growth cartilage and early cessation of 
growth. Girls who present before 6 years are reported to lose 12-15 centimetres in 
FH whereas those who present after 6 years lose 7-10 centimetres.
(27)
 The risk of 
short stature is higher in children with associated growth hormone (GH) 
insufficiency or limited potential to grow due to cranial or craniospinal irradiation. 
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Early puberty may result in a greater sitting height to leg length ratio at FH as an 
indicator of the premature bone maturation. 
 
1.2.1.2 Gonadotrophin-independent precocious puberty  
GIPP is characterised by pubertal sex steroid levels with pre-pubertal or suppressed 
gonadotrophins. Excess secretion of the hormone leads to hypertrophy of the target 
tissue as well as acceleration of growth and bone maturation. The source of hormone 
production can be gonadal, adrenal (tumour or congenital adrenal hyperplasia), 
ectopic (gonadotrophin- or human chorionic gonadotrophin-producing tumours) or 
exogenous. Additionally the McCune-Albright syndrome produces discordant sexual 
development and is characterised by irregular pigmented café-au-lait patches and 
polyostotic fibrous dysplasia. Pubertal signs are usually discordant with early 
bleeding in girls and no evidence of gonadotrophin cyclicity. In this condition, 
growth acceleration may also be due to hyperthyroidism or GH excess. It occurs due 
to mosaicism for a sporadic post-zygotic activating mutation in the G&AS1 (guanine 
nucleotide binding protein alpha stimulating activity polypeptide) which prevents 
down regulation of cyclic adenosine monophosphate (cAMP) signalling in endocrine 
tissues leading to overactivity.
(28)
 In males, testoxicosis or familial male precocious 
puberty can lead to pubertal changes and growth acceleration. The testes are often 
small for the degree of virilisation.
(29)
 In all of these conditions the excess sex steroid 
production leads to advanced epiphyseal maturation which can predict the timing of 
the onset of central puberty as there is remarkable synchrony between the onset of 
central puberty and skeletal maturation across the various disorders of puberty.
(30)
 
Central puberty may occur due to exposure of the hypothalamus to high levels of sex  
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steroids; this phenomenon is known as “priming”. 
 
Although puberty tends to be delayed in hypothyroid children, severe longstanding 
hypothyroidism may cause GIPP probably mediated by thyroid stimulating hormone 
(TSH) stimulation of the follicle-stimulating hormone (FSH) receptor.
(31)
 
Characteristically there is testicular enlargement without significant virilisation in 
boys and breast development, uterine bleeding and multicystic ovaries in girls. 
Thyroxine treatment can lead to resumption of the normal consonance of puberty and 
catch-up growth.
(32)
 However, FH may be reduced attributable to a rapid advance in 
epiphyseal maturation.
(33)
  
 
1.2.2 Delayed pubertal development  
Delayed puberty is the failure to develop secondary sexual characteristics by a 
certain age usually set as two standard deviations from the mean. In girls, pubertal 
delay is usually defined as a lack of breast development by 13 years, lack of pubic 
hair by 14 years, lack of menarche by 16 years or greater than 5 years between 
thelarche and menarche. In boys, puberty is considered delayed if testicular 
enlargement does not occur by 14 years, lack of pubic hair by 15 years, or more than 
5 years are required to complete genital enlargement. Children with delayed puberty 
continue to grow at a pre-pubertal rate. Natural slowing of linear growth, just before 
onset of puberty may be exaggerated, emphasising the difference in size from peers 
who are accelerating in growth.  
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1.2.2.1 Primary delay of growth and puberty 
 This condition, often referred to as constitutional delay in growth and adolescence 
(CDGA), typically affects boys. The clinical features include relative short stature for 
chronological age, delayed puberty and delayed bone maturation in otherwise healthy 
adolescents. Because the timing of the onset of puberty, pubertal growth spurt, and 
epiphyseal fusion are determined by a child’s skeletal age (biological age) children 
with CDGA are often referred to as “late developers”. A relatively short upper body 
segment is common at presentation and persists at attainment of FH.
(34)
 Although FH 
is predicted to be normal based on BA estimation, adolescents with CDGA are 
usually shorter than their mid-parental height.
(34-37)
 There is often a family history of 
delayed puberty
(38)
 or a personal history of atopy.
(39) 
The decrease in FH may be 
explained by the short stature at onset of puberty, shorter duration between onset of 
puberty and pubertal growth spurt and compromised peak HV.
(40) 
A short course of 
testosterone enanthate or low doses of oxandrolone can accelerate the pubertal 
growth spurt without altering FH.
(41;42)
 However, FH in boys with CDGA may be 
improved by treatment with aromatase inhibitors by delaying bone age 
progression.
(43)
 
 
1.2.2.2 Secondary delay of growth and puberty 
A delay in puberty can be seen in virtually any chronic disease of childhood.
(44)
 
Several factors influence the degree to which growth and pubertal development are 
affected. These include age, duration of illness and its severity, nutritional status and 
medications. This form of delayed puberty is often mistaken for CDGA but may be 
more profound and protracted depending on the underlying condition.  
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1.2.2.3 Hypogonadotrophic hypogonadism 
Hypogonadism can be classified according to the serum gonadotrophin levels; high 
levels indicate primary gonadal failure and low levels indicate disorders at the 
hypothalamo-pituitary level. In hypogonadotrophic hypogonadism, such as 
Kallman’s syndrome, puberty may be completely absent. The pubertal component of 
the infancy-childhood-puberty model will be lacking so childhood growth will 
continue at its slowly declining rate. In untreated individuals growth will continue 
until the third decade and FH may actually be taller than average due to this 
persistence of the childhood component of growth. However, this results in abnormal 
body proportions with a relatively longer lower body segment. Short stature may be 
seen initially relative to chronological age but a normal FH is achieved after sex 
steroid replacement.
(45)
 
 
1.2.2.4 Hypergonadotrophic hypogonadism 
This condition results from a primary defect of the gonads which renders them 
unresponsive to gonadotrophins. A similar growth pattern to those affected by 
hypogonadotrophic hypogonadism is observed. However, the commonest cause of 
primary hypogonadism in boys is Klinefelter syndrome (47,XXY) which is 
associated with tall stature. Often there is a normal onset of puberty but pubertal 
arrest can occur at any stage. If spontaneous puberty does occur then the magnitude 
and timing of pubertal growth is reported to be normal, with a mean FH of 186 
centimetres. The tall stature may be attributable to the extra sex chromosome. 
Although testes are of normal size and consistency at birth they fail to grow normally 
during puberty and seldom exceed 4 millilitres. Testicular involution then occurs and 
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androgen deficiency occurs. Plasma testosterone levels are significantly lower by 16 
years of age.
(46)
 In boys with prenatal testicular atrophy for example due to “the 
vanishing testes syndrome” the childhood component of growth is reported to be 
normal. Whereas, in girls the commonest cause of primary hypogonadism is ovarian 
dysgenesis in association with Turner syndrome. 
 
1.2.2.5 Turner syndrome 
Turner syndrome (TS) is a congenital disorder caused by the loss of all, or a critical 
part, of one X chromosome and is associated with a combination of characteristic 
features of which the most common are short stature and ovarian dysgenesis. It is 
estimated to affect around 3% of all female foetuses
(47)
 but the majority of foetuses 
with TS are spontaneously miscarried and only 1% survive to term.
(48) 
The number of 
females born with TS is estimated to range from 25 to 210 per 100 000 live births.
(49)
 
Individuals with TS commonly present with short stature or delayed puberty. Other 
organs and systems may be affected resulting in congenital malformations and 
characteristic physical features such as webbed neck, broad chest and cubitus valgus 
(widened carrying angle). The 45,X karyotype accounts for 50-70% of cases and is 
associated with the classical, more dysmorphic, phenotype and a higher proportion of 
foetal deaths than live births indicating that a foetus with 45,X is less likely to 
survive to term than other TS karyotypes.
(50)
 The remaining cases of TS are 
associated with a range of karyotypic abnormalities which include abnormalities of 
the second X chromosome and mosaicism. Mosaicism occurs when some of the cells 
in the body have a TS chromosome component, while others have a different 
chromosome component which may be normal (45,X/46,XX) or abnormal 
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(45,X/47,XXX). As such a small proportion of 45,X foetuses survive to term it is 
likely that all TS patients are actually mosaics and may only be detected if multiple 
tissues are analysed using specialised staining techniques.
(51)
 Short stature is the most 
consistent feature of TS. The cause of this remains unknown but is thought to be due 
to a primary bone defect. Some of the height deficit is accounted for by haplo-
insufficiency of the short stature homeobox (SHOX) gene. Although there is no 
evidence of classical GH deficiency
(52;53)
 it has been suggested that partial GH and/or 
insulin-like growth factor (IGF) insensitivity at the level of the growth plate may 
play a role.
(52-54)
 Ovarian insufficiency is common and typically affects around 95% 
of females with TS.
(55)
 This usually occurs during the first few months or years of 
life. However, spontaneous puberty can occur in girls with TS and in a recent Italian 
study the incidence was 16% which is higher than previously thought.
(56)
 It was more 
frequently associated with mosaicism than with the 45,X karyotype. However in 
those with spontaneous puberty, premature ovarian failure frequently ensues and the 
occurrence of natural pregnancy is low (less than 5%).
(47;56) 
Girls with TS usually 
demonstrate mild growth retardation in utero followed by slow growth during 
infancy with a delayed onset of the childhood component of growth and then slow 
growth during childhood and adolescence with absence of the pubertal growth spurt 
resulting in reduced FH.
(47;53;57) 
The average height of untreated women with TS is 20 
centimetres lower than the mean for normal women.
(58) 
 
 
1.2.2.6 Hypogonadism with other endocrinopathy 
Delayed puberty is often seen in patients with GH deficiency or a GH receptor 
defect. A common feature to both these conditions is low or lack of IGF-1 function. 
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This highlights the possible role of IGF-1 in the regulation of puberty.
(59;60)
 In Type 1 
Diabetes Mellitus pubertal delay has also been described. However, this was not 
confirmed in more recent studies where FH was unaffected. Nonetheless, the 
pubertal growth spurt in Type 1 Diabetes Mellitus may be attenuated.
(61)  
 
Primary hypothyroidism can also be associated with hypogonadotrophic 
hypogonadism which is reversible with thyroxine treatment.
(62)
 Although children 
with primary hypothyroidism may continue to grow for a longer period after therapy 
is initiated, FH can still be restricted.
(63)
  
 
Cushing’s disease is associated with a delayed onset or mid-pubertal arrest of 
puberty which is reversible after removal of the source.
(64;65)
 GH deficiency is 
common following treatment of childhood onset Cushing’s disease and may persist 
for many years.
(66)
 Early investigation for diagnosis and treatment of GH deficiency 
is thus advocated.
(67)
 FH within target range can be achieved but excess adiposity 
remains a potential long-term complication.
(67)
          
 
1.3 Oestrogen family  
Oestrogens are a family of hormones produced mainly in the ovary. There are three 
main types: oestradiol, oestriol and oestrone. Oestradiol is the principle hormone 
active in pre-menopausal women and is produced by conversion of androgenic 
steroids by 17β-hydroxysteroid dehydrogenase (17βHSD) and aromatase (Figure 
1.1). In contrast, oestriol is only found in low levels apart from during pregnancy as 
it is produced by the placenta. The foetal adrenal cortex produces 
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dehydroepiandrosterone sulphate (DHEAS) which is then converted into oestriol. 
Levels of oestriol are used for screening for congenital abnormalities and forms part 
of the triple/quadruple test (low levels suggest an abnormality). The third hormone 
oestrone, is a weak oestrogen, but the only one present in any quantity in post-
menopausal women. Oestrone is produced by conversion of androstenedione by 
aromatase. Its derivative, oestrone sulphate, is long-lived and serves as a reservoir for 
oestrone and can be converted into the more active oestradiol by 17β-HSD. 
 
 
 
 
Figure 1.1 – Principal pathways in steroid biosynthesis 
(http://en.wikipedia.org/wiki/File:Steroidogenesis.svg) 
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1.4 Oestrogen receptor structure and function 
The execution of the biological effects of oestrogen is mediated by two isoforms of 
the nuclear ER, namely, ERα and ERβ. They are encoded by separate genes; ERβ is 
localised on human chromosome 14 whereas ERα is found on chromosome 6. The 
receptors are widely distributed throughout the body and have distinct tissue 
expression patterns (Figure 1.2). The ERs belong to the steroid/thyroid hormone 
superfamily of nuclear receptors, of which members share a common structural 
architecture. They are composed of 3 independent but interacting functional 
domains: the NH2-terminal or A/B domain, the C or DNA-binding domain, and the 
D/E/F or ligand-binding domain (LBD) (Figure 1.3).  
 
                       
 
Figure 1.2 – Overall distribution of human ERα and ERβ in different tissues 
From Gustafsson JA, 1999, Journal of Endocrinology, 163, 379-383 
© Society for Endocrinology 1999. Reproduced by permission.
(68)
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The A/B domain encodes a ligand-independent activation function-1(AF-1) which is 
responsible for activation of transcription and co-factor binding. ERα is very active 
in stimulation of reporter-gene expression from a variety of oestrogen response 
element (ERE)-reporter constructs in different cell lines
(69) 
but ERβ has negligible 
activity of the AF1 domain under the same conditions. The C/D domain is the DNA 
binding domain (DBD) and contains a two zinc finger structure which plays an 
important role in receptor dimerisation and in binding of receptors to specific DNA 
sequences. These domains are highly conserved in ERα and ERβ showing 97% 
homology (Figure 1.4). The D/F domain contains the ligand binding pocket as well 
as the ligand-dependent activation function-2 (AF-2) domain that directly contacts 
coactivator peptides. Upon ligand binding the ER dimerises and migrates to the 
nucleus where it interacts with specialised sequences of DNA in the promoter region 
of certain genes, with subsequent activation or inhibition of transcription.
(70)
 The 
genomic sequences capable of binding the ER-ligand complex include the ERE as 
well as more recently described alternative sequences.
(71;72)
 Oestrogens produce 
agonist effects through these interactions to varying degrees in oestrogen responsive 
tissues. 
 
 
 
 
Figure 1.3 – The structural organisation of nuclear receptors  
From Nilsson et al, 2001 used with permission.
(73) 
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Figure 1.4 – Comparison of the primary structures of ERα and ERβ The figures 
above the receptor representations indicate the number of amino acids, with number 
1 being the most N-terminal. The numbers within the ERβ receptor represent the 
degree of homology (%) between respective domains in the two receptors. From 
Gustafsson JA, 1999, Journal of Endocrinology, 163, 379-383 © Society for 
Endocrinology 1999. Reproduced by permission.
(68) 
 
A variety of non-steroidal ligands also bind the ER, but, these compounds produce 
distinct ER:ligand complex conformations
(74)
 and are known as selective oestrogen 
receptor modulators (SERMs). They interact with the ER to produce tissue specific 
oestrogen agonist or antagonist responses. Tamoxifen is an ER agonist in bone and 
uterus but an antagonist in the breast and has been a safe and effective adjuvant 
endocrine therapy for breast cancer for almost 20 years. Raloxifene has oestrogen-
like agonist effects in bone and cholesterol metabolism in ovariectomised (OVX) 
rats
(75)
 and postmenopausal women.
(76)
 However, raloxifene fails to produce 
oestrogen agonist effects on the uterus of OVX rats
(75)
 or postmenopausal women
(76)
 
allowing raloxifene to completely antagonise oestrogen effects in the uterus. This 
lack of significant oestrogen agonist activity in the uterus distinguishes raloxifene 
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from other SERMs which are partial agonists in the uterus. The relative binding 
affinity of oestrogen to ERα is about 10 times higher than that of raloxifene in the 
ER-positive MCF-7 breast cancer cell line.
(77)
 Tamoxifen binds equally to ERα and 
ERβ
(78)
, while raloxifene binds with about 2-fold greater affinity to ERβ than ERα.
(79)
 
Therefore differences in binding do not account for the difference in the activity of 
tamoxifen and raloxifene with ERs. Structural studies have revealed that tamoxifen 
and raloxifene produce different conformations of ERα with raloxifene causing a 
greater increase in the mobility of Helix 12 of the LBD.
(80)
 The resulting 3-
dimensional structure determines which coactivators and/or corepressors are 
recruited to the promoter. Thus, the relative level of corepressors and coactivators in 
a particular tissue is a critical determinant of SERMs agonist/antagonist activity. The 
ERα/ERβ ratio varies between tissues and which isoforms predominates also affects 
SERM activity. Thus the physiological response to a particular SERM results from a 
combination of factors including its chemical structure and the cellular and promoter 
context in which the SERM acts.         
 
1.5  Systemic effects of sex steroids on GH-IGF-1 axis 
1.5.1 GH-IGF-1 axis during puberty 
The striking increase in HV during puberty is under complex endocrine control. GH 
increases growth at puberty through the stimulation of IGF-1 production. During 
puberty the pulsatile secretion of GH increases (1.5- to 3- fold) along with a greater 
than 3-fold increase in serum IGF-1 levels.  Peak IGF-1 levels occur at 14.5 years in 
girls and one year later in boys.
(81)
 The rise in mean 24-hour GH levels results from 
an increase in the maximal GH secretory rate and also in the mass of GH per 
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secretory burst.
(82;83)
 The increase in GH secretion during puberty shows a sexually 
dimorphic pattern that parallels the change in HV. In girls, an increase in circulating 
GH is seen relatively early in puberty at Tanner breast stage 2 with peak levels 
coinciding with Tanner breast stages 3-4. In boys, this increase in GH is seen later 
with the peak occurring at Tanner genital stage 4.
(84)
 After secondary sexual 
development is complete, GH and IGF-1 levels fall to pre-pubertal levels in both 
sexes. The secretion of GH is mediated by two hypothalamic hormones: growth 
hormone releasing hormone (GHRH) and somatostatin. GHRH has a stimulatory 
effect whereas somatostatin has an inhibitory effect. These hypothalamic influences 
are tightly regulated by an integrated system of neural, metabolic and hormonal 
factors.
(85)
 In animal studies, performed principally in rodents, sex steroids influence 
GH synthesis and secretion with effects on both the hypothalamus and anterior 
pituitary. In the neonatal period, sex steroids influence the number of GHRH neurons 
which will be present in the adult hypothalamus and also their response to post-
pubertal steroids.
(86)
 Post-pubertally, androgens modify hypothalamic somatostatin 
synthesis whereas oestrogens modify GHRH synthesis. In addition, both neonatal 
and post-pubertal steroids influence the secretory pulsatility of anterior pituitary 
hormone release by altering hypothalamic synaptic organisation.
(86) 
At the level of 
the pituitary, sex steroids modify the response of somatotrophs to somatostatin.
(86) 
 
1.5.2 Effect of androgens  
Dihydrotestosterone (DHT) and oxandrolone increase HV in boys with delayed 
puberty without any alteration of serum GH/IGF-1.
(87-90) 
In contrast, testosterone, 
typically, increases HV in association with an increase in GH/IGF-1.
(90;91)
 This 
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ability of testosterone to stimulate GH secretion is principally due to its conversion to 
oestrogen by aromatisation. This is supported by a study in pubertal boys who 
showed a reduction in GH and IGF-1 when treated with tamoxifen.
(92)
 The non-
aromatisable androgens (DHT and oxandrolone) increase HV independent of 
GH/IGF-1 suggesting that “pure androgens” may stimulate growth through other 
mechanisms, possibly via a direct action on the androgen receptor within the growth 
plate cartilage.
(93)
  
 
1.5.3 Effect of oestrogens  
The stimulation of growth by oestrogen is largely dependent on pituitary GH and is 
mediated via the oestrogen receptors, ERα and ERβ, which are expressed in the 
anterior pituitary as well as in the hypothalamus. GH and oestrogen levels show 
positive correlations in pre-pubertal girls and boys.
(94;95) 
Endogenous oestrogen in 
peri-pubertal children increases GH sensitivity.
(96)
 Priming with oestrogen for GH-
stimulation testing has been shown to augment GH release in normal adolescents.
(97) 
Furthermore, GH secretion is reduced when oestrogen signalling is blocked.
(92;98) 
This tight relationship between oestrogen and GH status is further demonstrated by 
the strong correlation between oestrogen and GH concentrations throughout normal 
female puberty.
(99) 
GH levels are higher in women compared to men.
(100;101) 
As boys 
and girls with IGF-1 deficiency (Laron syndrome) do not have a discernible pubertal 
growth spurt
(102) 
a major part of the stimulation of growth by oestrogen is through the 
GH/IGF-1 axis. The effect of exogenous oestrogen depends on its form. If oestrogen 
treatment is administered orally (for hormone replacement therapy), large, supra-
physiological doses are required as oestrogen is actively metabolised by the hepatic 
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cytochrome system. This supra-physiological concentration in the portal circulation 
perturbs many aspects of hepatic function. The liver is the major site of GH-
regulated metabolism and the main source of IGF-1.
(103) 
Oral oestrogen 
administration leads to increased circulating GH levels and a reduction in IGF-1 
production. The high oestrogen concentration in the portal circulation impairs hepatic 
IGF-1 production and increases the concentrations of GH binding protein which 
binds to GH and thereby blunts its action. There is also stimulation of the synthesis 
of angiotensinogen, clotting factors, lipoproteins and the binding proteins for several 
steroid hormones. These negative metabolic sequelae are not seen with transdermal 
administration.
(104) 
 
1.6 Local effects of sex steroids on the growth plate 
1.6.1  Effect of growth hormone  
In addition to its systemic effects GH also has a direct action at the level of the 
growth plate. GH enhances the recruitment of resting zone chondrocytes and local 
IGF-1 production in the growth plate.
(105-108) 
The relative contribution of systemic 
versus local IGF-1 on longitudinal growth remains unclear. However, they both 
appear to have an impact on longitudinal growth (in mice at least). The liver-specific 
IGF-1 gene-deletion mouse model (LID) has normal growth but circulating IGF-1 
levels are only reduced by 75%. When the LID mice were crossed with the acid 
labile substance (ALS) gene-deleted mice (ALSKO) the LID/ALSKO mice had a 
further reduction in circulating IGF-1 levels, to 85-90% of normal levels, and 
showed early postnatal growth retardation.
(109) 
 But tissue IGF-1 may still play a role 
since the total IGF-1 knockout mice show more marked growth retardation. 
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However, basal IGF-1 production by growth plate chondrocytes is reported to be 
minimal.
(110;111)  
 
Sex steroids are likely to have a direct action on chondrocytes since the androgen 
receptor (AR) and both ERα and ERβ, have been demonstrated in growth plate tissue 
at the mRNA and protein level in several species, including rat, rabbit and human.
(93) 
 
1.6.2 Effect of androgens  
The AR has been demonstrated in all layers of the human growth plate at different 
ages with no significant gender variation.
(112-115) 
Several studies support a direct 
stimulatory effect of androgens on growth plate cartilage. In vitro studies have shown 
that DHT regulates proliferation and differentiation of cultured human epiphyseal 
chondrocytes, probably by promoting local IGF-1 synthesis and increasing IGF-1 
receptor expression.
(116)
 The sex-specific response of rat costochondral growth zone 
chondrocytes to testosterone requires its further metabolism to DHT and this DHT 
effect in the male growth plate is maturation-state dependent.
(117) 
Similarly in vivo, a 
non-specific ER blocker (Faslodex) did not prevent the advancement of bone 
maturation in mice treated with testosterone.
(118) 
Also, direct injections of 
testosterone into the rat tibial epiphyseal growth plate increased growth plate width 
without alteration of IGF-1 production.
(119) 
Furthermore, DHT stimulates longitudinal 
bone growth in OVX rats
(120)
 and testosterone increases growth plate width in 
castrated, hypophysectomised male rats.
(121) 
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1.6.3 Effect of oestrogens  
Classical ERs have been demonstrated in all maturational zones of the human growth 
plate during development and puberty. However, there is conflicting evidence from 
in vitro studies on the effect of oestrogen on chondrocyte proliferation and 
differentiation.
(122-129) 
Some of the discrepancies may be explained by the 
demonstrated ability of chondrocytes to synthesise oestrogen themselves.
(129-131) 
Activation of the ERs by locally produced oestrogen could minimise or eliminate the 
effect of exogenous oestrogen. To complicate matters further, oestrogen signalling 
can also occur via non-genomic pathways (Figure 1.5). In the genomic or classical 
pathway, oestrogen or SERMs bind to the ER by binding to ERE regulatory 
sequences in target genes and recruiting coregulatory proteins such as coactivators as 
described earlier (section 1.4). Non-genomic or rapid effects of oestrogen may also 
occur through the ER located in or adjacent to the plasma membrane which may 
necessitate the presence of adaptor proteins which target the ER to the membrane. 
Activation of the membrane ER leads to a rapid change in cellular signalling 
molecules and stimulation of kinase activity, which may in sequence affect 
transcription. Finally, other non-ER membrane-associated oestrogen-binding proteins 
(EBPs) may also generate an intracellular response. The new oestrogen receptor 
GPR30 (G Protein-coupled Receptor 30) is expressed in the human growth plate and 
down-regulated during pubertal progression.
(132)
 This new G-protein coupled 
receptor may explain some of the previous “non-genomic” actions of oestrogen and 
is also involved in regulating calcium levels.
(133) 
Furthermore, some of the rapid 
responses to oestrogen, including activation of protein kinase C (PKC), are limited to 
cells from female animals.
(126;134;135) 
In vivo, oestrogen inhibits chondrocyte cell 
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division in the proliferating zone of the rat growth plate.
(136-138) 
The age-related 
decrease in size of the hypertrophic chondrocytes
(139;140) 
is enhanced by 
oestrogen.
(138)
 In rats, the withdrawal of oestrogen by OVX stimulates longitudinal 
bone growth.
(141) 
This increase in bone length is associated with increased 
chondrocyte proliferation
(131)
, growth plate width
(131) 
and IGF-1 production.
(120;131) 
Similarly in humans, tall girls treated with high dose oestrogen display a rapid 
reduction in HV but have only a modest decrease in serum IGF-1 suggesting a direct, 
non-GH-dependent, effect of oestrogen.
(142)
 Moreover, children with precocious 
puberty and GH deficiency can have a pubertal growth spurt.
(143) 
 
Figure 1.5 – Models of oestrogen action From Deroo et al, 2006.(144) Key: Genomic 
pathway, i; Non-genomic pathway via ii) membrane-associated ER or iii) non-ER 
membrane-associated oestrogen-binding proteins (EBPs); PI3K, phosphoinositide 3-
kinase; MAPK, mitogen-activated protein kinase; NO, nitric oxide, CoReg, 
coregulator; ERE, oestrogen response element.  
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1.7 Lessons learned from ER knockouts in mouse and man  
Meta-analysis of longitudinal bone length in these knockouts has shown that the role 
played by the ERs in association with bone length may depend on sex and age 
(Tables 1.1 and 1.2).
(145-158) 
ERβ has an inhibitory effect on longitudinal bone growth 
only in adult female mice.
(146;147;151) 
It has been hypothesized that this inhibitory 
action is only seen in the presence of elevated serum oestrogen. This is supported by 
the finding that adult female ERβ knockout (BERKO) mice have the highest serum 
oestrogen levels
(152)
 during which period the inhibitory effect of ERβ is exclusively 
seen. Furthermore, female ERα knockout (ERKO) mice have shorter bones where 
ERβ is present compared to female ERα/ERβ knockout (DERKO) where both ERs 
are absent.
(146;147)
 Both of these strains have markedly elevated serum oestrogen 
levels due to an inactive feedback loop.
(146)  
 
Knocking out ERβ does not affect femur length in male mice of any age.(151;152;156) 
Finally, in the presence of high levels of oestrogen, ERβ induces fusion of the 
growth plate in older female mice.
(147;148) 
Knocking out ERα does not have an effect 
on the growth of the younger animal but may inhibit growth in the older mouse.
(145-
150;156;157) 
There is no evidence of sexual dimorphic effects. The patient lacking ERα 
(hERKO) carries a mutation at residue 157 in the protein, which would allow the 
short, 46-kDa spliced form of ERα to be synthesized.(159) This is one possible 
explanation for discordance in phenotype between mice and man. 
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1.8      Aims and Strategy 
1.8.1 Oestrogen action at the level of the growth plate  
The aim of the laboratory component of my thesis is to investigate the effect of 
oestradiol (E2) at the level of the growth plate chondrocyte. The ATDC5 
chondrocyte cell line, an in vitro model of chondrocyte proliferation, will be studied 
for the first part of the project.  This murine model is characterised by chondrocyte 
that progresses through the maturational stages of chondrogenesis and 
differentiation. Thereafter, the more physiological models of murine growth; primary 
chondrocytes and organ cultures, will be utilised in an attempt to gain a better 
understanding of oestradiol action at the level of the growth plate. Finally, in the 
absence of readily available physiological models of human growth, the effects of E2 
on the human C28/I2 cell line will be investigated. E2 and related chemicals, in 
particular those which alter the function of the classical ERs, will be employed to try 
to tease out the different functions of each ER in the growth plate.  My specific aims 
are: 
 
a) To confirm the presence of the oestrogen receptors, ERα and ERβ in 
chondrocytes 
 
b) To characterise the effects of E2 on the murine ATDC5 cell line 
 
c) To characterise the effects of E2 on physiological models of murine growth 
(primary chondrocytes and foetal metatarsal culture system) 
 
d) To characterise the effects of E2 on the human C28/I2 cell line 
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1.8.2 Effect of oral oestrogen on longitudinal growth in girls  
The aim of the clinical component of my thesis is to investigate the effect of oral 
oestrogen therapy on linear growth in girls with absent puberty due to primary 
ovarian insufficiency. A retrospective review of girls with primary ovarian 
insufficiency treated at a tertiary endocrinology clinic at the Royal Hospital for Sick 
Children, Glasgow over an eleven year period will be performed. My specific 
objectives are: 
 
a) To identify the incidence and prevalence of primary ovarian insufficiency within 
the West of Scotland 
 
b) To investigate the aetiology of primary ovarian insufficiency in a tertiary referral 
centre 
 
c) To describe oestrogen treatment prescribed and its effect on height velocity, bone 
maturation and final height 
 
The second clinical study will examine the effect of oestrogen on linear growth in a 
cohort of girls with TS who received a standardised course of oral ethinylestradiol 
(EE2) for pubertal induction and a standard dose of GH therapy as part of the UK 
Turner Study. My specific aims are: 
 
1) To assess the effect of a standardised oral oestrogen regime on HV, bony 
maturation and FH in girls with TS treated with a standard dose of GH therapy 
 
2) To identify what dose of oestrogen is associated with i) peak height velocity and 
i) bony fusion 
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2.1      Introduction 
A direct action of E2 on chondrocytes is suggested by the finding of both classical 
ERs in all maturational zones of the human growth plate during development and 
puberty. However, in vitro studies examining the role of E2 on chondrocyte 
proliferation and differentiation have conflicting results (Table 2.1). To date 
stimulation of epiphyseal chondrocyte proliferation has been described
(123;124) 
as well 
as an inhibition
(125-127) 
and more recently no effect.
(128;129) 
E2 has also been reported 
to stimulate incorporation of radioactive sulfate-35 (35S) into proteoglycans in rabbit 
and human chondrocytes implying increased chondrocyte differentiation.
(160;161) 
 
Our group has previously demonstrated that the pro-inflammatory cytokines, 
interleukin-1β (IL-1β) and tumour necrosis factor-α (TNFα), exert diverse inhibitory 
effects on ATDC5 chondrocyte dynamics and metatarsal growth.
(162) 
Exposure to 
TNFα and IL-1β led to a reduction in the proliferation of ATDC5 chondrocytes and 
a decrease in the expression of aggrecan and collagen types II and X. Treatment with 
TNFα or IL-1β also led to increased apoptosis of ATDC5 cells as determined by 
caspase-3 activity and was significantly greater in cells treated with TNFα compared 
to IL-1β.(162)  
 
E2 has been reported to play a protective role against cytokine-induced inflammation 
in a mouse model of multiple sclerosis (experimental autoimmune 
encephalomyelitis). Treatment with low-dose E2 has been shown to significantly 
inhibit the clinical signs and histopathological lesions of experimental autoimmune 
encephalomyelitis and is being used in clinical trials to treat multiple sclerosis.
(163) 
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This protective effect of E2 is mediated through ERα.
(163)
 A similar effect is seen in 
human vascular endothelial cells where E2 enhances growth and reduces TNFα 
induced apoptosis.
(164)
 Similarly, in a mouse model of inherited glaucoma E2 
treatment protected retinal ganglion cells through inhibition of ganglion cell 
apoptosis.
(165)
   
 
The established murine ATDC5 chondrogenic cell line allows the characterisation 
and comparison of effects of different E2 concentrations on specific maturational 
stages of growth plate chondrocyte maturation including cell proliferation and 
differentiation. It has been shown to undergo the temporal sequence of events that 
occur during longitudinal bone growth in vivo and thereby provides an excellent 
model to study the molecular mechanisms underlying the regulation of growth plate 
maturation and endochondral bone formation. 
(166-168)
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2.2 Hypothesis  
It was hypothesised that E2 would have a concentration-dependent effect on 
chondrocyte proliferation with an increase at low concentrations and a decrease at 
higher concentrations. Secondly it was hypothesised that E2 would attenuate the 
effects of cytokines on the ATDC5 chondrocytes and thereby play a protective role 
against cytokine-induced inflammation.      
 
2.3 Aims 
 
I. Confirm the presence of the classical oestrogen receptors, ERα and ERβ by 
semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) 
in proliferating and terminally differentiating ATDC5 cells  
 
II. Analyse the effect of different E2 concentrations on chondrocyte proliferation 
in ATDC5 cells during chondrogenesis and terminal differentiation 
 
III. Analyse the effect of E2 on alkaline phosphatase activity and proteoglycan 
production of ATDC5 cells during terminal differentiation 
 
IV. Compare the effect of co-incubating E2 and cytokines, IL-1β or TNFα, with 
cytokines alone on chondrocyte proliferation and apoptosis in ATDC5 cells  
  
Chapter 2                                                         Effect of E2 on murine ATDC5 cell line                                                                                                                                             
 
     
 36 
2.4 Materials and Methods 
2.4.1 Materials 
All chemicals were purchased from Sigma Aldrich (Dorset, UK) unless otherwise 
stated. PCR oligonucleotide primers were purchased from MWG Biotech (Ebersberg, 
Germany). Water soluble cyclodextrin-encapsulated 17β-oestradiol (Sigma) was 
used for all in vitro experiments. 
 
2.4.2 Cell culture 
2.4.2.1 Preparation of cell culture reagents 
Dulbecco’s Modified Eagle Medium/Ham’s F12 (DMEM: F12), containing 4500g/L 
glucose and L-glutamine, was purchased from Invitrogen, (Invitrogen, Paisley, UK). 
The DMEM: F12 was phenol red-free as phenol red has been shown to exhibit 
oestrogenic activity.
(173)
 All tissue culture reagents were prepared in a sterile 
category 2 hood. The maintenance medium of DMEM: F12 (Invitrogen) was 
supplemented with 5% heat-inactivated foetal bovine serum (FBS; Invitrogen), 
10µg/ml
 
human transferrin, 3 x 10
-8 
M sodium selenite, sodium pyruvate (1mM; 
Invitrogen) and gentamicin (50µg/ml; Invitrogen). The differentiation medium 
consisted of maintenance medium supplemented with insulin (10µg/ml). All media 
was filter-sterilised through a 0.22µM filter and stored at 4°C. 
 
2.4.2.2 Maintenance and differentiation of ATDC5 cells 
The ATDC5 chondrocyte cell line was obtained from the RIKEN cell bank (Ibaraki, 
Japan) and maintained as described by Atsumi et al.
(166) 
Cells were maintained in 
175cm
2
 tissue culture flasks (Greiner Bio-One Limited, Stonehouse, Gloucestershire, 
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UK) at a density of 250,000 cells/flask in maintenance medium. For individual 
experiments semi-confluent cultures were passaged with trypsin 
ethylenediaminetetraacetic acid (EDTA) and cultured (day 0) at a density of 6,000 
cells/cm
2
 in differentiation medium in multi-well plates (Costar, High Wycombe, 
UK). Cells were incubated at 37°C in a humidified atmosphere containing 5% 
CO2/95% air and the medium was changed every second or third day after reaching 
confluency (day 6). 
 
2.4.2.3 Freezing and thawing cells  
To freeze cells a monolayer was stripped with trypsin EDTA and counted using a 
haemocytometer. The cells were then centrifuged at 2000 revolutions per minute 
(rpm) for 5 minutes and resuspended in the appropriate volume of cell freezing 
buffer to give a cell concentration of 2-4 x 10
6 
cells per ml. The cells were stored at a 
temperature of -80°C for 4-7 days within a cryovial (Corning, Surrey, UK) and then 
moved to -150°C for longer term storage. Frozen cells were thawed at 37°C and 
added drop wise to 10 ml of culture medium. The cell suspension was then mixed 
and spun at 2000 rpm for 5 minutes to remove the dimethyl sulfoxide (DMSO) which 
is a major component of the freezing buffer. The cell pellet was resuspended in 
culture medium and transferred to a 175cm
2
 tissue culture flask (Greiner Bio-One 
Limited). 
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2.4.3 R5A Methods 
2.4.3.1 Isolation of total R5A from cells 
To isolate ribonucleic acid (RNA) from a cell monolayer the cells were scraped 
directly in Ultraspec
TM
 RNA isolation reagent (Biotecx, Houston, USA; 1 millilitre 
per 25 cm
2
) and transferred to a nuclease-free universal container. The cells were 
homogenised with an electric homogeniser in five 10-second bursts. Between each 
burst the container was returned to ice to prevent the build up of heat. The 
homogenised lysate was then passed through a 2-mililitre syringe and 25-gauge 
needle repeatedly to create a uniform lysate to which chloroform (200µl per 
millilitre) was added. After extraction with chloroform, RNA in the aqueous phase 
was purified with isopropanolol and bound to 50µl RNA Tack resin, before washing 
with 75% ethanol. The RNA was then eluted from the resin pellet in 100µl nuclease 
free water to which ribonuclease (RNase) inhibitors (Promega, Southampton, UK) 
and deoxyribonuclease (DNase) to degrade any contaminating DNA (Ambion, 
Warrington, UK) were added. For each sample the 260/280 ratio was determined and 
the samples diluted to a concentration of 50ng/µl and stored at -70°C until required.  
 
2.4.3.2 Reverse transcription  
Reverse transcription PCR allows the production of complementary 
deoxyribonucleic acid (cDNA) from any RNA template. Aliquots of 500ng RNA (or 
an equivalent volume of water as a control) were reverse transcribed in 20µl 
reactions with 200ng random hexamers and 200U Superscript II reverse transcriptase 
using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). The 
following PCR cycle was used: 25°C for 10 minutes, 42°C for 50 minutes and 70°C 
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for 15 minutes for annealing, elongation and termination respectively. The cDNA 
was stored at -20°C until required for analysis. 
 
2.4.3.3 Polymerase chain reaction  
E2 was added to the cells during both chondrogenesis (days 6-10) and terminal 
differentiation phases (days 13-17) at a final concentration of 10
-6 
M. Cells were 
grown in the presence of E2 for 4 days, at which point RNA was extracted, reverse 
transcribed and analysed for ERα and ERβ gene expression by semi-quantitative RT-
PCR.
(174-176)
 PCR was performed in 20µl reactions containing cDNA equivalent to 
10ng RNA and 200nM gene-specific primers in 11.1x PCR buffer (Table 2.1).
(177)
 
The cycling profile was 1 minute at 92°C (first cycle 2 minutes), 1 minute at 55°C, 
and 1 minute at 70°C. The number of cycles performed was titrated to ensure that the 
reactions were in the exponential phase. The reaction products were run on 1.5% 
agarose gels in the presence of ethidium bromide (250µg/l), and a digital image of 
each gel was captured using a gel documentation system (Bio-Rad Laboratories Ltd, 
Hemel Hempstead, UK). The protein Classic 18S (Ambion) was used as an internal 
standard (Table 2.2).  
 
 
Table 2.2 – Primer sequences and product sizes for murine  
ERα and ERβ genes analysed by RT-PCR 
 
Primer sequence Gene 
Forward primer 
Reverse primer 
Cycles Product size 
(base pairs) 
Classic 18S Unknown, purchased commercially from Ambion 20 488 
ERα 
(murine) 
5’ - GGA GAA TGT TGA AGC ACA AGC - 3’ 
5’ - GGA GCA AAC AGG AGC TTC - 3’ 
35 433 
ERβ 
(murine) 
5’ - GGA CAC CTC TCT CCT TTA GC - 3’ 
5’ - CCT TAC ATC CTT CAC AGG ACC - 3’ 
35 262 
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2.4.4 Protein concentration determination  
The concentration of protein was determined using the BioRad protein assay kit 
(Bio-Rad Laboraties Ltd) which employs gamma-globulin as a standard and is based 
on the method described by Bradford.
(178) 
Nine standards of gamma globulin were 
prepared ranging from 10µg/millilitre to 90µg/millilitre. 160µl of each standard was 
pipetted in duplicate into a 96 well plate along with a buffer blank. The protein that 
was to be measured was diluted in the same buffer as gamma-globulin and added to 
the wells in duplicate. 40µl of dye reagent concentrate was added to each well and 
mixed. The plate was incubated at room temperature for 5 minutes and the 
absorbance read at 595 nm by a microplate reader. The absorbencies of the samples 
were compared to a standard curve generated from the absorbencies from the 
standards. 
 
2.4.5 Cell proliferation and differentiation assays 
2.4.5.1 [3H]Thymidine incorporation assay 
E2 was added to cells in 24-well plates at day 7 and day 14 at a final concentration of 
10
-6 
M, 10
-8 
M, 10
-10 
M and compared with control cultures which received vehicle 
(sterile distilled water) only and incubated for a 24 hour period. Murine TNFα 
(Autogen Bioclear, Calne, Wiltshire, UK) and IL-1β (Autogen Bioclear) were added 
at a final concentration of 10ng/millilitre to cells cultured in 24-well plates on day 16 
in the presence and absence of E2 at a final concentration of 10
-6 
M. Control cells 
received vehicle only. The cells were then incubated for a 24 hour period. The rate of 
chondrocyte proliferation was assessed by incubating the cells with 0.2µCi/millilitre 
[
3
H]thymidine (37MBq/ml; Amersham Pharmacia Biotech, Little Chalfont, 
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Buckinghamshire, UK) for the last 2 hours of the incubation period and measuring 
the amount of radioactivity incorporated into trichloroacetic acid insoluble 
precipitates.
(176) 
 
2.4.5.2 Alcian Blue staining of cell monolayer  
Proteoglycan synthesis was assessed by staining with Alcian Blue.
(167)
 The ATDC5 
cells were washed twice with phosphate buffered saline (PBS), fixed in 95% 
methanol for 20 minutes and stained with 1% Alcian Blue 8GX in 0.1M hydrochloric 
acid (HCl) overnight and rinsed with distilled water. Alcian Blue stained cultures 
were extracted with 6M Guanidine-HCl for 6 hours at room temperature and the 
optical density was measured at 630nm using a Jenway 6105 spectrophotometer.
(176)
 
Blanks for spectrophotometry used 6M Guanidine-HCl only. 
 
2.4.5.3 Alkaline phosphatase assay  
E2 was added to ATDC5 cells at day 13 at a final concentration of 10
-6 
M and the 
cells were then incubated for 7 days. For analysis of alkaline phosphatase (ALP) 
activity, cells were rinsed with PBS and lysed with 0.9% NaCl and 0.2% Triton-X 
100 and centrifuged at 12000g for 15 minutes at 4°C. The supernatant was assayed 
for protein content and ALP activity as a measure of cell number and chondrocyte 
differentiation, respectively. The protein content of the supernatant was measured as 
described in 2.4.3. Enzyme activity was determined by measuring the cleavage of 
10mM p-nitrophenyl phosphate (pNPP) at 410nm. Total ALP activity was expressed 
as nmoles pNPP hydrolysed/min/mg protein.
(176) 
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2.4.6 Apoptosis assay 
Apoptosis was assessed by measuring the cytoplasmic histone-associated DNA 
fragments (mono- and oligo- nucleosomes) by photometric enzyme-immunoassay 
(cell death detection ELISA
PLUS
; Roche Applied Science, Roche Diagnostics, 
Burgess Hill, UK). IL-1β and TNFα were added to the cells at a final concentration 
of 10ng/ml in the presence or absence of E2 at a final concentration of 10
-6 
M and 
compared with control cells. Apoptosis was measured following the manufacturers’ 
protocol in cells cultured in 96-well plates over a 24 hour period starting on day 16.  
 
2.4.7 Statistical analysis 
Data were analysed by one-way analysis of variance (ANOVA). All data are 
expressed as the mean ± SEM of at least six replicates within each experiment, and 
statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) software package (SPSS Inc., Chicago, USA; version 15). 
Significance was determined as P <0.05. 
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2.5 Results  
2.5.1 Expression of classical oestrogen receptors in ATDC5 cells  
ATDC5 murine chondrocytes expressed ERα and ERβ during both chondrogenesis 
and terminal differentiation (Figure 2.1). The expression was unaffected by exposure 
of chondrocytes to E2, at a final concentration of 10
-6 
M for 4 days. 
 
   
 
 
                               
  
                              
 
 
 
 
 
 
 
2.5.2 Effect of E2 on cell proliferation during chondrogenesis and terminal 
 differentiation 
ATDC5 chondrocyte proliferation during chondrogenesis or terminal differentiation 
was unaffected by exposure to E2 for 24 hours, at a final concentration of 10
-10 
M, 
10
-8 
M and 10
-6 
M,  as analysed with [
3
H]thymidine incorporation on day 8 and day 
15 (Figure 2.2A, Figure 2.2B respectively). However, as expected there was much 
lower rates of proliferation in the terminally differentiated cells.  
  
Figure 2.1 – ERα and ERβ expression in ATDC5 cells as detected by semi-
quantitative RT-PCR during chondrogenesis and terminal differentiation in cells 
treated with E2 (10
-6 
M) or in control cells (Con) 
 
ER-α 
ER-β 
Blank   Con     E2        Con      E2  
 
 
 
Chondrogenesis             Terminal differentiation              
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Figure 2.2 – Effect of E2 on ATDC5 proliferation as assessed by [3H]thymidine 
uptake after 24 hours exposure. (A) ATDC5 proliferation during chondrogenesis. (B) 
ATDC5 proliferation during terminal differentiation. Data are expressed as means ± 
SEM (n = 6).   
A 
B 
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I therefore found that exogenous E2, at physiological and pharmacological 
concentrations (10
-10
 to 10
-6 
M), had no effect on ATDC5 chondrocyte proliferation. 
Whilst undertaking this project Chagin et al published their findings in the human 
HCS-2/8 chondrocyte cell line (Table 2.1).
(129) 
The authors reported that exogenous 
E2 (10
-10
 to 10
-6 
M) had no effect on cell number or thymidine incorporation in HCS-
2/8 chondrocytes. However, the chondrocytes themselves were shown to produce E2 
which could be of physiological importance. The production of E2 was dependent on 
the stage of chondrocyte differentiation, being high in proliferative (non-confluent) 
cells and gradually decreasing in more differentiated and over-confluent cell cultures. 
Rodd et al recently reported a similar lack of response to E2 in primary foetal bovine 
chondrocytes.
(128)
 Exogenous E2 had no effect on cell number or viability at a range 
of doses (10
-13
 to 10
-7
 M). However, at a pharmacological concentration (10
-7 
M) E2 
induced maturation of prehypertrophic chondrocytes toward the hypertrophic 
phenotype. This was associated with the appearance of type X collagen and an 
increase in ALP activity. In addition, Gruber et al reported that exogenous E2 (10
-10
 
to 10
-6
 M) did not alter ALP activity in ATDC5 cells.
(171)
 Based on these reports, an 
E2 concentration of 10
-6
 M was employed for all further ATDC5 cell culture 
experiments.  
 
2.5.3 Effect of E2 on ALP activity and proteoglycan production  
In ATDC5 chondrocytes the production of extra-cellular matrix, as reflected by 
proteoglycan synthesis, was unaltered after exposure to E2 at a final concentration of 
10
-6 
M for 7 days (Figure 2.3A). In a similar fashion ALP activity was unaffected by 
E2 exposure at a final concentration of 10
-6 
M for 7 days (Figure 2.3B).  
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Figure 2.3 – Effect of E2 on ATDC5 differentiation after 7 days exposure at 10-6 
M A) Proteoglycan production as assessed by Alcian Blue uptake (OD at 630nm) in 
ATDC5 cells during terminal differentiation. B) ALP activity (nmoles pNPP 
hydrol/min/mg protein) in ATDC5 cells during terminal differentiation. Data are 
expressed as means ± SEM (n = 6).  
 
2.5.4 Effect of co-incubating E2 and pro-inflammatory cytokines on 
chondrocyte proliferation and apoptosis  
The cytokines, IL-1β and TNFα (10ng/ml), led to a reduction in proliferation in 
ATDC5 chondrocytes after 24 hours exposure as analysed with [
3
H]thymidine 
incorporation with a reduction in proliferation of 84.5% and 95% respectively 
(Figure 2.4). The co-incubation of E2 at a final concentration of 10
-6
 M with either of 
the cytokines (Figure 2.4) did not alter the reduction observed in cell proliferation. 
B 
A 
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Similarly, both IL-1β and TNFα (10ng/ml) increased apoptosis in the ATDC5 
chondrocytes after 24 hours exposure (Figure 2.5). TNFα had a significantly greater 
effect on apoptosis by 1238% compared with 297%. Exposure of the ATDC5 cells to 
E2 at a final concentration of 10
-6 
M had no effect on apoptosis either alone or in 
combination with either of the cytokines (Figure 2.5).   
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Figure 2.4 – Effect of co-incubating E2 with Il-1β or T5Fα on ATDC5 
proliferation as assessed by [3H]thymidine uptake after 24 hours exposure. Data are 
expressed as means ± SEM (n = 6). ***P < 0.001 compared with controls.  
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Figure 2.5 – Effect of co-incubating E2 with Il-1β or T5Fα on apoptosis in 
ATDC5 cells as assessed by photometric enzyme-immunoassay (cell death detection 
ELISA
PLUS
) after 24 hours exposure. Data are expressed as means ± SEM (n = 6).  
*P < 0.05, ***P < 0.001 compared with control cells. 
*   * 
 *** *** ***  *** 
*** *** 
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2.6 Discussion 
Exogenous E2 had no effect on proliferation, terminal differentiation or apoptosis in 
the ATDC5 chondrocyte cell line. These findings are in agreement with the recent 
publications by Rodd et al and Chagin et al.
(128;129) 
The inconsistent effects of E2 on 
epiphyseal chondrocytes in vitro reported in the literature may be due to differences 
in the age, gender and species from which the cells have been derived. In addition 
cell culture conditions play a crucial role as they will influence endogenous E2 
production. The presence of FBS in cell media allows E2 to work in concert with 
other factors or hormones present in the serum. Furthermore, in some of the older 
studies
(122;123)
 chondrocytes were cultured in the presence of phenol red (a pH 
indicator) which is now known to have significant oestrogenic activity at the 
concentrations found in tissue culture media.
(179) 
Recent studies have used serum-free 
media or media with charcoal treated serum (CTS). Charcoal treatment reduces the 
concentration of steroid hormones found in the serum. Exogenous E2 has been 
shown to have no effect on cell number or proliferation in a human chondrocyte cell 
line 
(129) 
and in primary foetal bovine chondrocytes.
(128)
 Likewise no effect was seen 
on ALP activity in a murine chondrocyte cell line (ATDC5 cell line).
(171)
 In two older 
studies that also used serum-free media (without phenol red) E2 exposure led to an 
increase in 
35
S incorporation in primary human and rabbit chondrocytes which was 
age-dependent.
(160;161)
 E2 stimulated 
35
S incorporation in primary human 
chondrocytes derived from females aged 2-7 years but had no effect on those 
obtained from girls aged 4-months to 1 year. Male-derived cells were only exposed 
to DHT.
(160)
 E2 also had an age-dependent stimulatory effect on 
35
S incorporation in 
primary rabbit chondrocytes.
(161)
 The maximal response to E2 was observed in foetal 
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chondrocytes (79%; pooled male and female cells). During the first 5 days of life 
chondrocytes were moderately responsive with an increase in 
35
S incorporation 
which was greater in female derived cells. However, E2 had no effect on cells aged 
from 5 to 30 days which corresponds to the time period of maximum basal sulfate 
incorporation in untreated cells. A stimulatory effect of E2 was then observed in cells 
aged 32-62 days with a greater response in female derived cells. This time period 
corresponds with the timing of puberty in rabbits.
(180)
 Thereafter cells were 
unresponsive to E2 (62-75 days). However, in at least one of these studies epiphyseal 
“articular” chondrocytes were cultured.
(161)
 Articular chondrocytes may respond 
differently to epiphyseal growth plate chondrocytes and may react more like 
osteoblasts to E2. In the human osteoblast-like SaOS cell line exposure to E2 led to 
an increase in proliferation, ALP activity and oestocalcin levels.
(181)
 Fohr et al 
investigated the effect of E2 on four established osteosarcoma cell lines representing 
different stages of osteogenic maturation and concluded that the response to E2 
depends on its osteoblastic commitment rather than its gender.
(181) 
 
Whereas, in the presence of FBS, E2 led to a concentration-dependent inhibition of 
proliferation together with stimulation of differentiation in primary rat chondrocytes 
(aged 1-month).  These responses to E2 were limited to cells from female 
animals.
(126;169)
 E2 is reported to activate PKC by rapidly increasing intracellular 
calcium concentration through a capacitative entry mechanism
(182)
 resulting in 
increased phospholipase C (PLC) activity.
(183;184)
 Further work showed that E2 led to 
a rapid concentration-dependent activation of mitogen-activated protein kinase 
(MAPK) dependent on PKC and PLC which was blocked by tamoxifen and did not 
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require gene transcription or translation. Thus, E2 appears to regulate MAPK through 
a sex-specific membrane-mediated mechanism that does not involve cytosolic ERs in 
a traditional sense and extra-cellular signal related kinases 1 and 2 (ERK1/2) and p38 
mediate the downstream biological effects of the hormone.
(169)
 In a similar fashion, 
the response to E2 observed in primary human articular chondrocytes in the presence 
of FBS was limited to female derived cells.
(170)
 In contrast to epiphyseal 
chondrocytes a rapid concentration-dependent stimulation of proliferation was 
observed in articular chondrocytes in response to E2. Chondrocyte differentiation 
was also promoted with an increase in ALP activity and 
35
S incorporation. E2 caused 
a rapid increase in PKC activity in chondrocytes. The E2-dependent stimulation of 
matrix synthesis is likely to be mediated by PKC as chelerythrine (a general PKC 
inhibitor) completely blocked its stimulatory effects.   Thus, exposure to E2 in the 
presence of FBS appears to have an inhibitory effect on proliferation in epiphyseal 
chondrocytes and a stimulatory effect in articular chondrocytes (and osteoblasts). In 
all, treatment with E2 stimulates chondrocyte differentiation.  
 
To summarise, the ATDC5 cell line may not have responded to E2 as it is male-
derived (Professor Hiraki, personal communication) and the previously described 
rapid responses to E2 in the presence of FBS, including activation of PKC, were 
limited to cells from female animals
(126;134;135) 
However, this lack of response may be 
attributable to endogenous E2 production as chondrocytes are able to synthesize E2 
which may be physiologically important.
(129-131)
 It is possible that endogenously 
produced E2 constantly activates ERs and therefore prevents any further effect of 
exogenous E2.  
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Exposure of ATDC5 chondrocytes to the pro-inflammatory cytokines, IL-1β and 
TNFα, led to a comparable reduction in cell proliferation as analysed by thymidine 
incorporation at a concentration of 10ng/ml (84.5% versus 95% respectively). 
Similarly, both cytokines increased apoptosis in ATDC5 cells but a significantly 
greater effect was observed after treatment with TNFα (1238% versus 297%). These 
inhibitory effects of IL-1β and TNFα  on ATDC5 chondrocyte dynamics have been 
previously documented by our group.
(162)
 In addition, treatment with IL-1β or TNFα 
(10ng/ml) has previously been shown to decrease proteoglycan synthesis (75% 
versus 86%) and markedly reduce aggrecan, collagen II and collagen X gene 
expression.
(162)
 ATDC5 cells treated with IL-1β (10ng/ml) for 2 or 7 days followed 
by a cytokine-free recovery period of 12 or 7 days respectively showed a reduction 
of only 12% or 38% in proteoglycan synthesis compared to control cells at the end of 
the culture period at 14 days.
(162)
 Recovery from TNFα exposure could not be 
studied in ATDC5 cells because of its toxicity to the cells when added during the 
chondrogenesis period of maturation.
(185)
 In view of these previous findings the 
effect of co-incubating E2 with cytokines was investigated in this study during 
terminal differentiation. The cytokine-induced inhibition of ATDC5 cell proliferation 
was not affected by co-incubation with E2, at a final concentration of 10
-6
 M. 
Likewise, the stimulation of apoptosis by the pro-inflammatory cytokines was 
unaltered by co-incubation with E2. Thus E2 does not appear to have a protective 
effect on ATDC5 cells against cytokine-induced changes on proliferation or cell 
survival. This is in contrast to the protective effects of E2 reported in other cell types. 
In human umbilical vein endothelial cells (HUVEC) exposure to TNFα led to a 
decrease in DNA synthesis (thymidine uptake) and an increase in apoptosis.
(164)
 This 
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was associated with an up-regulation in ERK1/2 activity and expression of 
intercellular and vascular cell adhesion molecules. TNFα effects were significantly 
attenuated by co-incubation with E2 which included 4 hours of pre-incubation with 
E2. The inhibitory effect of E2 was blocked by Faslodex suggesting its action was 
mediated via classical ERs. ERβ is the most likely candidate as HUVEC express ERβ 
but lack ERα. E2 treatment significantly attenuated ERK1/2 activation but had no 
affect on other signalling molecules. ERK1/2 are members of the MAPK super 
family that can mediate cell proliferation and apoptosis. Similarly in bovine carotid 
artery endothelial cells both E2 and raloxifene analogue (LY117018) prevented 
caspase-3 dependent apoptosis induced by TNFα through activation of the ERs and 
ERK1/2 signalling pathway.
(186)
 Cells were pre-incubated with E2 or raloxifene 
analogue for 30 minutes. E2 treatment is also reported to protect against apoptosis 
induced by other mechanisms. For example in a cell culture model of Parkinson’s 
disease (PC12 cancer cell line MPP+) E2 exposure suppressed apoptosis and 
improved cell viability.
(187)
 The beneficial effects of E2 were due to suppression of 
the pro-apoptotic protein IL-β converting enzyme (also known as caspase 1) and 
stimulation of the anti-apoptotic protein Bcl-xL. The latter inhibits mitochondrial 
cytochrome C release into the cytoplasm and subsequent activation of caspase-3. 
Further, in the murine C8-DIA astrocyte cell line, E2 suppressed hypoxia-induced 
apoptosis by 50%.
(188)
 The hypoxia-induced apoptosis was associated with an 
increase in phosphorylated ERK1/2 which was attenuated by pre-incubation with E2. 
Likewise in primary foetal rat cortical neurones E2 treatment inhibits glutamate-
induced apoptosis.
(189)
 Exposure to E2 prevents the release of cytochrome C from 
mitochrondria into the cytoplasm and subsequent down-regulation of caspase-3. No 
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pre-incubation with E2 was performed. More recently, a caspase-independent 
pathway involving calpain (apoptotic protease) and apoptosis inducing factor (AIF) 
has been shown to mediate some of the apoptotic effects of glutamate in primary rat 
cortical neurones. This pathway is similarly inhibited by E2. Primary rat cortical 
neurones express both ERs but ERβ expression is greater than ERα. (190)  
 
In the various cell types studied E2 appears to have an effect on caspase-dependent 
apoptotic pathways and in particular on the anti-apoptotic protein Bcl-xL and 
mitochondrial cytochrome C which are both downstream of the Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) signalling pathway. In 
addition, effects on the ERK1/2 signalling transduction pathway have been reported. 
It is possible that E2 is exerting its effect via the suppressor of cytokine signalling 
(SOCS) family of proteins which are inhibitors of STATs as E2 mediates its 
inhibition of the GH/JAK/STAT pathway via SOCS-2.
(191) 
In cardiac myocytes 
SOCS-1 prevented TNF-α induced apoptosis in cardiac myocytes via activation of 
the ERK1/2 pathway activation.
(192) 
ERK1/2 can mediate both cell proliferation and 
apoptosis.  The Ras–Raf–MEK–ERK signalling cascade controlling cell proliferation 
has been well studied but the mechanisms involved in ERK1/2-mediated cell death 
are largely unknown.  Activated ERK1/2 is usually translocated to the nucleus but 
certain proteins are involved in the cytosolic retention of activated ERK1/2.
(193)
 
Cytosolic retention of ERK1/2 denies access to the transcription factor substrates that 
are responsible for the mitogenic response.  In addition, cytosolic ERK1/2, besides 
inhibiting survival and proliferative signals in the nucleus, potentiates the catalytic 
activity of some proapoptotic proteins in the cytoplasm but further work is required 
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to further define the function of cytosolic ERK1/2 and its cytosolic substrates that 
enhance cell death.
(193)
 
 
Possible explanations for the lack of response we observed when co-incubating 
oestradiol with cytokines on the ATDC5 cells include differences in cell type with 
possible differences in cell signalling pathways. In addition, experimental conditions 
could be important as some but not all of the studies described above included a 
period of pre-incubation with oestradiol where the cells received oestradiol for a 
variable period (from thirty minutes to four hours) before the addition of cytokines. 
This may be relevant as the protective effect of oestradiol may require this period of 
pre-incubation perhaps to effect a change of cell signalling pathways e.g. up-
regulation of certain anti-apoptotic pathways. Lastly, it may be due to the distribution 
of the ERs within the different cell types and the proportion of ERα compared to 
ERβ. In chondrocytes both ERs appear to be fairly equally distributed whereas some 
of the cells described above mainly or only expressed ERβ.  
 
2.7 Conclusions 
The murine ATDC5 chondrocyte cell line expresses ERα and ERβ during 
chondrogenesis and terminal differentiation. Exogenous oestradiol had no effect on 
proliferation during chondrogenesis or terminal differentiation. The markers of 
chondrocyte differentiation, ALP activity and Alcian Blue staining, were also 
unaffected by exposure to oestradiol. Similarly, programmed cell death was 
unaltered by oestradiol treatment. In addition, oestradiol did not convey a protective 
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effect on the cytokine-induced inhibition of proliferation and stimulation of apoptosis 
by TNFα and IL-1β.  
  
Chapter 3                                                           Effect of E2 on human C28/I2 cell line 
 
    
 56 
 
 
Chapter 3 
Effect of oestradiol on human 
C28/I2 chondrocyte cell line 
 
Chapter Contents 
3.1 Introduction  
3.2 Hypothesis 
3.3 Aims 
3.4 Materials and Methods 
 3.4.1 Materials 
 3.4.2 Methods 
   3.4.2.1 C28/I2 chondrocyte cell culture 
   3.4.2.2  Chondrocyte proliferation assay 
   3.4.2.3 Apoptosis assay     
   3.4.2.3  Semi-quantitative RT-PCR 
 3.4.3 Statistical analysis    
3.5 Results 
 3.5.1 Gene expression 
 3.5.2 Effect of oestradiol 
 3.5.3 Effect of oestradiol-related chemicals 
3.6 Discussion 
3.7 Conclusions 
  
Chapter 3                                                           Effect of E2 on human C28/I2 cell line 
 
    
 57 
3.1 Introduction 
The culture of primary chondrocytes of human origin can be difficult as the source of 
cartilage cannot be controlled leading to variability in chondrocyte preparations. In 
addition, the large numbers of cells required for individual experiments are not 
readily available from random operative procedures. Therefore immortalized 
chondrocytes of human origin have been developed to serve as a reproducible model 
for studying chondrocyte function. Some of the first human chondrocyte cell lines 
were established by retroviral-mediated transfection of primary rib chondrocytes 
with the large T antigen of Simian virus 49.
(194) 
The chondrocytes were derived from 
costal cartilage from a 15-year old female. The T/C-28a2 cell line was obtained 
initially, from which the C-28/I2 and T/C-28a4 were derived.
(194) 
These cells retain 
chondrocytic morphology and maintain continuous proliferation in monolayer 
culture. Moreover they have been used in numerous studies to investigate 
chondrocyte-specific response patterns.
(194;195) 
Of these cell lines C28/I2 showed the 
highest SOX-9 (SRY-related HMG-box gene 9; master gene of chondrocytic cell 
differentiation) levels and appears to most closely resemble primary chondrocytes 
with respect to anabolic and catabolic gene expression.
(196)
 However, these cell lines 
mainly proliferate and show lower expression of genes involved in matrix synthesis 
and turnover. 
 
3.2 Hypothesis  
As E2 had no effect on the male-derived ATDC5 cell line it was hypothesised that 
the effect of E2 may be limited to female chondrocytes.  
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3.3 Aims 
 
I. Confirm the presence of the oestrogen receptors, ERα and ERβ, by semi-
quantitative RT-PCR in C28/I2 cells  
 
II. Analyse the effect of different E2 concentrations on proliferation in C28/I2 
cells  
 
III. Investigate the effect of E2-related chemicals (including specific ER 
inhibitors) on chondrocyte proliferation and apoptosis  
 
3.4      Materials and methods 
3.4.1 Materials 
All chemicals were purchased from Sigma Aldrich (Dorset, UK) unless otherwise 
stated. PCR oligonucleotides were purchased from MWG Biotech (Ebersberg, 
Germany). 17β-Oestradiol: cyclodextrin-encapsulated water soluble; tamoxifen: 
SERM,  principally ERα antagonist; raloxifene: SERM, principally ERβ agonist; 
Methyl-piperidino-pyrazole (MPP) dihydrochloride: selective ERα antagonist.
(197)
 
Faslodex: non-specific high affinity ER antagonist (Tocris Bioscience, Bristol, UK). 
 
3.4.2 Methods 
3.4.2.1 C28/I2 chondrocyte cell culture 
The C28/I2 chondrocyte cell line was kindly supplied by Dr. Goldring (Boston, 
USA) and maintained as described by Goldring et al.
(198) 
Cells were maintained in 
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T175 tissue-culture flasks (Greiner Bio-Pne GmbH) at a density of 750,000 
cells/flask in a maintenance medium of DMEM: F12 without phenol red (Invitrogen) 
supplemented with 10% FBS (Invitrogen), and gentamicin (50µg/ml Invitrogen). For 
individual experiments semi-confluent cultures were passaged with trypsin EDTA 
and cultured (day 0) at a density of 12,500 cells/cm
2
 in multi-well plates (Costar) in 
maintenance medium. Cells were incubated at 37°C in a humidified atmosphere 
containing 95% air/5% CO2 and the medium was changed every second/third day. In 
selected experiments cells were cultured in serum-free medium. 
 
3.4.2.2 Chondrocyte proliferation assay 
E2 and related chemicals were added to the cells at a final concentration of 10
-6 
M in 
0.01% DMSO and incubated for a 24 hour period. Control cells received 0.01% 
DMSO. Chondrocyte proliferation was assessed by incubating the cells with 
0.2µCi/ml [
3
H]thymidine (37MBq/ml; Amersham Pharmacia Biotech) for the last 2 
hours of the incubation period and measuring the amount of radioactivity 
incorporated into trichloroacetic acid-insoluble precipitates.
(176)
 
 
3.4.2.3 Apoptosis assay 
Apoptosis was assessed by measuring the cytoplasmic histone-associated DNA 
fragments (mono- and oligo- nucleosomes) by photometric enzyme-immunoassay 
(cell death detection ELISA
PLUS
; Roche Applied Science). E2 and related chemicals 
were added to the cells at a final concentration of 10
-6 
M in 0.01% DMSO and 
compared with control cultures which contained 0.01% DMSO only. Apoptosis was 
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measured following the manufacturers’ protocol in cells cultured in 96-well plates 
over a 24 or 48 hour period starting on day 2. 
 
3.4.2.4 Semi-quantitative RT-PCR 
Semi-quantitative PCR was performed as described in chapter 2 (2.4.3) and the 
sequence of the primer pairs used (human ERα, human ERβ) are shown in Table 3.1. 
 
 
Table 3.1 - Primer sequences and product sizes for human  
ERα and ERβ genes analysed by RT-PCR 
 
 
Primer sequence Gene 
Forward primer  
Reverse primer  
Cycles Product 
size 
(base pairs) 
Classic 
18S 
Unknown, purchased commercially  
from Ambion 
20 488 
ERα 
(human) 
5’- GAC CGA AGA GGA GGG AGA A - 3’ 
5’ - CCA AGA GCA AGT TAG GAG CAA - 3’ 
35 460 
ERβ 
(human) 
5’ - TAG TGG TCC ATC GCC AGT TAT - 3’ 
5’ - GGG AGC CAC ACT TCA CCA T - 3’ 
35 323 
 
 
3.4.3 Statistical analysis 
Data were analysed by ANOVA. All data are expressed as the mean ± SEM of at 
least six replicates within each experiment, and statistical analysis was performed 
using SPSS (version 15). Significance was determined as P<0.05. 
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3.5 Results 
3.5.1 Gene expression 
The oestrogen receptors, ERα and ERβ, were both expressed in C28/I2 chondrocytes 
(Figure 3.1). 
 
                Blank    C28/I2 cells 
                
 
                      
                                   
 
Figure 3.1 – ERα and ERβ expression in C28/I2 cells as detected by semi-
quantitative RT-PCR analysis 
 
3.5.2 Effect of oestradiol 
Exposure to E2 for 24 hours, in the presence of 10% FBS, led to a significant 
reduction in cell proliferation as analysed with [
3
H]thymidine incorporation (Figure 
3.2A). Cell proliferation was inhibited in a concentration-dependent manner with a 
decrease in [
3
H]thymidine incorporation of 8.4%, 14.7% and 17.2% in C28/I2 cells 
exposed to E2 at a final concentration of 10
-10
 M, 10
-8
 M and 10
-6
 M respectively    
(P<0.05, P<0.001 and P<0.001). E2 treatment for 48 hours at a concentration of 10
-8 
M and 10
-6 
M also led to a significant reduction in cell proliferation (32.7% and 
28.1% decrease in [
3
H]thymidine incorporation, P<0.01) but had no effect at a final 
concentration of 10
-10 
M (Figure 3.2B). Whereas, exposure to E2 for 24 hours in 
serum-free medium had no effect on cell proliferation as analysed with 
[
3
H]thymidine incorporation (Figure 3.3). Exposure of C28/I2 cells to E2 for 24 
hours in the presence of FBS had no effect on the level of apoptosis as assessed by 
photometric enzyme-immunoassay (Figure 3.6). 
 ERα 
 ERβ  
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Figure 3.2 – Effect of E2 on C28/I2 proliferation in the presence of FBS as 
assessed by [
3
H]thymidine uptake (A) C28/I2 proliferation after 24 hours exposure 
*P<0.05, **P<0.01, ***P<0.001 compared with control cells. (B) C28/I2 
proliferation after 48 hours exposure *P<0.05 compared with control cells. All data 
are expressed as mean ± SEM (n = 6). 
 
 
   ***    ***     * 
      ** ** 
A 
B 
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Figure 3.3 – Effect of E2 on C28/I2 proliferation in serum-free medium as 
assessed by [
3
H]thymidine uptake after 24 hours. Data are expressed as mean ± SEM 
(n= 6).  
 
3.5.3 Effect of oestradiol-related chemicals 
The E2-induced decrease in proliferation of cells, cultured in medium with 10% 
FBS, was not observed in the presence of tamoxifen or raloxifene at a final 
concentration of 10
-6 
M (Figure 3.4). Exposure of Faslodex, the high-affinity non-
specific ER antagonist, led to a decrease in cell proliferation when administered 
either alone (36.6% decrease in thymidine incorporation, P<0.001) or in combination 
with E2 (40.7% decrease, P<0.001) (Figure 3.4). The E2-related chemicals, 
raloxifene and MPP at a final concentration of 10
-6 
M had no effect on cell 
proliferation when given alone (Figure 3.5). However, exposure to raloxifene and 
MPP for 24 hours at a final concentration of 10
-6 
M led to a significant decrease in 
cell proliferation (21.7% decrease in thymidine incorporation, P<0.001). This 
reduction in proliferation was also observed in the presence of E2 at a final 
concentration of 10
-6
 M (21.7% decrease, P<0.001).  
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Figure 3.4 – Effect of E2 alone and in combination with Tamoxifen, Raloxifene 
or Faslodex on C28/I2 proliferation as assessed by [3H]thymidine uptake after 24 
hour exposure at 10
-6
 M. Data are expressed as mean ± SEM (n = 6). *P<0.05, 
***P<0.001 compared with control cells. 
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Figure 3.5 – Effect of E2, Raloxifene or MPP alone and in combination on 
C28/I2 proliferation as assessed by [3H]thymidine uptake after 24 hours exposure. 
Data are expressed as mean ± SEM (n = 6). *P<0.05, ***P<0.001 compared with 
control cells. 
 
 
  *    ***   *** 
   ***   ***   * 
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Exposure of C28/I2 chondrocyte cells to E2, raloxifene or Faslodex (at a final 
concentration of 10
-6
 M) for 24 hours had no effect on the level of apoptosis as 
assessed by photometric enzyme-immunoassay (Figure 3.6A). However, a significant 
increase in apoptosis was observed after 24 hour exposure to the combination of 
raloxifene and MPP at a final concentration of 10
-6 
M (32.5% increase compared to 
control cells; P<0.05). Similarly there was no difference observed in the level of 
apoptosis after 48 hours of exposure to E2, raloxifene or Faslodex at a final 
concentration of 10
-6
 M compared to control cells (Figure 3.6B). The combination of 
raloxifene and MPP at a final concentration led to a significant increase in apoptosis 
after 48 hours exposure (20% increase compared to control cells; P<0.05).    
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Figure 3.6 – Effect of E2, Faslodex, Raloxifene or Raloxifene & MPP on 
apoptosis of C28/I2 cells at 10-6 M as assessed by photometric enzyme-
immunoassay (cell death detection ELISA
PLUS
). Data are expressed as mean ± SEM 
(n = 6). A) After 24 hours exposure *P<0.05 compared with control cells. B) After 
48 hours exposure *P<0.05 compared with controls. 
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3.6 Discussion  
The reduction in cell proliferation observed after exposure to E2 only occurred in the 
presence of foetal bovine serum. This suggests that the E2-induced inhibition of 
proliferation is dependent on a compound found in the serum. However, the response 
is concentration-dependent which suggests that E2 is having a true effect. This effect 
was blocked by the addition of tamoxifen, a first generation SERM which functions 
principally as an ERα antagonist, suggesting that ERα is important in mediating this 
effect. As tamoxifen blocks the action of PKC it is possible that E2 is exerting its 
effect via the non-genomic pathway of E2 signalling (PLC/PKC/MAPK/ERK1/2 
pathway) in a similar fashion to the sexually dimorphic E2 effects previously 
reported by McMillan et al where a response to E2 was limited to cells from female 
animals.
(169)
 
 
Exposure of C28/I2 cells to Faslodex, the high-affinity non-specific ER antagonist, 
led to a significant reduction in cell proliferation (decrease of 36% compared to 
controls P<0.001). This suggests that endogenous E2 may play an important role in  
maintaining cell proliferation. However, we found that Faslodex did not alter 
apoptosis in the human C28/I2 cell line. This is in contrast to the findings of Chagin 
et al where they observed a reduction in proliferation along with an increase in 
caspase-dependent apoptosis in the human chondrocyte HCS-2/8 cell line after 
exposure to Faslodex.
(129)
 This effect was concentration-dependant as an increase in 
apoptosis was only observed after 48 hours when cells were exposed to Faslodex at 
10
-6
 M whereas those exposed to a final concentration of 10
-5
 M showed a reduction 
at 24 hours. Faslodex-induced apoptosis is therefore cell-type dependent. Similar 
  
Chapter 3                                                           Effect of E2 on human C28/I2 cell line 
 
    
 68 
cell-type dependent apoptotic effects have been described with the glucocorticoid, 
dexamethasone. Chrysis et al reported an increase in apoptosis after exposure of the 
HCS-2/8 chondrocyte cell line to dexamethasone
(199)
 whereas no effect was observed 
in the ATDC5 cell line.
(185) 
 
 
Raloxifene, a SERM which functions mainly as an ERβ agonist, had no effect on cell 
proliferation or apoptosis when used alone. However, when used in combination with 
a selective ERα antagonist (MPP) a reduction in cell proliferation was observed in 
association with an increase in apoptosis. As this combination is likely to be exerting 
its effects via ERβ (as MPP specifically blocks ERα) it suggests that ERβ has an 
inhibitory effect on cell growth and cell survival and is acting as a “brake”. This is 
supported by studies of other tissue types which also possess classical ERs (ERα, 
ERβ). In human colon for example, ERβ, the predominant ER subtype expressed, 
has been observed to be significantly decreased in colonic tumours compared with 
normal mucosa whereas ERα  expression appears to be unaffected.
(200;201)
 Further, 
ERβ has been shown to be a potent inhibitor of cell proliferation in the HCT8 human 
colon cancer cell line through regulation of cell cycle components.
(202)
  
 
3.7 Conclusions  
The C28/I2 chondrocyte cell line expresses both classical ERs (ERα and ERβ). 
Exposure of this human female-derived chondrocyte cell line to E2 led to a 
concentration-dependent inhibition of proliferation. This effect was indirect as it only 
occurred in the presence of FBS and did not occur in the male, murine ATDC5 cell 
line. The effect was blocked by tamoxifen, a PKC inhibitor, suggesting it may be 
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mediated via the non-genomic pathway of E2 signalling (PLC/PKC/MAPK/ERK1/2 
pathway).  
 
Treatment with the non-specific ER antagonist, Faslodex led to a marked reduction 
in cell proliferation which was not associated with an increase in apoptosis. As 
Faslodex blocks and downgrades both of the classical ERs it suggests that 
endogenous E2 plays an important role in maintaining cell proliferation but has little 
impact on apoptosis in the human C28/I2 cell line.  
 
However, when the function of the ERs were manipulated by selectively blocking 
ERα with MPP and exposing the cells to raloxifene, an E2-agonist with higher 
affinity for ERβ, a significant inhibition of cell proliferation and stimulation of 
apoptosis was observed. This suggests that ERβ may act as a “brake” on the growth 
of the chondrocyte.  
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4.1      Introduction 
The foetal murine metatarsal culture system is an established procedure to directly 
investigate bone growth and is recognised to provide a more physiological model 
than the culture of isolated chondrocytes. The growth rate of foetal bones in culture 
is similar to that found in vivo and in contrast to monolayer cell culture the metatarsal 
culture system maintains cell-cell and cell matrix interactions, and allows the direct 
assessment of bone growth and histological architecture. Our group has extensive 
experience of this model, having first published its use for studying childhood 
growth.
(203)  
 
Similarly, the murine primary chondrocyte culture system is an established method 
of investigating chondrocyte function. In contrast to human primary chondrocyte 
cells they are easily obtained and retain their differentiated phenotype for several 
days in  culture.
(204)
 These physiological models of murine growth were therefore 
chosen to further investigate the effect of E2 on chondrocyte function. A limitation 
of the primary chondrocyte culture system is the large number of cells required for 
each experiment. For this reason the number of experiments performed with this 
system was restricted to assessing the effects of E2 and the E2-related chemicals, 
Faslodex, MPP and raloxifene.  
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4.2 Hypothesis  
The hypothesis of this study was that exogenous E2 would have no effect on linear 
growth in the metatarsal culture system (as E2 had no effect on chondrocyte cell 
lines in the absence of FBS) but Faslodex, by blocking endogenous E2 activity, 
would decrease both primary chondrocyte proliferation and linear growth of 
metatarsals in culture. Secondly, it was hypothesised that ERβ has an inhibitory 
effect on chondrocyte proliferation and metatarsal growth. As MPP is a selective 
antagonist of ERα and raloxifene a SERM that functions mainly as an ERβ agonist it 
was hypothesised that in combination they would lead to a reduction in primary 
chondrocyte proliferation and longitudinal growth of metatarsals in culture. 
 
4.3 Aims 
 
I. Analyse the effect of E2 and oestradiol-related chemicals on the 
longitudinal growth and mineralising zone growth of foetal murine 
metatarsals maintained in culture   
 
II. Analyse the effect of E2 at varying concentrations on primary murine 
chondrocyte proliferation 
 
III. Analyse the effect of the oestradiol-related chemicals: Faslodex, MPP & 
raloxifene on primary murine chondrocyte proliferation  
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4.4 Materials and methods 
The experimental protocol was approved by the Roslin Institute’s Animal Users 
Committee and the animals were maintained in accordance with Home Office 
guidelines for the care and use of laboratory animals. 
 
4.4.1 Foetal murine metatarsal organ culture 
The middle three metatarsals were aseptically dissected from 18-day old embryonic 
Swiss mice that had been killed by decapitation. Bones were individually cultured at 
37°C in a humidified atmosphere of 95% air/5% CO2 in 24-well plates (Costar) for 
up to 14 days. Each well contained 300 µl of serum-free α-MEM without nucleosides 
(Invitrogen) supplemented with 0.2% Bovine Serum Albumin Cohn fraction V; 0.1 
mmol/l β-glycerophosphate; 0.05 mg/ml L-ascorbic acid phosphate (Wako, Fukuoka, 
Japan), 0.292 mg/ml L-glutamine (Invitrogen), 0.05 mg/ml gentamicin (Invitrogen) 
and 1.25 µg/ml fungizone (Invitrogen). E2 (cyclodextrin-encapsulated water soluble) 
at a final concentration of 10
-5 
M or 10
-6 
M and oestradiol-related chemicals at a final 
concentration of 10
-5 
M or 10
-6 
M in 0.01% DMSO/0.1% ethanol were added to the 
bones and the medium was changed every second or third day. The control groups 
(medium only or 0.01% DMSO/0.1% ethanol) and each experimental group 
contained 6-9 metatarsals. 
 
4.4.2 Morphometric analysis of metatarsals 
Images were taken of the metatarsals every 2 to 4 days of culture using a digital 
camera attached to a Nikon TE300 microscope. The total length of the bone and the 
length of the mineralising zone were determined using Image Tool (Image Tool 
  
 
Chapter 4                                                 Effect of E2 on physiological murine models  
 
    
 74 
version 3.00, University of Texas Health Life Science Centre, San Antonio, USA) 
(Figure 4.1). All results are expressed as a percentage change from harvesting length, 
which was regarded as baseline to demonstrate the rate of growth over time.  
 
                              
 
Figure 4.1 - Foetal murine metatarsal culture model. Total length (black arrow) 
and mineralising zone length (white arrow) are shown in a control metatarsal (A) On 
the day of harvesting (B) After 14 days of culture. 
 
 
4.4.3 Sex determination of mouse embryos 
In view of the age and size of the mouse embryos it was not possible to determine the 
sex by direct examination alone. As the sex determining region protein (SRY) gene 
is encoded by the Y chromosome and is well conserved among species PCR allows 
the rapid and accurate detection of male DNA. Therefore, DNA was isolated from 
mouse embryo tail biopsies. Each tail biopsy was placed into a labelled tube 
containing 1ml of tail digest buffer: 0.3M sodium acetate, 10mM Tris HCl pH 7.9, 
1mM EDTA pH 8, 1% SDS and 200µg/ml Proteinase K. The samples were 
incubated overnight at 37°C and frozen at -20°C for storage until needed. Prior to 
PCR analysis, samples were centrifuged at 13200 rpm at 4°C for 15 minutes, and 
then kept on ice. This process was repeated twice, and insured the sodium dodecyl 
Day 1 
 
Day 14 
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sulphate (SDS) present in the tail digest buffer was sedimented and did not interfere 
with the PCR reaction. SRY gene expression was analysed by semi-quantitative RT-
PCR as described in chapter 2.0 (2.4.3). The sequences of the primer pairs used are 
shown in Table 4.1. The efficacy of this system was assessed by analysing the SRY 
gene expression in DNA from eight mice that had previously undergone tail biopsies 
for other experiments in whom the sex was known. The results are shown in Figure 
4.2. 
Table 4.1 - Primer sequences and product size for murine SRY gene 
Primer sequence Gene 
Forward primer 
Reverse primer 
Cycles Product size 
(base pairs) 
Classic 
18S 
Unknown, purchased commercially  
from Ambion 
20 488 
SRY 
(murine) 
5’ - TGG GAC TGG TGA CAA TTG TC - 3’ 
5’ - GAG TAC AGG TGT GCA GCT CT - 3’ 
35 402 
 
 
  
 
     
 
Figure 4.2 – SRY gene expression to determine sex of mice embryos DNA from 
eight mice in whom the sex was previously known, and depicted above each lane of 
the PCR gel (♀= female; ♂ = male), was analysed for SRY gene expression by semi-
quantitative RT-PCR.  
 Blank  ♀   ♀    ♀    ♂    ♂    ♂    ♂   ♂ 
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4.4.4 Isolation of primary murine chondrocytes 
Primary cultures of chondrocytes from rib growth plates of 3-day old mice were 
prepared using the culture system developed by Lefebvre et al.
(204) 
The rib cage and 
sternum were dissected from nine 3-day old mice, rinsed in PBS, and incubated with 
pronase in PBS (2 mg/ml; DAKO, Glostrup, Denmark) for 30 minutes at 37°C, 
rinsed again with PBS and then incubated with bacterial collagenase (3mg/ml; 
collagenase D, Worthington type II) in DMEM at 37°C for about 90 minutes until all 
soft tissues detached from the cartilages with a few pipettings. Cartilages from male 
and female mice were pooled and carefully washed several times with PBS and 
separated from soft tissue residues. They were then digested with collagenase for 3 
hours in a petri dish, and undigested bony parts were discarded. Chondrocytes were 
pelleted by centrifugation and washed twice with DMEM. On average 1.1 x 10
6 
chondrocytes were obtained per mouse. 
 
4.4.5  Primary chondrocyte cell culture 
Chondrocytes were cultured in 24-well plates in a medium of DMEM: F12 without 
phenol red (Invitrogen) supplemented with 10% FBS (Invitrogen), gentamicin 
(50µg/ml Invitrogen) and ascorbic acid (10µg/ml). Cells were incubated at 37°C in a 
humidified atmosphere containing 95% air/5% CO2.  
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4.4.6  Chondrocyte proliferation assay 
E2 at a final concentration of 10
-10 
M, 10
-8 
M and 10
-6 
M was added to cells cultured 
in 24-well plates on day 2 and compared with control cultures which contained 
medium only. Faslodex, raloxifene and MPP were added to the cells at a final 
concentration of 10
-6 
M in 0.01% DMSO on day 2 and compared with control 
cultures which contained 0.01% DMSO only. The cells were then incubated for a 24 
hour period. The rate of chondrocyte proliferation was assessed by incubating the 
chondrocytes with 0.2µCi/ml [
3
H]thymidine (37MBq/ml; Amersham Pharmacia 
Biotech) for the last 4 hours of the incubation period and measuring the amount of 
radioactivity incorporated into trichloroacetic acid-insoluble precipitates.
(176)
 
 
4.4.7 Statistical analysis 
Data were analysed by ANOVA. All data are expressed as the mean ± SEM of at 
least six replicates within each experiment, and statistical analysis was performed 
using SPSS (version 15). Significance was determined as P<0.05. 
 
4.5       Results  
4.5.1 Longitudinal growth of foetal metatarsal culture system  
Foetal murine metatarsals grown in the presence of oestradiol, at a final 
concentration of 10
-6
 M or 10
-5 
M, paralleled control bone growth (Figure 4.3A, 
4.3B). Likewise, foetal murine metatarsals treated with Faslodex, at a final 
concentration of 10
-6 
M or 10
-5
 M, had unaffected growth compared to controls 
(Figures 4.3A, B). In a similar fashion, murine metatarsals exposed to raloxifene at a 
final concentration of 10
-5
 M had unaffected longitudinal growth (Figure 4.4).  
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Figure 4.3 – Effect of E2 or Faslodex on longitudinal growth of murine 
metatarsals isolated from 18-day old foetal Swiss mice (♦= control; ■ = E2; ▲ = 
Faslodex). A) After 14 days exposure at 10
-6
 M; B) After 13 days exposure at 10
-5
 M. 
Data are expressed as means ± SEM (n = 6). 
 
 A 
B 
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Figure 4.4 – Effect of Raloxifene on longitudinal growth of murine metatarsals 
isolated from the hind legs of 18-day old foetal Swiss mice and cultured for 14 days 
at  10
-5
 M  (♦= control; ● = Raloxifene; ▲ = Faslodex). Data are expressed as means 
± SEM (n = 6).  
 
 
Whereas, metatarsals treated with the combination of raloxifene and MPP, at a final 
concentration of 10
-5 
M, were significantly shorter than control bones from day 5 
onwards (Figure 4.5). Metatarsals treated with MPP alone, at a final concentration of 
10
-5 
M, also showed significant growth retardation (Figure 4.5). The combination of 
raloxifene and MPP inhibited metatarsal growth to a greater extent than MPP alone 
with the reduction in total length: 29% vs. 16% on day 3; 55% vs. 25% on day 5; 
57% vs. 23% on day 7; 68% vs. 41% on day 10 and 74% vs. 39% on day 14. There 
was no difference observed in response between metatarsals isolated from female 
and male embryos (Figure 4.6). 
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Figure 4.5 – Effect of Raloxifene, MPP or Raloxifene & MPP on longitudinal 
growth of murine metatarsals cultured over a 14-day period at 10-5 M (♦= control; 
● = Raloxifene ■ = MPP; ▲ = Raloxifene & MPP. Data expressed as at means ± 
SEM (n = 6). ***P<0.001 compared with controls. 
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Figure 4.6 – Effect of Raloxifene, MPP or Raloxifene & MPP on longitudinal 
growth of male or female murine metatarsals (♦= control; ● = Raloxifene ■ = 
MPP; ▲ = Raloxifene & MPP. Female metatarsals = broken line; male metatarsals = 
continuous line). Data expressed as means.  
*** 
*** 
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4.5.2 Mineralising zone growth of foetal metatarsal culture system  
After 14 days of culture E2, at a final concentration of 10
-6
 M and 10
-5
 M, had no 
effect on the length of the mineralising zone (Figure 4.7A, 4.7B). Whereas, 
metatarsals treated with Faslodex at a final concentration of 10
-6
 M showed a 
reduction of the length of the mineralising zone (17.2% reduction vs. control bones, 
P<0.05; Figure 4.7B). A greater reduction of the mineralising zone length was 
observed in metatarsals exposed to Faslodex at a final concentration of 10
-5
 M 
(50.9% reduction vs. control bones, P<0.001; Figure 4.7B). A reduction of the 
mineralising zone length was also observed in metatarsals treated with raloxifene and 
MPP alone at a final concentration of 10
-5
 M (36.1% and 22.2% reduction 
respectively vs. control bones, P<0.001; Figure 4.8A). In addition, a greater 
reduction was observed when these compounds were used in combination (65.2% 
reduction vs. control bones, P<0.001; Figure 4.8A).    
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Figure 4.7 – Effect of E2, Faslodex or Raloxifene on mineralising zone growth of 
metatarsals cultured over 14 days. Data are expressed as means ± SEM (n = 6). (A) 
Effect of E2 or Faslodex at 10
-6 
M *P<0.05 compared with controls.  (B) Effect of E2 
or Faslodex at 10
-5
 M ***P<0.001 compared with controls. (C) Effect of Faslodex or 
Raloxifene at 10
-5
 M ***P<0.001 compared with controls. 
   * 
***  *** 
 A 
B 
 *** 
C 
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Figure 4.8 – Effect of MPP, Raloxifene or Raloxifene & MPP on mineralising 
zone growth of metatarsals at 10-5 M from 18-day old foetal Swiss mice cultured 
over 14 days. (A) Data expressed as means ± SEM (n = 6). ***P<0.001 compared 
with controls. (B) Digital image of a control metatarsal (control) and metatarsals 
treated with Raloxifene (Ral), MPP and the combination of Raloxifene & MPP (Ral 
& MPP) after 14 days exposure. 
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*** 
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4.5.3 Primary murine chondrocytes  
Primary murine chondrocytes are reported to retain their differentiated phenotype in 
culture for several days. This is demonstrated in the primary murine chondrocytes 
used in these experiments as they show positive staining with Alcian Blue on day 10 
of culture reflecting the deposition of cartilage matrix (Figure 4.9). 
  
 
              
 
 
                    
               
 
Figure 4.9 – Primary murine chondrocytes after Alcian Blue staining (A) Naked 
eye view on day 10 after 18 hours exposure to Alcian Blue (B) Magnified view  
 
E2 exposure for 24 hours at a final concentration of 10
-10 
M, 10
-8 
M and 10
-6 
M had 
no effect on primary murine chondrocyte proliferation as analysed with 
[
3
H]thymidine incorporation on day 3 of culture (Figure 4.10).  
A   
B    
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Figure 4.10 – Effect of E2 on primary murine chondrocyte proliferation as 
assessed by [
3
H]thymidine uptake after 24 hour exposure. Data are expressed as 
means ± SEM (n=6).  
 
Exposure of the primary chondrocytes to Faslodex, the non-specific ER antagonist, at 
a final concentration of 10
-6
 M for 24 hours resulted in a decrease in proliferation 
(10% reduction vs. control, P<0.001; Figure 4.11). A similar reduction in cell 
proliferation was observed after 24 hour exposure to raloxifene and MPP in 
combination at a final concentration of 10
-6 
M (11% reduction vs. control, P<0.001; 
Figure 4.11).  
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Figure 4.11 – Effect of Faslodex or Raloxifene & MPP on primary murine 
chondrocyte proliferation as assessed by [3H]thymidine uptake after 24 hour 
exposure at 10
-6
 M. Data are expressed as means ± SEM (n = 6). ***P<0.001 
compared with control cells. 
 ***  *** 
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4.6      Discussion 
Exogenous E2, at a final concentration of 10
-6
 M or 10
-5
 M, had no effect on 
longitudinal growth in the foetal murine metatarsal culture model. Similarly, 
blocking the effect of endogenous E2 with Faslodex, the non-specific ER antagonist, 
also did not affect linear growth. A similar pattern of growth was observed in 
metatarsals obtained from female and male embryos. Chagin et al have also 
investigated the effect of E2 and Faslodex on the growth of the foetal rat metatarsal 
culture system and their findings were published during the completion of this 
project.
(129) 
Their experiments were performed in a very similar fashion: the three 
middle metatarsals were dissected from the hind legs of 20-day old rat embryos and 
cultured for 19 days in serum-free medium. They found no effect of E2 on 
longitudinal growth at a final concentration of 10
-8
 M or 10
-6
 M. Metatarsals derived 
from both male and female embryos showed no response to E2. After 7 days of 
culture ERα and ERβ were widely expressed within the metatarsals and associated 
mainly with resting and proliferative chondrocytes. Whereas, aromatase P450 (key 
enzyme in oestrogen synthesis) was mainly expressed in hypertrophic chondrocytes. 
In contrast to our findings they found that Faslodex, at a final concentration of 10
-5 
M, reduced linear growth significantly after 7 days of culture. This response was 
concentration-dependent as exposure to Faslodex at a final concentration of 10
-6
 M 
had no effect. After exposure to Faslodex they found a relative decrease of intensity 
of IGF-1, IGF-2 and IGF-1Rβ immunostaining. The response to Faslodex in the 
foetal rat metatarsal culture system therefore differed to that observed in the mouse 
system. As the methodology was remarkably similar between the two studies it 
suggests that the discordant responses are likely due to species differences. It is the 
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only published report of the effect of E2 on metatarsal organ culture. Other groups 
have described the effect of E2 on culture of the mandibular condyle, as an 
alternative model of endochondral ossification. Talwar et al described the effects of 
E2 on the postnatal rat mandibular condyle culture system.
(205) 
Mandibular condyles, 
obtained from 8-week old female rats, were exposed to E2 at 10
-8
 M in the presence 
of 10% FBS and cultured for 4 days. E2-treated condyles had a significant decrease 
in total cartilage thickness and mitotic index. There was an associated increase in 
type X collagen deposition into the extracellular matrix in the hypertrophic zone in 
the E2-supplemented group after 2 days. Similar results in the rat mandibular 
condyle culture system were described by Ng et al.
(206)
 Female-derived rat condyles 
exposed to E2 at 10
-8
 and 10
-6 
M for 4 days had a qualitative decrease in hypertrophic 
chondroblasts, thickness of condylar cartilage and significant decrease in 
proteoglycan production. The effects of E2 on the mouse mandibular condyle culture 
system have also been reported.
(124)
 Condyles obtained from 3.5 to 5.5 week old male 
and female mice were cultured in media supplemented with 2% FBS and exposed to 
E2, testosterone or DHT at a final concentration of 10
-8
 M for 3 days. The sex 
steroids had a direct stimulatory effect on DNA synthesis (thymidine uptake) which 
was sex-specific with male-derived condyles responding maximally to testosterone 
and female-derived condyles to E2. The E2-induced stimulation of proliferation in 
female-derived condyles was dependent on age with an increase of 80% observed at 
4 weeks of age compared to only 40% at 5 weeks of age. In spite of the E2-induced 
stimulation of proliferation E2-treated male-derived condyles were 25% smaller than 
controls on morphometric analysis (data not shown for female-derived condyles). 
Thus, the effect of E2 on the proliferation of the mandibular condyle culture system 
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differed between the two species. This could be due to differences in species, age of 
the animals (3.5-5.5 week old mice compared to 8 week old rats) or experimental 
conditions. Further, the mandibular condyle may not be the most suitable model for 
investigating the effect of E2 on linear growth as there are differences reported 
between the process of endochondral ossification in condyles and in long bones in 
mice.
(207)
   
 
We found no effect of raloxifene on the linear growth of the foetal murine metatarsal 
model. There are no other reports of the effect of raloxifene on GP chondrocytes in 
vitro. The only published data of the effects of raloxifene on longitudinal bone 
growth are two studies which describe the effects of raloxifene in vivo on OVX 
rabbits
(208) 
and rats.
(209)
 Nilsson et al found that raloxifene had E2-like effects on the 
GP of OVX rabbits. Both E2 and raloxifene inhibited GP function and led to a 
decrease in chondrocyte proliferation and rate of longitudinal bone growth. 
Raloxifene had E2-like effects on the structure of the GP with a decrease in GP 
height, decrease in the number of proliferative and hypertrophic cells per column and 
decrease in terminal hypertrophic cell height. Both raloxifene and E2 hastened 
epiphyseal fusion.
(208)
 Evans et al also found an E2-like reduction in longitudinal 
bone growth compared to sham-operated control rats.
(209)
 Raloxifene acts as an E2-
agonist at the growth plate and as E2 had no effect on linear growth it is perhaps to 
be expected that raloxifene would similarly have no effect on the murine foetal 
metatarsal culture system. When raloxifene, a SERM with higher ERβ binding 
affinity, was co-incubated with a specific ERα antagonist (MPP) there was a marked 
reduction in linear growth suggesting that ERβ agonists inhibit linear growth in mice. 
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This inhibitory effect of ERβ on longitudinal growth is supported by the findings of 
Chagin et al in female knock-out mice models (see Table 1.1).
(147)
 Young adult 
BERKO mice showed an increase in axial and appendicular skeletal growth 
suggesting that ERβ inhibits skeletal growth in young adult female mice. 
Interestingly, the growth plates were consistently fused in the appendicular skeleton 
of 18-month-old ERKO mice. The growth plate fusion that occurred in αERKO mice 
must be mediated through ERβ because old DERKO (ERα-/-β-/-) mice displayed 
unchanged, unfused growth plates. Both of these knockouts have supra-physiological 
serum levels of E2 due to disturbed feedback regulation. In addition, exposure of the 
foetal murine metatarsals to MPP alone led to a reduction in longitudinal growth. As 
MPP is a specific ERα antagonist
75
, it suggests that ERα agonists stimulate growth in 
mice. This is in accordance with female ER knock-out mice models where ERKO 
mice (ERβ present) have reduced femur length compared to BERKO mice (ERα 
present).
(147) 
There are no previous reports of the effect of raloxifene and MPP on 
longitudinal bone growth either in vivo or in vitro.  
 
Exogenous E2, at a final concentration of 10
-6 
M and 10
-5
 M, did not alter the growth 
of the mineralising zone of the metatarsals. However, blocking the effect of 
endogenous E2 with Faslodex led to a reduction in the growth of the mineralising 
zone. This effect was concentration-dependent with a greater reduction observed in 
metatarsals exposed to Faslodex at a final concentration of 10
-5
 M. Interestingly, both 
raloxifene and MPP alone, at a final concentration of 10
-5
 M, led to a reduction in 
mineralising zone length with a more marked reduction when used in combination. 
As raloxifene is principally an ERβ agonist and MPP an ERα antagonist this suggests 
  
 
Chapter 4                                                 Effect of E2 on physiological murine models  
 
    
 90 
that ERα stimulates mineralisation whereas ERβ inhibits it. As the total metatarsal 
length was unchanged, this suggests that one or more of the zones must be increased 
in size to compensate for the reduction in the length of the mineralising zone. There 
may be an increase in the size of the hypertrophic zone as fewer chondrocytes are 
undergoing terminal differentiation. Endogenous E2 may play an important role in 
the terminal differentiation of chondrocytes.  
 
In primary murine chondrocytes exposure to E2 had no effect on cell proliferation. 
This is in agreement with the findings in the murine ATDC5 chondrocyte cell line in 
chapter 2. Whereas, a reduction in cell proliferation was observed after exposure to 
Faslodex, the non-specific ER antagonist, suggesting that endogenous E2 may be 
important in the maintenance of murine chondrocyte proliferation in monolayer 
culture. Exposure to raloxifene and MPP in combination also led to a reduction in 
primary murine cell proliferation.  
 
4.7     Conclusions 
Exposure to exogenous E2 had no effect on either physiological model of murine 
growth.  However, endogenous E2 appears to be important for maintaining cell 
proliferation in monolayer culture of primary murine chondrocytes but is not a 
prerequisite for normal longitudinal growth in the murine foetal metatarsal culture 
system. However, Faslodex did significantly reduce the length of the mineralising 
zone in the metatarsal culture system suggesting that endogenous E2 plays a role in 
mineralisation which may involve the terminal differentiation of hypertrophic 
chondrocytes within the growth plate. The mineralising zone was also reduced after 
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exposure to the selective ERα antagonist, MPP, suggesting that E2 may mediate its 
effect on mineralisation via ERα. The classical ERs appear to have opposing roles in 
the control of linear growth and mineralisation of the foetal murine metatarsal culture 
system.  The data suggest that ERα stimulates growth and mineralisation whereas 
ERβ inhibits them.  
  
 
Chapter 5                              Investigation of growth inhibition by Raloxifene & MPP 
 
    
 92 
 
 
Chapter 5 
Investigation of growth inhibitory 
effect of Raloxifene & MPP 
 
 
Chapter Contents 
5.1 Introduction 
5.2 Hypothesis 
5.3 Aims  
5.4 Materials and Methods  
 5.4.1 ATDC5 cell culture 
 5.4.2 Western blotting analysis 
5.5 Results 
5.6 Discussion 
5.7 Conclusions 
 
  
 
Chapter 5                              Investigation of growth inhibition by Raloxifene & MPP 
 
    
 93 
5.1 Introduction 
In chapter 4 it was observed that treatment with raloxifene and MPP in combination 
led to retardation of longitudinal growth in the foetal murine metatarsal culture 
system. In the absence of readily available primary chondrocytes the ATDC5 cell 
line is an excellent model to investigate the molecular mechanisms causing growth 
restriction in metatarsals exposed to raloxifene and MPP. It has previously been 
established that the ATDC5 cell line undergoes the temporal sequence of events that 
occur during longitudinal bone growth in vivo.  
 
It has been described previously that different growth plates within the same animal 
grow at different rates.
(210) 
These differences in growth velocity are mainly due to the 
duration of the G1 phase in proliferating chondrocytes
(211)
 which suggests that cell 
cycle genes regulating G1 progression are of crucial importance in regulating 
endochondral bone growth. Progression through the cell cycle is controlled by 
cyclin-dependent kinases (CDKs) and changes in their activity can alter chondrocyte 
proliferation at three different points.
(212)
 Firstly, increased CDK activity is required 
to accelerate proliferation when cells enter the proliferative zone of the growth plate; 
secondly, changes in CDK activity can affect the speed of cell cycle proliferation and 
thus proliferation in the proliferative zone and thirdly inhibition of CDK activity is 
necessary for exit of the cell cycle upon onset of hypertrophic differentiation. The 
regulators of the G1 phase, which include cyclin D1 and p21, have been shown to be 
targets of both extracellular and intracellular signalling pathways during cartilage 
development. Within the growth plate, cyclin D1 is specific for the proliferative zone 
at the mRNA
(213)
 and protein levels
(214)
 and multiple mitogenic stimuli seem to 
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converge on cyclin D1 gene. The cyclin E gene controls the G1/S transition in a 
complex with CDK2 and is also a target of mitogenic signalling in chondrocytes. p21 
is one of seven CDK inhibitors. p21 gene expression is controlled by several 
different pathways which include:  FGF signalling through STAT-1
(215-217)
 thyroid 
hormone
(218)
, bone morphogenetic protein (BMP)-2
(219)
, SOX-9
(220)
 and signalling 
through the c-Raf/MEK/ERK MAP kinase cascade.
(221;222)
  
 
E2 is a potent mitogen in a number of target tissues including the mammary gland 
where it plays a critical role in the development and progression of breast carcinoma. 
This E2-induced mitogenesis has been shown to be associated with the recruitment 
of non-cycling, G0 cells into the cell cycle and an increased rate of progression 
through G1 phase. Further studies have elucidated that E2 regulates the expression 
and function of the cell cycle proteins, c-Myc and cyclin D1, and activates cyclin E-
CDK2 complexes, all of which are rate limiting for progression from G1 to S 
phase.
(223;224)
  
 
5.2 Hypothesis 
It was hypothesised that raloxifene and MPP in combination may have an inhibitory 
effect on cell cycle progression and reduce G1/S phase transition. 
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5.3 Aims 
To assess the effect of raloxifene and MPP alone and in combination on the cell 
cycle proteins: cyclin D1, cyclin E, c-Myc and p53 in ATDC5 chondrocytes using 
Western blotting analysis.  
 
5.4 Materials and methods   
5.4.1 ATDC5 cell culture 
ATDC5 cell culture was performed as described in chapter 2 (2.4.2). On the second 
day of culture, ATDC5 cells were treated with raloxifene, MPP or raloxifene & MPP 
at a final concentration of 10
-6 
M in 0.01% DMSO. Control cells received 0.01% 
DMSO. The cells were then cultured for a further 48 hours.  
 
5.4.2 Western blotting analysis  
ATDC5 cells were lysed on day 4 in PhosphoSafe extraction buffer (Merck 
Chemicals Limited, Nottingham, UK) and protein concentration measured as 
previously described (2.4.4). Lysates (corresponding to 25 µg protein) were run on 
10%
 
Bis–Tris gels (Invitrogen) and transferred onto a nitrocellulose
 
membrane. The 
membranes were blocked with 5% non-fat dry milk
 
in Tris-buffered saline/Tween-20 
(TBST; 50 mM Tris–HCl,
 
300 mM NaCl, 0.1% Tween-20, pH 7.6) at 4°C overnight 
with
 
gentle shaking. The membranes were probed for 1 hour at room temperature
 
with primary antibodies raised in mouse against cyclin D1, c-Myc, and p53 (1:500 
dilution in 5% milk) and raised in rabbit against cyclin E (1:500 dilution). β-actin 
expression was also measured as a loading control (1:5000 dilution in 5% milk). The 
blots were washed four times in TBST, each wash lasted 15 minutes. The membranes
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were then incubated with goat anti-mouse or anti-rabbit secondary antibody for 1 
hour (1:5000 dilution in 5% milk). The antibodies used are listed in Tables 5.1 and 
5.2. The membranes
 
were washed, as described above, and developed using the 
electrogenerated
 
chemiluminescent labelling (ECL)-plus Western Blotting Detection
 
System (Amersham Biosciences).
  
 
 
Table 5.1 – Primary antibodies used for western blotting analysis 
Protein Antibody Source Dilution 
  
Cyclin E Rabbit polyclonal  AbCam 1:100 
Cyclin D1 Mouse monoclonal  AbCam 1:200 
C-Myc Mouse monoclonal  AbCam 1:500 
p53 Mouse monoclonal  AbCam 1:500 
β-actin Mouse monoclonal  Sigma 1:5000 
 
 
 
 
Table 5.2 – Secondary antibodies used for western blotting analysis 
Protein Antibody Source Dilution 
  
Cyclin E Goat anti-rabbit IgG 
peroxidase 
Cell Signalling 
Technology 
1:5000 
Cyclin D1 Goat anti-mouse IgG 
peroxidase 
Sigma 1:5000 
C-Myc Goat anti-mouse IgG 
peroxidase 
Sigma 1:5000 
p53 Goat anti-mouse IgG 
peroxidase 
Sigma 1:5000 
β-actin Goat anti-mouse IgG 
peroxidase 
Sigma 1:5000 
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5.5 Results 
Expression levels of the cell cycle proteins, cyclin E, cyclin D1, C-Myc and p-53, 
were determined by Western blotting analysis using polyclonal or monoclonal 
antibodies. A control housekeeping protein, β-actin, was used to indicate the relative 
levels of the protein loaded on to the gel. Exposure of ATDC5 cells to raloxifene and 
MPP in isolation, for 48 hours at a final concentration of 10
-6 
M, had no effect on the 
cell cycle proteins: cyclin E, cyclin D1, C-Myc and p-53 compared to control cells 
(Figure 5.1). Whereas exposure of the ATDC5 cells to raloxifene and MPP in 
combination, for 48 hours at a final concentration of 10
-6 
M, led to a reduction in 
both cyclin E and p-53 protein levels. Cyclin D1 and c-Myc were unaffected by 
raloxifene and MPP treatment (Figure 5.1).   
 
Figure 5.1 – Western blot: Effect of Raloxifene, MPP or Raloxifene and MPP on 
cell cycle proteins compared to control ATDC5 cells (C) after 48 hours exposure at 
10
-6
 M.  
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5.6 Discussion  
The levels of the cell cycle proteins were unchanged in the ATDC5 cells treated with 
raloxifene or MPP alone. However, when the cells were exposed to the same 
compounds in combination a decrease in cyclin E and p53 protein levels were 
observed. Cyclin E specifically regulates the G1/S phase transition of the cell cycle. 
A high level of cyclin E accelerates the transition of the cell through the G1 phase 
and is of prognostic value in breast cancer, with high levels of cyclin E in the tumour 
correlating with a poorer outcome and low levels with a good outcome.
(225) 
The G1/S 
phase cell cycle check point controls the commitment of cells to transition through 
the “gap” phase (G1) and enter into the DNA synthesis phase (S). Two cell cycle 
kinase-complexes, CDK4/6-cyclin D and CDK2-cyclin E, work in collaboration to 
relieve inhibition of a dynamic transcription complex that contains the 
retinoblastoma protein, Rb, and the transcription factor, E2F. Several different 
stimuli exert control over the checkpoint acting through transcription factors to 
induce specific members of the INK4 or KIP/CIP families of CDK inhibitors (Figure 
5.2). p15, p16, p18 and p19 are members of the INK4 tumour suppressor family and 
exert control over the CDK4/6-cyclin D complex whereas p21 and p27 influence the 
CDK2-cyclin E complex. As exposure of ATDC5 cells to raloxifene and MPP in 
combination led to a decrease in cyclin E protein levels but did not alter cyclin D 
levels it suggests that the effects of Raloxifene and MPP may be mediated by the 
CDK inhibitors p21 or p27. These findings suggest a possible mechanism for the 
growth retardation observed in the foetal metatarsal culture system exposed to 
raloxifene and MPP. As MPP is a specific ERα antagonist and raloxifene is mainly 
an ERβ agonist it is likely that the effects are mediated by ERβ. Similar findings 
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have been reported in the HCT8 human colon cancer cell line where over-expression 
of ERβ inhibited cell proliferation through regulation of cell cycle components. 
Investigation of the cell cycle showed a decrease in cyclin E and an increase in the 
CDK inhibitor p21 which was similar to our findings. Flow cytometry analysis 
provided evidence for blocking of the G1/S phase progression which was induced by 
ERβ over-expression.  Further, the magnitude of this effect was affected by the level 
of ERβ over-expression.
(202)
 Therefore ERβ may regulate cell proliferation through 
the control of key cell cycle modulators and arrest in G1/S phase transition in 
chondrocytes as well as in colonic cells.  
 
 5.7 Conclusions 
Exposure of ATDC5 chondrocyte cells to raloxifene or MPP in combination led to a 
decrease in the cell cycle proteins cyclin E and p53. The decrease in cyclin E could 
reflect a decrease in progression of the G1/S phase in the cell cycle. Therefore, ERβ 
may regulate cell proliferation in chondrocytes through the control of key cell cycle 
modulators.  
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Figure 5.2 – Control of the G1/S cell cycle checkpoint  
Pathway diagram reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com) 
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6.1      Introduction 
In chapter 4 it was observed that E2 treatment had no effect on the mineralising zone 
length of the foetal murine metatarsal model whereas Faslodex led to a reduction in 
the mineralising zone length but with no effect on overall longitudinal growth. As the 
calcium concentration of bone is a reflection of the amount of mineralisation that has 
occurred a measure of the calcium concentration of metatarsals treated with E2 and 
Faslodex would be invaluable. A reduction in the calcium concentration of 
metatarsals treated with Faslodex in support of the findings from the murine 
metatarsal culture system would be expected. Anderson et al describe a highly 
sensitive and simple assay which is an alternative to the routinely used radiometric 
biomineralisation assay which employs radioactive 
4.5
Ca.
(226)
 In addition, as the well 
established ATDC5 chondrocyte cell line has been shown to undergo the temporal 
sequence of events that occur during longitudinal bone growth in vivo it provides an 
excellent model to investigate the possible enzymatic mechanisms leading to the 
reduction in mineralising zone length observed in metatarsals treated with Faslodex.  
 
6.2 Aims 
 
I. Analyse the calcium content of metatarsals treated with E2 and the non-
specific ER antagonist Faslodex 
 
II. Investigate the effect of the E2-related chemicals, Faslodex and raloxifene on 
ALP activity of ATDC5 cells during terminal differentiation 
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6.3 Materials and methods 
6.3.1 Foetal metatarsal organ culture 
The metatarsals were treated with Faslodex or E2, at a final concentration of 10
-5 
M, 
in 0.1% ethanol for 14 days as described in chapter 4 (4.4.1). Control metatarsal 
bones received 0.1% ethanol only. At the end of the culture period the metatarsals 
were washed with sterile PBS and stored at -20°C until analysis.  
 
6.3.2 5on-radioactive calcium phosphate deposition assay 
Each metatarsal was placed in a glass vial with 1 ml of 0.6N HCl and solubilised for 
24 hours. The calcium content of the HCl supernatant was then determined 
colorimetrically by the O-cresolpthalein complexone method (Calcium Kit, 
Sigma).
(226)
 Five standards of calcium were prepared, ranging from 0.6125 mM to 10 
mM, from a calcium standard (10mg/dl, Calcium kit). 2 µl of calcium standard or 
sample (acidified supernatant) was incubated with 200 µl of calcium working reagent 
(Colour Reagent and Base Reagent Mix). The 96-well plate was then incubated at 
room temperature for 1 minute and the absorbance read at 570 nm using a microplate 
reader. The absorbencies of the samples were compared to a standard curve generated 
from the absorbencies from the standards. 
 
6.3.3 ALP activity in ATDC5 chondrocytes 
ATDC5 cell culture was performed as described in chapter 2 (2.2.2). Faslodex or 
raloxifene were added to ATDC5 cells at day 13, at a final concentration of 10
-6 
M, 
and the cells were then incubated for 7 days. For analysis of ALP activity, cells were 
rinsed with PBS and lysed with 0.9% NaCl and 0.2% Triton-X 100 and centrifuged 
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at 12000g for 15 minutes at 4°C. The supernatant was assayed for protein content 
and ALP activity as a measure of cell number and chondrocyte differentiation, 
respectively. The protein content of the supernatant was measured as described in 
chapter 2 (2.4.3). Enzyme activity was determined by measuring the cleavage of 
10mM p-nitrophenyl phosphate (pNPP) at 410nm. Total ALP activity was expressed 
as nmoles pNPP hydrolysed/min/mg protein.
(176) 
 
6.3.4 Statistical analysis 
Data were analysed by ANOVA. All data are expressed as the mean ± SEM of at 
least six replicates within each experiment, and statistical analysis was performed 
using SPSS (version 15). Significance was determined as P <0.05. 
  
 
Chapter 6                                                                        Effect of E2 on mineralisation 
 
    
 105 
6.4 Results 
6.4.1  Calcium content of metatarsals treated with Faslodex or E2 
Exposure to E2 for 14 days, at a final concentration of 10
-5 
M, had no effect on the 
calcium concentration in the metatarsal bones whereas Faslodex, at a final 
concentration of 10
-5 
M, caused a reduction in the calcium concentration (Figure 6.1). 
After the calcium assay was performed the mineralising zones were no longer 
present in the metatarsal bones demonstrating that the calcium mineral has been 
leached (Figure 6.2). 
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Figure 6.1 – Effect of E2 or Faslodex on calcium concentration of metatarsals 
from 18-day old foetal Swiss mice cultured over 14 days at 10
-5
 M as assessed by 
calcium assay. (A) Data are expressed as means ± SEM (n = 6). *P<0.05 compared 
with control metatarsals. (B) Digital image of a control metatarsal on day 14 of 
culture (I) and after the calcium assay was performed (II). 
   * 
 I II 
A 
B 
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6.4.2 ALP activity in ATDC5 cells treated with Faslodex or Raloxifene 
After 7 days of exposure both Faslodex and Raloxifene, at a final concentration of 
10
-6 
M, reduced ALP activity of ATDC5 chondrocytes during terminal differentiation 
compared to control cells (Figure 6.2).  
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Figure 6.2 – Effect of Faslodex or Raloxifene on ALP activity in ATDC5 cells 
(nmoles pNPP hydrol/min/mg protein) after 7 days exposure at 10
-6
 M. Data are 
expressed as means ± SEM (n = 6). **P<0.01 compared with control cells.  
 
 
6.5 Discussion 
The foetal murine metatarsals exposed to Faslodex showed a reduction in calcium 
concentration when compared with control bones after 14 days in culture. These 
findings are in accordance with the data obtained from the foetal metatarsal culture 
system where Faslodex treatment led to a reduction of the mineralising zone length. 
Exogenous E2 had no effect on the mineralisation of foetal metatarsals with an 
unchanged mineralising zone length and calcium concentration after 14 days of 
    **  ** 
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culture. In contrast, a reduction in mineralisation was observed when endogenous E2 
action was blocked with the non-specific ER antagonist, Faslodex suggesting that 
endogenous E2 is important for mineralisation. As the overall length of metatarsals 
treated with Faslodex was not affected it suggests that the proliferative and/or the 
hypertrophic zones of the metatarsals are increased following the withdrawal of E2 
action by Faslodex. There may be an increase in non-mineralised hypertrophic 
chondrocytes. Exposure of the ATDC5 chondrocyte cell line to Faslodex or 
raloxifene led to a reduction in ALP activity during terminal differentiation as 
compared to control cells. Whereas, exposure to exogenous E2 did not alter the ALP 
activity of ATDC5 chondrocytes as previously described in chapter 2. The process 
by which chondrocytes mineralise their extracellular matrix is complex and tightly 
controlled both temporally and spatially and is limited to a few layers of hypertrophic 
chondrocytes at the chondro-osseous border. Terminally differentiated hypertrophic 
chondrocytes are characterised by an increase in intracellular calcium concentration 
which is essential for the production of matrix vesicles. These small membrane-
enclosed particles are released from chondrocytes
(227;228)
 and allow calcium 
phosphate precipitation into mineral crystals. However, the mechanisms regulating 
matrix mineralisation are not completely understood and it is still unclear whether it 
is an active process effected by the presence of promoters of mineralisation or a 
passive process occurring in the absence of mineralisation inhibitors.
(229) 
However, it 
is clear that mineralisation of the matrix is a biphasic process with the first phase 
occurring completely within the matrix vesicle and is dependent on the attainment of 
sufficiently high concentrations of inorganic phosphate for the formation of de novo 
hydroxyapatite crystals. The generation of the inorganic phosphate was previously 
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attributed to the actions of ALP
(230)
 whereas it is now evident that other phosphatases 
also play a role, such as pyrophosphatase, 5’AMPase, and ATPase and the recently 
described PHOSPHO1, which are known to be present in matrix vesicles.
(230-233)
 In 
addition, ALP has been localised to the outer surface of the matrix vesicle and has 
been shown to act as a pyrophosphatase in vivo. During the second phase, the 
mineral crystals pierce the matrix vesicle membrane and enlarge with the addition of 
calcium and phosphate ions present in the extravesicular space. These mineral 
sphericules associate closely to collagen fibrils. The process of mineralisation, along 
with the low oxygen tension, attracts blood vessels from the underlying primary 
spongiosa.(234) Thereafter, the remaining hypertrophic chondrocytes undergo apoptosis, 
which leaves a scaffold for new bone formation. ALP is therefore a matrix vesicle 
associated phosphatase which is involved in mineralisation along with other 
phosphatases. Thus, the reduction observed in the mineralisation of foetal murine 
metatarsals treated with Faslodex or raloxifene could be due to a direct effect on 
ALP activity or alternatively the decrease in ALP levels could represent a decrease in 
differentiation of the chondrocytes. A reduction in the mineralisation of foetal 
murine metatarsals is also reported after exposure to the glucocorticoid 
dexamethasone however a reduction in overall growth is also seen with a non-
significant increase in hypertrophic zones. Whereas, metatarsals exposed to IGF-1 
show a reduction in mineralisation along with an increase in overall length and size 
of hypertrophic zones.  
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6.6 Conclusions 
Foetal murine metatarsals exposed to Faslodex, the non-specific ER antagonist, 
showed a reduction in calcium concentration after 14 days exposure. Faslodex-
treated metatarsals had been shown to have normal longitudinal growth but a reduced 
mineralising zone growth in chapter 4. In the ATDC5 cell line exposure to Faslodex 
or raloxifene during terminal differentiation led to a reduction in ALP activity. Thus, 
the decrease in mineralisation observed in murine metatarsals treated with Faslodex 
or raloxifene could be due to a direct effect on ALP activity or it may reflect a 
decrease in chondrocyte differentiation.  
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7.1      Introduction 
During the first ten weeks of development, the primordial germ cells undergo 
multiple mitotic divisions and differentiate into primordial follicles. The primordial 
follicle consists of a primary oocyte surrounded by a layer of spindle-shaped 
granulosa cells. A primary oocyte is an oocyte that has not yet undergone its first 
meiotic division. Primordial follicles continue to multiply by mitosis and girls are 
endowed with their maximum number of 6-7 million at approximately 20 weeks of 
gestation.
(235)
 Before birth, the primary oocytes enter a final round of DNA synthesis 
and are then arrested in prophase of the first meiotic division until shortly before 
ovulation. Thereafter, there is a gradual decrease in the number of follicles due to 
atresia, which is independent of ovulation. At birth, the number of follicles has 
decreased to 700 000 and fallen further to 400 000 at the time of puberty. Each 
month the antral or Graafian follicle, a completely new secretory structure, develops 
within the ovary from a primordial follicle. The persistent atresia of oocytes together 
with monthly ovulation leaves few follicles remaining at menopause.
(236)
  
Menopause, defined as the permanent cessation of menses, is due to the depletion of 
potentially functional primordial follicles and usually occurs at a mean age of 50 
years.
(237)
 If menopause occurs before the age of 40 years it is considered to be 
premature. In view of the constant oocyte atresia, early menopause could occur in 
any female who begins life with a decreased number of follicles, or experiences 
accelerated follicle apoptosis or destruction. This condition is now referred to as 
primary ovarian insufficiency (POI) in preference to previous nomenclature 
(premature menopause, premature or primary ovarian failure, hypergonadotrophic 
hypogonadism).
(238;239)
 POI is said to exist when a woman who is less than 40 years 
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old has amenorrhea for 4 months or more, with two serum FSH levels obtained at 
least 1 month apart within the menopausal range.
(240;241) 
POI differs from menopause 
in that the ovarian function is variable and unpredictable in 50% of cases, and 
approximately 5 to 10% of women conceive and deliver a child after the diagnosis 
has been made.
(240;242-245)
 Thus, POI includes a continuum of impaired ovarian 
function rather than a dichotomous state.
(238)
 In the majority of women diagnosed 
with spontaneous POI the cause remains unclear. However, spontaneous POI in 
46,XX individuals can occur as part of a syndrome while many single genes (bone 
morphogenetic protein 15, diaphanous homolog 2, and inhibin alpha subunit) have 
been associated with non-syndromic POI. Structural abnormalities in the X 
chromosome apart from specific gene mutations are also implicated. POI occurs 
through two principal mechanisms: follicle depletion and follicle dysfunction.
(241)
 
Follicle depletion signifies that no primordial follicles remain in the ovary. This may 
be due to an inadequate initial pool of primordial follicles in utero, accelerated 
expenditure of follicles or destruction of follicles (see Table 7.1). By contrast, the 
term follicle dysfunction indicates that follicles remain in the ovary but a 
pathological process is preventing their normal function (see Table 7.2).  
 
The most common genetic condition associated with POI is Turner syndrome (TS) 
and is the result of follicle depletion. Girls with TS have a normal quantity of oocytes 
until the third month of gestation, but apoptosis is then accelerated
(246-248)
 usually 
resulting in the depletion of oocytes by the first decade of life. Therefore, only 10% 
of TS women reach menarche. However, patients with 45,X/46,XX mosaicism 
comprising a normal second X chromosome in the 46,XX cell line are more likely to 
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menstruate (40%) and may not develop overt POI for many years. Undetected X 
chromosome mosaicism could explain some cases of spontaneous POI.
(249) 
The cause 
of the ovarian dysfunction remains unclear despite the identification of a critical 
region of the X chromosome for ovarian development and function (Xq13 to Xq26 
with the exception of Xq22).
(250)
  
 
Table 7.1 – Causes of ovarian follicular depletion  
Adapted from Nelson et al, 2009
(239)
 
 
Cause 
 
Findings Gene Identification 
(location) 
Insufficient follicle number 
Blepharophimosis, 
ptosis, epicanthus 
inversus syndrome 
(BPES) 
Familial POI; Pervasive block in primordial 
follicle development in knockout mouse 
FOXL2 
Forkhead transcription 
factor (3q23) 
Spontaneous accelerated follicle loss    
Turner syndrome
   
Normal pool of primordial follicles 
established in foetal ovary but accelerated 
apoptosis of follicles usually depletes stores 
before puberty; in oocytes, both X 
chromosomes must be present and active to 
prevent accelerated follicular atresia; 
individual genes responsible not identified 
 
Metabolic-toxin-induced follicle loss 
Galactosaemia Abundant, normal appearing follicles in 5-
day-old infant but rare follicles, fibrous-streak 
stroma, and immature-hyalinised follicles in 
post-pubertal females  
GALT 
Galactose-1-phosphate 
Uridylyltransferase 
(9p13) 
Iatrogenic 
Surgery 
 
 
 
 
Chemotherapy  
 
 
 
 
 
Radiotherapy 
After unilateral oophorectomy women have 
higher FSH levels and poorer response to 
ovarian stimulation and an earlier menopause 
than women with two ovaries  
 
8% of childhood cancer survivors at 18y 
develop POI; associated factors include: 
Hodgkin’s lymphoma, alkylating agents 
(cyclophosphamide/procarbazine), and older 
age at diagnosis (>12y)  
 
30% develop POI when treated with radiation 
and alkylating agents in combination. POI is > 
50% in women >21y treated with alkylating 
agents and almost 100%, regardless of age, in 
women undergoing preparation for bone 
marrow transplantation 
 
Environmental-toxin–induced follicle loss 
Industrial exposure to  
2-bromopropane 
POI in 16 Korean women exposed to cleaning 
solvent  
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Table 7.2 – Causes of ovarian follicular dysfunction 
Adapted from Nelson et al, 2009
(239)
  
 
 
Cause 
 
Findings Gene Identification 
(location) 
Signal defect 
FSH-receptor mutation 
 
 
 
 
LH-receptor mutation 
 
 
 
G-protein mutation 
Primary amenorrhoea, small ovaries and 
elevated FSH levels; presence of ovarian 
follicles on biopsy; rare except in Finland 
(founder effect) 
 
Primary amenorrhoea, low E2, elevated LH 
levels and cystic ovaries; ovarian follicles on 
ultrasound 
 
Secondary amenorrhea, high LH/FSH and 
low E2 levels that responded to 
gonadotrophin in pseudohypoparathyroidism 
FSHR 
FSH receptor 
(2p21-p16) 
 
 
LHCGR 
LH/choriogonadotrophin 
receptor (2p21) 
Enzyme deficiency 
Isolated 17,20-lyase 
deficiency 
 
 
Aromatase deficiency 
 
 
 
 
Lipoid congenital 
adrenal hyperplasia 
Primary amenorrhea, high LH/FSH enlarged 
cystic ovaries due to block in E2 synthesis 
 
 
Primary amenorrhea; ovarian enlargement or 
hyperstimulation as ovary unable to 
aromatise androstenedione to E2 
 
 
Severe adrenal insufficiency; progress 
through puberty but cycles anovulatory and 
develop high LH levels and polycystic 
ovaries; lipoid deposition in theca cells 
disrupts StAR-independent steroidogenesis  
CYP17A1 
17-α hydroxylase/17,20-
lyase enzyme (10q24-3) 
 
CYP19A1 
Cytochrome P450, 
family 19, subfamily A, 
polypeptide 1 
 
StAR 
Steroidogenic acute 
regulatory protein 
(8p11-2) 
Autoimmunity 
Autoimmune 
lymphocytic oophoritis 
 
 
- Polyglandular failure 
type 1 or APECED 
(Autoimmune  
PolyEndocrinopathy-
Candidiasis-Ectodermal 
Dystrophy) 
 
- Polyglandular failure 
type 2 
Lmphocytic infiltration of antral follicles 
into theca, but sparing of primordial follicles, 
multifollicular ovaries 
 
Mucocutaneous candidiasis, 
hypoparathyroidism and adrenal 
insufficiency accompanied by POI in 60% of 
cases 
 
 
 
Adrenal insufficiency and hypothyroidism 
associated with POI in 10% of cases 
 
 
 
 
AIRE 
Autoimmune regulator 
(21q22-3) 
 
 
 
 
HLA association 
Insufficient follicle number  
Luteinized Graafian 
follicles 
40% of idiopathic spontaneous 46,XX POI 
have antral follicles on ultrasound, on 
histology >60% are luteinised, major 
mechanism of follicular dysfunction 
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 POI affects approximately 1 in 100 women by the time they reach 40 years of 
age
(251)
 and an underlying cause is only identified in the minority of cases. In a recent 
series of 357 consecutive women presenting with POI a genetic cause was only 
determined in 7%.
(252)
 The aetiology and prevalence of POI in girls below 18 years of 
age has not previously been described.   
 
7.2      Aims 
 
I. To identify the incidence and prevalence of primary ovarian insufficiency 
within children in the West of Scotland 
 
II. To investigate the aetiology of primary ovarian insufficiency in a tertiary 
referral centre 
 
III. To describe the oestrogen treatment prescribed and its effect on height 
velocity, bone maturation and final height 
 
7.3 Subjects and Methods 
7.3.1 Subjects 
All girls who attended the endocrinology clinic at the Royal Hospital for Sick 
Children (RHSC), Glasgow with a diagnosis of POI from January 1989 to January 
2000 and aged from 0 to 18 years were included.  They were identified using the 
database established by the endocrinology service in 1989 after the appointment of 
Dr Malcolm Donaldson, Senior Lecturer in Child Health. The diagnostic categories 
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retained were as follows: primary ovarian failure/insufficiency, TS, gonadal or 
ovarian dysgenesis, galactosaemia, ovarian failure associated with cancer related 
therapies and autoimmune ovarian failure.  
 
7.3.2 Methods 
To determine the prevalence of POI the number of affected girls aged from 0 to 16 
years attending the endocrine clinic each year from 1989 to 2000, with a West of 
Scotland postcode, were ascertained and the mean number calculated for the 11-year 
period. The denominator or female population aged between 0 and 16 years in the 
West of Scotland was obtained from the statistics section of the General Register 
Office for Scotland (www.gro-scotland.gov.uk). The areas included were Ayrshire, 
Argyll & Bute, City of Glasgow, Dunbartonshire, Dunbartonshire, Lanarkshire and 
Renfrewshire. To determine the incidence of POI the number of new cases of POI 
diagnosed each year from 1989 to 2000 was determined by examining the endocrine 
database at the Royal Hospital for Sick Children (the tertiary centre for these 
postcodes), and the mean number calculated for the 11-year period. The denominator 
used was the same for calculating prevalence. It was assumed that the endocrine 
team would be consulted on all cases of POI in the West of Scotland. POI is a rare 
event, because the absolute numbers measured for incidence and prevalence per year 
were less than 100, Poisson distribution was assumed. 95% Confidence Intervals 
were obtained by multiplying the number of events by the appropriate confidence 
level factors from a table.
(253)
 The 95% Confidence Interval for each event was then 
divided by the denominator to give the 95% Confidence Interval for prevalence or 
incidence. A retrospective review of case notes of girls identified by the database, 
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who were born before January 1991 and would have now reached FH, was 
performed to investigate the effects of oestrogen therapy on pubertal growth and FH. 
The following data were recorded:  age at diagnosis, aetiology, karyotype, clinical 
presentation, parental heights and family history.  At each outpatient clinic visit 
during oestrogen treatment the following information was collected: height, weight, 
pubertal staging, blood pressure, bone age, pelvic ultrasound, serum gonadotrophins 
(LH, FSH) and treatment regime. Bone age was determined according to the Tanner 
and Whitehouse radius, ulna, short bones score (TW2 method).
(254)
 At the end of 
pubertal induction the age of bony fusion (bone age scored as 16 years), uterine 
development on pelvic ultrasound and final height was recorded.  
 
7.3.3  Ethical approval 
This work was acknowledged by our local Research & Development department to 
constitute audit therefore ethical approval was not required. 
 
7.3.4  Statistical analysis 
Unpaired T-tests were used to investigate any differences, for continuous normally 
distributed data, between TS girls with spontaneous menarche and those who 
required pubertal induction with oral oestrogen using SPSS version 15. Significance 
was determined as P<0.05. For girls with non-TS associated POI descriptive analysis 
was only performed in view of the small number of patients. All results are described 
as mean (SD) unless otherwise indicated. 
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7.4 Results 
One hundred and forty-one girls attended the endocrinology clinic with a diagnosis 
of POI over the 11 year period. The majority of girls either had TS (83.7%) or 
acquired POI associated with total body irradiation (TBI) and bone marrow 
transplantation (12.8%). The aetiology of POI is shown in Figure 7.1. 
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Figure 7.1 – Aetiology of POI in patients who attended RHSC from 1989 to 2000 
(n = 141): GD; gonadal dysgenesis. 
 
The prevalence of all cases of POI in the West of Scotland during 1989 and 2000 
was 32 (95% Confidence Interval 25 to 40) per 100 000 girls aged between 0 and 16 
years. The incidence of all cases of POI was 4 (95% Confidence Interval 1 to 7) per 
100 000 girls per year. The prevalence of TS in the West of Scotland paediatric 
population was 30 (95% Confidence Interval 23 to 38) per 100 000 girls and the 
incidence was 3 (95% Confidence Interval 1 to 7) per 100 000 girls per year. The 
prevalence of non-TS associated POI was 2 (95% Confidence Interval 0.4 to 5) per 
100 000 girls; and the incidence 0.5 (95% Confidence Interval 0.01 to 3) per 100 000 
girls per year.  
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7.4.1 POI associated with Turner syndrome  
One hundred and eighteen girls attended the endocrine clinic with TS confirmed by 
karyotype and their characteristics are shown in Table 7.3.  
 
Table 7.3 - Characteristics of all girls with TS who attended the endocrine clinic 
in RHSC between 1989 and 2000 
 
 
 
 
  
       
 
       *Median (range) 
 
Ninety-three girls are now 18 years or over and have reached final height. However, 
eleven girls have moved out with the West of Scotland so follow up data are not 
available. The characteristics of the remaining 82 girls who are now 18 years or over 
and have reached final height are depicted in Table 7.4. Sixteen girls (17.2%) had 
spontaneous puberty (SP) including menarche and therefore did not require pubertal 
induction. Sixty-six girls required induction of puberty and were treated with 
incremental doses of oral oestrogen; 64 girls received oral ethinylestradiol (EE2) and 
2 girls received oestradiol valerate (Progynova) initially and then oral EE2. The oral 
EE2 regimes used to induce puberty are described in Table 7.5 and the uterine 
findings on pelvic ultrasonography are shown in Table 7.6. The girls’ most recent 
bone ages along with their corresponding daily EE2 dose are shown in Figure 7.2. 
 TS girls (n = 118) 
  
Age at diagnosis (y) 5 (0 - 17.3)* 
Target height (cm)  160.6 (4.9) 
Birth weight (kg)  2.8 (0.6) 
Gestation (wk)  38.8 (2.5) 
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Table 7.4 – Characteristics of TS girls who attended the endocrine clinic 
between 1989 and 2000 who have reached final height (n = 82) 
 
 Induction 
 with oral 
EE2 
 
n=64 
Induction  
with oral  
Progynova 
 
n=2 
Spontaneous 
puberty 
(SP) 
 
n=16 
  
 
At start of oestrogen (or  B1 if SP) 
Age at diagnosis (y)* 5.9 (5.8) 8 (4) 8.9 (4.1)* 
Age (y)  13.6 (1.7) 11.7 (0.7) 11.1 (0.8) 
Height (cm) 137.4 (11) 119.5 (1.1) 129.8 (5.3) 
Height SD score -2.8 (1.1) -3.9 (0.2) -2.1 (0.5) 
Target height (cm) 161.2 (4.7) 156.1 (4.5) 159.8 (4.5) 
Sitting height (cm) 76 (5.2) - 72 (2.3) 
Sitting height SD score -2.5 (1.1) - -1.9 (0.6) 
 
At end of induction (or B5 if SP) 
Age (y) 17.9 (1) 14.7 (0.1) 15.9 (0.7) 
Height (cm) 150.2 (7) 133.4 (1.1) 149.3 (5) 
Height SD score -2.2 (1.2) -4.4 (0.2) -2.2 (0.8) 
Sitting height (cm) 83.2 (3.1) 74.1 (3.4) 83 (2.5) 
SH SD score -2.7 (1.1) - 4.2 (1.1) -2.2 (0.8) 
∆ Height SD score 0.6 (0.6) -0.5 (0.1) 0.1 (0.6) 
∆ SH SD score -0.3 (0.8) - -0.3 (0.6) 
Peak height velocity Not observed Not observed 8.1 (0.9) 
            *Excluding antenatal diagnosis in 2 girls 
 
 
Table 7.5 - Oral ethinylestradiol regimes employed to induce puberty in  
 girls with POI associated with TS (n = 64) 
 
 
 
 
 
 
 
 
 
 
 
Dose of EE2 
     (µg/day) 
Duration of EE2 
(y) 
5umber of patients 
(max 64) 
  
0.5 0.8 (0.2) 2 
1  1.1 (0.5) 5 
2  1.4 (1.1) 62 
4  1.3 (0.9) 61 
5  0.7 (0.4) 3 
6  0.5 (0.6) 51 
8  0.4 (0.3) 49 
10  0.6 (0.3) 52 
14  0.2 1 
15 0.3 (0.2) 9 
16 0.2 1 
Total duration of EE2 4.3 (1.4) 49 
EE2 duration if incomplete 
induction at transfer 
3.6 (1.8) 16 
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Table 7.6 – Uterine development of girls with TS at beginning and end of 
puberty as assessed by pelvic ultrasonography 
 
 Induction with 
oral oestrogen 
(n=66) 
Spontaneous 
puberty 
(n=16) 
  
 
At start of oestrogen (or B1 if SP) 
Age (y)  13.5 (1.7) 11.1 (0.8) 
Uterine length (cm)  3.8 (1)
NS
 3.3 (0.7)
 NS
 
Fundal-cervical ratio 0.8 (0.3)
NS
 0.9 (0.2)
 NS
 
 
At end of induction (or B5 if SP) 
Age (y) 17.8 (1) 15.9 (0.7) 
Uterine length (cm)  6 (1.2)* 6.9 (1.2)* 
Fundal-cervical ratio 1.2 (0.3)* 1.5 (0.3)* 
   Difference between groups: *P<0.05; NS: not significant.  
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Figure 7.2 – Latest bone age performed in TS girls who required pubertal 
induction with corresponding daily oral EE2 dose 
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7.4.2 5on-Turner syndrome associated POI  
Twenty-three girls had POI that was not associated with TS and their mean age (SD) 
at diagnosis was 14.1 (2.6) years. The majority of these girls (78.3%) had POI 
associated with total body irradiation (TBI) for bone marrow transplantation (BMT); 
6 for solid malignancy, 11 for leukaemia and 1 for β-Thalassaemia major. Their 
underlying conditions are shown in Figure 7.3.  
ALL
AML
Wilm's tumour
Philadelphia +ve CGL
Thalassaemia
Glioma
Neuroblastoma
Rhabdomyosarcoma
 
Figure 7.3 – Initial diagnosis of patients with POI associated with late effects of 
cancer-related treatment including TBI (n=18): ALL, acute lymphoblastic 
leukaemia; AML, acute myeloid leukaemia. 
 
The mean age (SD) at diagnosis in girls with POI associated with TBI and bone 
marrow transplantation was 13.7 (2.6) years. Nine girls presented with absent 
puberty and the remaining nine girls presented with secondary amenorrhea or 
oligomenorrhea. So far, sixteen girls have commenced oral EE2 and their 
characteristics are depicted in Table 7.7. No further growth data are available for 
three of the girls who presented with absent puberty (1 died; 1 moved, 1 followed up 
in local tertiary centre). The oral EE2 regimes used to induce puberty are shown in 
Table 7.8.  
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Table 7.7 – Characteristics of girls with POI associated with TBI  
and BMT treated with oral EE2 (n=16) 
 
 Absent puberty  Amenorrhea  
5umber of patients 6 3 7 
  
At start of EE2 
Age (y)  13.2 (1.3) 12.7 (0.3) 16.7 (1.9) 
Height (cm) 138.8 (6.1) 150.4 (4.4) 161.2 (4.1) 
Height SD score -2.6 (1.3) -1 (0.6) -0.2 (0.8) 
Sitting height (cm) 68.7 (1.7) 76.6 83.2 (2.2) 
Sitting height SD score -4.7 (1.9) -1.6 -2.1 (1.4) 
Uterine length (cm) 3 (0.9) 3 3.8 (0.2) 
Fundal-cervical ratio 0.8 (0.2) - 1 (0) 
At end of induction (daily EE2 dose reached 20mcg) 
Age (y) 16.5 (1.4) 17 (1.7) 
Height (cm) 152.3 (8.7) 161.2 (4.1) 
Height SD score -1.8 (1.5) -0.2 (0.8) 
Sitting height (cm) 80.7 (4.7) 83.2 (2.2) 
Sitting height SD score -3.4 (1.5) -2.2 (1.3) 
∆ Height SD score 1 (1.1) 0 
Uterine length (cm) 4.4 (1.1) 5.7 (1) 
Fundal-cervical ratio  1.1 (0.4) 
 
 
 
No data 
available 
1.6 (0.4) 
 
 
Table 7.8 – Oral ethinylestradiol regimes used in girls with POI  
associated with TBI and BMT 
 
 
 
 
 
 
 
In the five remaining girls, POI was associated with galactosaemia (n=3), APECED 
(Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy; n=1) and 
gonadal dysgenesis (n=1).  The mean (SD) age at diagnosis was 16.2 (1.6) years. 
Four girls presented with amenorrhea or oligomenorrhea and had already reached 
their FH when EE2 was commenced. The remaining girl presented with absent 
Duration of EE2 (y) Dose of oral 
EE2 
(µg/day) 
Absent puberty  
(n=6) 
Amenorrhea 
(n=7) 
  
2  1.2 (0.7) 0.1 (0) 
4  1.3 (0.7) 0.1 (0) 
5  1.3  - 
6  0.3 (0.2) 0.1 (0) 
8  0.2 (0) 0.1 (0) 
10  0.9 (0.5) 0.6 (0.3) 
14 2.3 0.3 
15 0.5 - 
Total  3.3 (1.6) 0.3 (0.5) 
   
Chapter 7                                                                       Effect of oral oestrogen in POI                                                                                                                                                           
 
    
 124 
puberty associated with galactosaemia and subsequently moved to Aberdeen to live 
in a residential school and no further data are available. Their characteristics are 
therefore not shown.  
 
7.5 Discussion 
The commonest cause of POI in this cohort of girls is, not surprisingly, Turner 
syndrome. As the reported frequency of TS is 1 in 2500 live female births the 
number of girls in the West of Scotland diagnosed with TS would be expected to be 
approximately 40 per 100 000 girls. The prevalence of TS in this cohort of girls from 
the West of Scotland was 30 per 100 000 with 95% Confidence Intervals of 23 to 38. 
There would, therefore, appear to be a shortfall in the numbers of girls diagnosed 
with TS in the West of Scotland between 1989 and 2000. It is possible that girls with 
TS were diagnosed and seen out-with the endocrinology clinic at RHSC particularly 
during the early part of the study period before Dr Donaldson’s endocrinology 
service was fully established. During the first 5 years of the study the prevalence of 
TS in the West of Scotland was 27 per 100 000 girls compared with 32 per 100 000 
girls for the last 5 years of the review period. In addition, some girls with TS whose 
presenting features were solely pubertal delay or pubertal arrest may have been 
referred to the adult sector. Therefore the numerator used for the prevalence and 
incidence calculations may be an underestimate.  
 
In this cohort of TS girls the median age at diagnosis was 5 years which compares 
favourably with other centres.
(255)
 The mean birth weight was 2.8 kg (-1.1 SD score) 
at 38.8 weeks gestation. The frequency of spontaneous menarche of 17.2% in this 
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cohort is very similar to that reported in Italian TS girls by Pasquino et al in 1997.
(56)
 
Spontaneous puberty was most frequently associated with the mosaic karyotypes: 
45,X/47,XXX (n=5) and 45,X/46,XX (n=4). Only 1 girl had a classic 45,X 
karyotype. They demonstrated acceleration of growth during puberty with a mean 
peak height velocity of 8.1 cm per year. In girls who required an artificial induction 
of puberty the effect of exogenous oestrogen on growth depended on the dose 
employed. In two girls who initially received a relatively high dose of oral oestrogen, 
in the form of oestradiol valerate (Progynova), subsequent linear growth was reduced 
with a mean FH of 133.4 centimetres and a mean delta height SD score of -0.5 SD 
score. Sixty-four girls received incremental doses of oral ethinylestradiol from a 
mean age of 13.6 years. To begin with, very small daily doses of 0.5 to 2 µg were 
used. Linear growth continued and a mean FH of 150.2 centimetres was reached at a 
mean age of 17.9 years with a mean delta height SD score of +0.6 SD score. Their 
FH was similar to girls with spontaneous puberty who reached a mean FH of 149.3 
centimetres. However, the actual oral EE2 regime followed in individual girls was 
highly variable with no consistency in the dose or duration of each increment. It was 
therefore not possible to assess the effect of EE2 dose on HV in such a disparate 
group. Pre-pubertal pelvic ultrasound findings were similar in TS girls with 
spontaneous and induced puberty with a mean uterine length of 3.3 centimetres at 11 
years and 3.8 centimetres at 13.6 years respectively (P=0.151). These uterine lengths 
are on the 10
th
 and 3-10
th
 centile, respectively, on reference charts derived from 
normal unaffected girls. These smoothed centile curves for uterine length and fundal-
cervical ratio (FCR) were devised by Griffin et al (see Appendix 2 and 3).
(256)
 On 
completion of puberty, girls with a spontaneous onset had a mean uterine length of 
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6.9 centimetres (25
th
 centile) which was larger than those who required pubertal 
induction who had a mean of 6 centimetres (3-10
th
 centile; P=0.029). Similarly, the 
FCR in girls with spontaneous and induced puberty were initially 0.9 (25-50
th
 
centile) and 0.8 (3-10
th
 centile; P=0.527) and after puberty were 1.5 (25
th
 centile) and 
1.2 (3-10
th
 centile; P=0.033) respectively. TS girls with spontaneous puberty 
therefore achieved the normal post-pubertal heart shaped configuration of the uterus 
(FCR > 1) whereas this only occurred in 48% of girls who required pubertal 
induction. The poor uterine development in girls with TS who have required artificial 
induction of puberty with oral EE2 therapy has previously been described by 
Paterson et al.
(257)
 Reduced uterine dimensions after pubertal induction with oral 
oestrogen has also been described by other groups in which a variety of different 
preparations of oestrogen were employed.
(258-260) 
The underdevelopment of the uterus 
observed in TS girls treated with oral EE2 may be a reflection that the oestrogen 
regime currently employed is suboptimal. EE2 is a synthetic oestrogen usually 
administered orally and extensively metabolised by the liver before it reaches the 
systemic circulation it is therefore possible that a natural transdermal oestrogen 
formulation may improve uterine development. Normal uterine development has 
been claimed in TS girls treated with either natural conjugated oral E2 (oestradiol 
valerate) or topical E2 gel in early to mid-adolescence however FCR were not 
described.
(261;262) 
There may nevertheless be an underlying abnormality of the uterus, 
in association with TS, which makes it less responsive to exogenous oestrogen 
therapy. In TS women who undergo assisted conception with donor oocytes there is a 
higher incidence of first trimester miscarriage of 50-60% compared to other groups 
with POI.
(263-265) 
In TS women difficulties in embryo transfer have been attributed to 
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reduced endometrial thickness
(265)
, hypoplastic uteri
(265)
, suboptimal endometrial 
response
(264)
 and uterine malformation.
(265) 
Achievement of normal uterine 
dimensions may reduce the number of pregnancy-related problems faced by TS 
women who undergo assisted conception.  
 
Non-TS associated POI was most commonly due to TBI in combination with BMT. 
Fifty percent of the girls had reached menarche prior to developing their principal 
diagnosis. During the initial phase of treatment for their underlying condition 
troublesome vaginal bleeding was common and usually controlled with oral 
norethisterone or subcutaneous LHRH analogue therapy (Zoladex). The effect of oral 
oestrogen on growth could only be assessed in six patients of whom four also had 
GH deficiency with or without hypothyroidism. They started EE2 at a mean age of 
13.2 years and on average completed their induction in 3.3 years. Their mean FH was 
152.3 centimetres (-1.8 SD score) with a mean delta height SD score of +1.0. Their 
mean final sitting height SD score was -3.4 reflecting a marked reduction in spinal 
height due to previous spinal irradiation. A similar effect of radiotherapy was 
observed on uterine growth. The mean uterine length and FCR, after completing 
pubertal induction with oral EE2, were 4.4 centimetres (3-10
th
 centile) and 1.1 (3
rd
 
centile) respectively. Uterine development after EE2 therapy was better in the girls 
who had full pubertal development prior to developing their illness. Their mean 
uterine length and FCR, after completing a more rapid incremental regime of oral 
EE2 with an average duration of 0.3 years, was 5.7 centimetres (25
th
 centile) and 1.6 
(25
th
 centile) respectively. Radiotherapy is reported to have a greater effect on 
uterine development when administered at an early age.
(266)
 The effect of EE2 on 
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bone maturation and in particular the dose of EE2 associated with bony fusion was 
difficult to assess as only six bone ages were scored as 15.5 years or greater. The 
corresponding daily EE2 dose ranged from 2 to 20 µg.  
 
POI is a continuum and this is emphasised by a girl with galactosaemia who 
conceived spontaneously 6 years after she presented with secondary amenorrhea 
associated with elevated gonadotrophins and reduced uterine length on ultrasound. 
She had been taking oestrogen replacement, in the form of Prempak C, when she 
conceived and subsequently went on to deliver a healthy baby boy at term.  
 
As non-TS associated POI is an uncommon condition even in a tertiary referral 
centre the introduction of evidence-based guidelines would improve patient care. It is 
most commonly observed in girls who have received cancer-related therapies in 
particular TBI and BMT. After the diagnosis has been made it is important that a 
delay in starting oestrogen therapy is avoided as these girls often have other risk 
factors for developing osteoporosis for example previous prolonged corticosteroid 
therapy, extended periods of reduced mobility and acquired GH deficiency. Although 
long term outcome data is not available two girls have reduced bone mineral density 
on DXA scanning at 18-19 years and a further 2 girls have values within the 
osteoporotic range. Non-compliance with oestrogen treatment is also an issue as 
many girls on standard replacement doses, after pubertal induction has been 
completed, continue to have elevated serum gonadotrophins. Adherence to therapy 
may be increased by improving patient education for example with an information 
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booklet explaining the rationale of treatment and in particular describing the possible 
consequences of poor compliance with therapy.  
 
7.6 Conclusions 
Primary ovarian insufficiency is an uncommon condition with low prevalence rates 
in the West of Scotland in girls aged 16 years and under. The commonest cause of 
POI is not surprisingly associated with Turner syndrome. The next leading cause is 
iatrogenic POI secondary to the effects of cancer related therapy in particular total 
body irradiation associated with bone marrow transplantation. Girls with POI 
associated with TS were treated with oral oestrogen at a mean age of 13.6 years to 
induce puberty. Initially low doses of oestrogen (mostly EE2) were used to allow 
linear growth to continue. TS girls with a spontaneous onset of puberty showed a 
different growth pattern during puberty with evidence of a growth spurt and better 
uterine development at the end of puberty on pelvic ultrasound compared to those 
who required artificial induction with oral oestrogen. The actual oestrogen regime 
followed in individual patients for pubertal induction was highly variable so it was 
not possible to meaningfully analyse the effects of the oestrogen dose on height 
velocity or bone maturation in this retrospective audit. An accurate analysis of the 
effect of oestrogen on linear growth and bone maturation in Turner syndrome is 
therefore only likely to be possible within the context of a prospective clinical trial 
where ethically agreed protocols, including a standardised regime of oral oestrogen 
for pubertal induction, are strictly adhered to and is the focus of the next chapter.  
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8.1      Introduction 
Short stature in girls with TS is almost universal. Although there is no evidence of 
classical GH deficiency
(52;53)
 biosynthetic GH in supra-physiological doses has been 
shown to accelerate growth
(267;268)
 and its efficacy in improving FH outcome has 
been established.
(269;270)
 The mean “height gain” (mean FH – projected height) in the 
Canadian randomised controlled trial of GH therapy in TS was 7.3 cm.
(270)
 A target 
height of 150 centimetres is now a realistic goal in most girls with TS.
(268;271)
 
However all studies have shown marked variation in individual outcome with some 
girls doing badly despite GH treatment.
(269)
 At least some of the response to GH is 
explained by an X-linked imprinting effect as TS girls who retain a maternal X 
chromosome are reported to have a greater mean height gain with GH than those 
with a paternal X chromosome.
(272) 
Although some studies have reported an 
improved FH outcome with early GH treatment
(273-275)
 a number of other studies 
have failed to support this association.
(276;277)
 Recent reports suggest that the number 
of years of GH therapy prior to pubertal induction may be predictive of 
outcome.
(273;278)
 It has been suggested that a minimum of four oestrogen-free years of 
GH treatment should be the goal.
(279)
  
 
Most girls with TS have primary ovarian insufficiency due to gonadal dysgenesis and 
require oestrogen treatment for pubertal induction. The optimal age at which to start 
oestrogen replacement remains controversial. Delaying puberty for as long as 
possible has previously been advocated in an attempt to prolong the growth period 
before epiphyseal fusion.
(280)
 However, there may be psychological and social 
consequences of late pubertal induction. In addition, a recent study has indicated that 
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delayed puberty does not affect FH outcome.
(277)
 Furthermore, data from the US and 
the Netherlands suggest that if GH is started early enough, puberty can be induced at 
an age-appropriate time of 11-12 years without a negative effect on FH.
(273;281)
 In 
addition to oestrogen deficiency, adolescents and adults with TS and gonadal 
dysgenesis also have reduced levels of serum androgens as the ovary usually 
produces 50% of circulating androgens.
(282;283) 
As androgens also promote 
longitudinal growth the addition of oxandrolone at the age that adrenarche usually 
occurs has been advocated to promote growth in TS. The use of this weak synthetic 
non-aromatisable anabolic steroid in the promotion of growth in TS remains 
contentious. Oxandrolone has been shown to increase HV and improve short term 
growth when used in combination with GH,
(268;271)
 while a favourable effect on FH 
has now been reported when oxandrolone was used in combination with GH. 
However these studies did not include a comparison group
(271;284)
 and other studies 
have failed to show this benefit.
(280;285)
 More recently Stahnke et al have reported an 
increase in mean FH of 3.4 centimetres in girls treated with combination therapy 
compared to GH alone.
(286)
 However, after initial randomisation to either GH alone 
or in combination with oxandrolone, 0.1 mg/kg/day for the first year followed by 
0.05 mg/kg/day, some of the participants underwent a change in treatment regime. 
This was either due to the development of side effects in the combination arm, in the 
form of virilisation, or a waning HV in the GH-only arm. In addition, the GH dose 
was not standardised throughout the study period between the 2 groups. The 
virilisation was observed during the first year of the study when the higher dose of 
oxandrolone was used (0.1 mg/kg/day).
(286) 
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8.2 Hypothesis 
It was hypothesised that pubertal induction with oestrogen would have a dose-
dependent effect on HV with an increase of HV at low doses of oestrogen and a 
decrease in HV at higher doses. Secondly, the age of pubertal induction (at either 12 
or 14 years) would not affect FH as girls who started oestrogen earlier would show a 
greater response to oestrogen and grow faster but for a shorter period so that total 
height gained would be the same between the two groups. 
  
8.3 Aims 
 
I. To assess the effect of a standardised oestrogen regime on height velocity, 
bone maturation and final height in girls with TS treated with a standard dose 
of growth hormone 
 
II. To identify what dose of oestrogen is associated with 1) peak height velocity 
and 2) bony fusion 
 
8.4 Subjects and Methods 
The United Kingdom Turner study is a randomised, double-blind placebo-controlled 
study of growth promoting treatment in TS organised by the British Society for 
Paediatric Endocrinology and Diabetes (BSPED) and running from 1999 to 2009. 
The study objectives are to examine the influence on FH of a) oxandrolone versus 
placebo from 9 years of age and b) the introduction of oral oestrogen therapy at 
either 12 or 14 years. The population studied were girls with TS who were receiving 
a standard dose of GH (10 mg/m
2
/week by daily injection). The effect of oestrogen 
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on height velocity in these girls is not part of the UK study protocol and is the subject 
of this chapter. 
 
8.4.1 Subjects 
One hundred and six girls with TS were enrolled from 36 hospitals in the United 
Kingdom during the period of recruitment (November 1999 to December 2003). TS, 
defined as a loss or abnormality of the second X chromosome in a major cell line, 
was confirmed by karyotype. Inclusion criteria were girls with genetically confirmed 
TS and primary ovarian insufficiency who participated in the UK Turner study and 
therefore received a standard dose of GH therapy (10 mg/m
2
/week) and who both 
required and completed the pubertal induction protocol with oral oestrogen. Girls 
were excluded from the study if they had any associated conditions which may 
interfere with growth e.g. inflammatory bowel disease. Girls with spontaneous 
puberty and normal FSH levels from 11 years of age (<10 IU/L, performed 
annually), usually in association with either 45,X/46,XX or 45,X/47,XXX 
mosaicism, and who did not therefore require pubertal induction were included but 
analysed separately. Written informed consent was obtained from the girls and their 
parents or guardians. The original study protocol was approved by Multi-Centre 
Research Ethics Committee (MREC). Additional approval was obtained from MREC 
in September 2008 to allow me to analyse the anonymised raw data (Appendix 1). 
The Dysmorphology Scoring system was devised by Dr Malcolm Donaldson and 
Emma Jane Gault (Turner Research Assistant) for the UK Turner Study to quantify 
the presence and severity of certain dysmorphic features which commonly occur in 
TS and is shown in Table 8.1. The maximum possible score is 28. 
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Table 8.1 – Dysmorphology scoring system 
DYSMORPHIC FEATURES 
0 = Feature not present; 1 = Mild-moderately affected;  
2 = Severely affected. If in doubt select lower category 
 
0 
 
1 
 
2 
• Hyperconvex nails +/- nail-fold oedema     
• Short fourth/fifth 
 
metacarpal     
• Cubitus valgus     
• Naevi     
• Ptosis     
• Epicanthic folds     
• Oblique palpebral fissures     
• Low set/rotated ears     
• High palate     
• Dental overcrowding     
• Micrognathia     
• Neck webbing/low hairline     
• Broad chest     
• Lymphoedema hands/feet/limbs     
 
8.4.2 Study design 
Recruits were randomised to oxandrolone (0.05 mg/kg/day; maximum 2.5 mg) or 
placebo from 9 years and further randomised to oestrogen or placebo at 12 years with 
the placebo group starting oestrogen at 14 years. Girls enrolling after 9 years of age 
were immediately randomised to oxandrolone or placebo. Oestrogen was 
administered as EE2 tablets: 2 µg/day in year one, 4 µg/day in year two, for the third 
year 6 µg/day for 4 months followed by 8 µg/day for 4 months and then 10 µg/day 
for the remaining 4 months. Thereafter, 20 µg/day was given as an adult replacement 
dose. Norethisterone 5 mg tablets for the first 5 days of each calendar month were 
commenced when either the daily EE2 dose reached 10 µg or when breakthrough 
bleeding occurred. Girls recruited after 12 years were not randomised and 
automatically assigned to start EE2 at 14 years and formed the “late group”. At 
enrolment participants were commenced on GH or had their existing GH dose 
adjusted to 10 mg/m
2
/week. GH was then administered by daily subcutaneous 
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injections at bedtime until FH. The GH dose was adjusted to calculated body surface 
area every 4 to 6 months to maintain a fixed dose. FH was defined as HV less than 1 
centimetre per year and a BA score of 15.5 years or greater. Height, sitting height 
and weight were measured at enrolment and at subsequent visits until FH. HV was 
calculated using the formula: heightcurrent – height previous/agecurrent – ageprevious and 
expressed as centimetre/year. Where possible the interval between heights was 1 year 
with a minimum of 0.5 year and a maximum of 1.3 years. Peak height velocity 
(PHV), defined as the maximum HV observed during the adolescent growth spurt, 
was determined by measuring sequential HV three years before and after the onset of 
breast development. If a peak consistent with PHV was identified, and in particular if 
this coincided with documentation of puberty, the age and magnitude were recorded.  
The height standard deviation (SD) score was calculated using reference values for 
healthy UK girls.
(287)
 Mid-parental height was calculated using the formula: ½ x 
(heightmother + heightfather – 12.5) centimetres. During GH  pubertal stages were 
assessed according to Tanner
(288)
. BA was determined by a single observer (WP) 
according to the Tanner and Whitehouse radius, ulna, short bones score (TW2 
method).
(254)
  
 
 8.4.3 Statistical analysis   
Analysis of the effect of oxandrolone, late pubertal induction and interaction of the 2 
independent variables on FH was performed by multiple regression using DataDesk 
software package (Data Description Incorporated, version 6.2.1) by Professor Tim 
Cole. I performed all subsequent statistical analysis using SPSS version 15: unpaired 
T-tests to investigate the effect of oxandrolone or onset of EE2 on continuous 
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normally distributed data; general linear model (GLM) with repeated measures to 
investigate effect of oxandrolone, onset of EE2 or GH duration prior to EE2 on HV; 
ANOVA to assess effect of pubertal onset, either spontaneous or artificial at 12 or 14 
years, on height gained during puberty. Significance was determined as P<0.05. 
Results are expressed as mean (SD) unless otherwise indicated. 
 
8.5 Results 
One hundred and six girls were recruited at a median age of 10 years (7.3-13.6). 
Their progress through the study is shown in Figure 8.1. Fifty-one girls were 
randomised to oxandrolone treatment and 55 to placebo. Fourteen girls have 
withdrawn leaving a study population of 92 (43/49 in oxandrolone/placebo arm 
respectively). Four participants were withdrawn in the initial stages due to 
organisational errors which resulted in significant protocol violations. The remaining 
10 girls have withdrawn due to significant non-adherence, poor attendance or 
personal choice. Seven girls withdrew before the second randomisation. Sixty girls 
were randomised to start EE2: 29 girls at 12 years (12 previously randomised to 
oxandrolone), 31 girls at 14 years (14 previously randomised to oxandrolone). 
Twenty-one girls were recruited after EE2 randomisation would have occurred and 
commenced EE2 at 14 years; these were designated as the “late group”. Ten of these 
girls were randomised to oxandrolone treatment. 18 participants had SP with normal 
FSH levels (<10 IU/L) and did not require EE2 therapy. 11 girls had previously been 
randomised to oxandrolone and 7 to placebo. Girls with SP had the following 
karyotypes: 45, X/46, XX n= 12; 45, X/46, XrX n=1; 45, X/46XiXq n=1; 45, 
X/47,XXX n=2; 46, XX with deletions n=2. To date, 75 girls have reached FH. 
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8.5.1 Effect of Oxandrolone on final height 
The baseline and FH status of the participants of the UK Turner study according to 
initial randomisation to oxandrolone or placebo are shown in Table 8.2. Oxandrolone 
was shown by multiple regression to increase FH by 5.0 centimetres (p=0.0002, 
n=75). There were no significant adverse events reported such as voice deepening or 
clitoromegaly.  
Table 8.2 – Participant characteristics according to Oxandrolone randomisation 
 
 
 
 
  
 
 
 
8.5.2 Effect of age of Ethinylestradiol initiation on final height 
The characteristics of participants according to EE2 randomisation at baseline and 
FH are shown in Table 8.3. Neonatal data were similar between the four groups with 
a mean birth weight of 2.8 kilograms (-1.1 SD score) at 38.9 weeks gestation. Girls 
were enrolled at a similar age apart from the “late group” who by definition were 
assigned to EE2 at 14 years of age because they had enrolled later than 12.25 years. 
The height SD scores and target heights were similar between all the groups at 
enrolment. The girls who had a spontaneous onset of puberty, and did not require 
EE2, were diagnosed later at a median age of 7.2 years. None of the girls with 
spontaneous puberty had a classical 45,X karyotype whereas in the EE2 at 12 years, 
 Oxandrolone  Placebo  
  
 
At enrolment 
 
n = 51 
 
n = 55 
Age (y) 10.3 (1.6) 10.3 (1.6) 
Height (cm) 126.7 (8.7) 125.6 (7.9) 
Height SDS -2.1 (0.8) -2.2 (0.8) 
Age at GH (y) 7 (2.5) 6.9 (3) 
 
At final height 
 
n = 35 
 
n = 40 
Age (y) 16.4 (1.3) 16.7 (1.3) 
Height (cm) 153.9 (4.8) 148.9 (6.2) 
Height SDS -1.4 (0.8) -2.3 (1) 
∆ Height SD score 0.6 (0.8) 0 (0.7) 
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EE2 at 14 years, and the “late group” this karyotype was found in 46.4%, 48.1% and 
37.1% of girls, respectively. Using multiple regression, the effect of the timing of 
EE2 initiation on FH was shown to be significant. Delaying the onset of EE2 to 14 
years was shown to increase FH by 3.7 centimetres (p = 0.03, n = 42).  
 
Table 8.3 – Participant characteristics according to EE2 randomisation 
 
 
 
Randomised 
to EE2 at 12y 
 
Randomised  
to EE2 at 14y 
 
“Late group” 
EE2 at 14y 
 
5o EE2  
required  
  
 
At enrolment 
 
n = 29 
 
n = 31 
 
n = 21 
 
n = 18 
Age (y)  9.6 (1) 9.7 (1.2) 12.6 (0.4) 9.9 (1.2) 
Bone age (y) 9.4 (1.4) 9.5 (1.7) 11.8 (1.3) 10.2 (1.9) 
Height (cm) 122.8 (6.9) 123.9 (7) 135.5 (5.7) 124.6 (8) 
Height SD score -2.2 (0.8) -2 (0.9) -2.5 (0.8) -2 (0.8) 
Target height (cm) 162.8 (3.8) 162.4 (4.9) 163.1 (3.2) 162.9 (4.5) 
Age at diagnosis (y)* 0.6 (0-9.8) 1.6 (0-9.8) 3.1 (0-13.4) 7.2 (0.5-10.4) 
Dysmorphology score* 6 (0-18) 5 (1-16) 6 (0-15) 4 (0-8) 
Age at GH (y)* 6.4 (2.4-10.2) 5 (2.2-10.5) 8.9 (4-13.8) 8.2 (1.7-10.9) 
 
At final height 
 
n = 22 
 
n = 20 
 
n = 19 
 
n = 14 
Age (y) 16.2 (1) 17 (0.8) 17.6 (1) 15.1 (0.9) 
Height (cm) 149.2 (6.9) 153.2 (4.4) 151.9 (6) 150.8 (6.5) 
Height SD score -2.2 (1.2) -1.7 (0.7) -1.9 (1) -1.7 (1.1) 
∆ Height SD score 0 (0.6) 0.3 (0.9) 0.6 (0.8) 0.2 (0.9) 
       *Median (range) 
 
 
 
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
EE2 at 12y                 EE2 at 14y                 Late group           No EE2 reqd
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Figure 8.2 – Height SD score for chronological age at enrolment (■)  
and final height (■) according to EE2 randomisation 
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8.5.3 Effect of Oxandrolone and Age of Ethinylestradiol initiation on FH 
The baseline and final height characteristics of participants according to both 
oxandrolone and EE2 randomisations are demonstrated in Table 8.4. The effects of 
the double randomisation are depicted in Figure 8.3. The change in height SD score 
from enrolment to FH is shown for all groups in Figure 8.4. The effect of 
oxandrolone versus placebo on FH in girls who commenced EE2 at 12 years was 8.2 
centimetres. The effect of delaying EE2 from 12 years of age until 14 years on FH in 
the placebo group was 6.4 centimetres. Whereas, the effect of oxandrolone and 
delaying EE2 until 14 years of age on FH compared to the placebo group with EE2 at 
12 years of age was 8.4 centimetres. Therefore the interaction between oxandrolone 
and delaying pubertal induction to 14 years was negative, as an effect closer to 14 
centimetres would have been observed if the two interventions were synergistic, and 
close to significance (p=0.06, n = 42). The effect of oxandrolone or EE2 at 14 years 
versus placebo with EE2 at 12 years was 7.6 centimetres. 
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
  12y Ox                     12y Placebo              14y Ox                14y Placebo
H
e
ig
h
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S
D
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Enrolment
Final height
 
Figure 8.3 – Height SD score for chronological age at enrolment (■) and  
final height (■) according to Oxandrolone and EE2 randomisation 
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8.5.4 Effect of GH duration prior to Ethinylestradiol initiation on FH 
The characteristics of participants according to EE2 randomisation and duration of 
GH therapy prior to initiation of EE2 are depicted in Table 8.5. As it has been 
suggested that the duration of GH prior to pubertal induction may be predictive of 
outcome
(273;278)
 and a minimum of four oestrogen-free years should be the goal
(279)
 
this interval was used to evaluate the participants’ outcome in terms of FH attained. 
Surprisingly, a shorter duration of GH therapy before EE2 initiation was associated 
with a larger increase in delta height SD score as illustrated in Table 8.5. However, 
this is probably a reflection of the increase in height status (improvement in height 
SD score) that usually occurs during the first two years of GH therapy. With the 
moderate GH doses employed in this study, namely 10 mg/m
2
/week, an increase in 
height SD score usually occurs within the first two years of therapy but no further 
increase is observed thereafter with prolonged GH usage.
(281)
 However, when doses 
are increased from 10 mg/m
2
/week after the first year of therapy to 14 mg/m
2
/week 
subsequent increases in height SD score are observed after both four years and seven 
years of GH therapy.
(281) 
Thus, participants who had received GH treatment for 
longer than four years prior to initiation of EE2 therapy would already have 
improved their height SD score prior to enrolling in the study whereas participants 
who had only recently commenced GH therapy would show an improvement in 
height status during the study period. As the actual height at the time of commencing 
GH therapy was not recorded as part of the study protocol the “total height gained” 
from growth promoting therapies could not be estimated.  
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Table 8.5 – Participant characteristics according to EE2 randomisation  
and GH duration before EE2 
 
Randomised to  
EE2 at 12y 
Randomised to  
EE2 at 14y 
“Late group”  
(EE2 at 14y) 
 
GH < 4y GH >4y GH < 4y GH >4y GH < 4y GH >4y 
  
 
At enrolment 
 
n = 9 
 
n = 20 
 
n = 2 
 
n = 29 
 
n = 8 
 
n = 13 
Age (y) 9.6 (0.7) 9.7 (1.2) 10.7 (0) 9.6 (1.2) 12.8 (0.4) 12.6 (0.4) 
Ht (cm) 121 (4.9) 123.6 (7.7) 122.1 (3.7) 124 (7.2) 133.1 (3.4) 137 (6.4)  
Ht SD score -2.4 (0.6) -2.1 (0.8) -3 (0.5) -1.9 (0.8) -3 (0.7) -2.2 (0.8) 
Target Ht (cm) 162.5 (3.6) 163 (4) 166.3 (5.2) 162.1 (4.8) 161.8 (2.2) 163.9 (3.6) 
Age at GH (y) 9.2 (0.7) 5.6 (1.4) 10.3 (0.2) 5.2 (2) 12.2 (1.2) 7.2 (1.9) 
GH before E2 2.8 (0.7) 6.4 (1.4) 3.7 (0.2) 8.8 (2) 1.8 (1.2) 6.8 (1.9) 
 
At final height 
 
n = 7 
 
n = 15 
 
n = 2 
 
n = 18 
 
n = 7 
 
n = 12 
Age (y) 16.1 (0.6) 16.3 (1.1) 16.8 (1.6) 17 (0.8) 18.1 (0.7) 17.3 (1) 
Ht (cm) 150.7 (6.1) 148.5 (7.3) 150.9 (0.6) 153.5 (4.5) 151.9 (6.9) 152 (5.8) 
Ht SD score -2 (1) -2.4 (1.2) -2 (0.2) -1.6 (0.7) -2 (1.1) -1.9 (1) 
∆ Ht SD-score  0.4 (0.7) -0.2 (0.5) 0.9 (0.3) 0.3 (0.9) 1 (0.8) 0.3 (0.7) 
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Figure 8.5 – Delta height SD score in girls treated with EE2: according to 
randomisation to Oxandrolone (■) or placebo (■); Age at EE2 (12y or 14y) and 
GH duration pre-EE2 (>4y or <4y) 
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8.5.5  Effect of Ethinylestradiol on pubertal progression  
Girls who commenced oral EE2 at 12 years of age reached Tanner breast stage B2 at 
a mean age of 12.9 years and reached breast stage B5 at 15 years. The process of 
pubertal induction therefore lasted three years (Table 8.6). This “early” group 
therefore achieved breast stage B2 and B5 on average two years later than normal 
unaffected girls as the median age of menarche in a contemporary cohort of UK girls 
is 12.9 years.
(289)
 Age at menarche has changed little over the last 50 years since 
Tanner et al reported a median age of 13 years in a cohort of UK girls born in the 
1950’s.
(290)
 Girls, who started EE2 at 14 years of age, showed a similar rate of 
progression and reached breast stage B5 after 3 years of pubertal induction. They 
were therefore 4 years behind their peers in terms of pubertal development. By 
contrast, girls with spontaneous puberty, who did not require oestrogen therapy, 
demonstrated a normal pattern of pubertal development reaching breast stage B2 at 
11.4 years and menarche at 12.9 years. Some of the girls who received pubertal 
induction did show evidence of spontaneous breast development however this either 
did not progress or regressed before EE2 therapy was commenced. Unpaired T-tests 
were used to examine any effect of oxandrolone on pubertal progression in the three 
groups. No effect was observed with oxandrolone treatment, P values > 0.05. 
 
Table 8.6 - Pubertal progression with age at each Tanner breast stage achieved 
 
 EE2 at 12y 
(n = 28) 
EE2 at 14y 
(n = 47) 
5o EE2 required (SP) 
(n = 17) 
  
Tanner breast stage 2  12.9 (1.2) 14.1 (1.3) 11.4 (1.2) 
Tanner breast stage 3 13.9 (1) 15.1 (1.4) 12.2 (1.6) 
Tanner breast stage 4 14.8 (1) 16.1 (1.4) 13.1 (1.2) 
Tanner breast stage 5 15 (0.5) 17.1 (1.4) 13.4 (0.5) 
Spontaneous Menarche - - 12.9 (1) 
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8.5.6  Effect of Ethinylestradiol on height velocity 
The HV of girls who commenced oral EE2 at 12 years of age is demonstrated in 
Figure 8.6. During the first year of EE2 treatment the HV was similar to the rate 
observed in the year prior to the onset of EE2. Thereafter a deceleration in HV was 
observed. Girls who were randomised to oxandrolone treatment had a higher HV 
than those who received placebo until the age of 13 years (Figure 8.7A; P=0.008). 
Thereafter, there was no difference in HV between the two groups (P=0.935). 
Similarly, participants who had commenced GH less than 4 years before the 
initiation of EE2 were shown to have a higher HV until the age of 12 years (before 
the onset of EE2 therapy) than those girls who had been established on GH therapy 
for longer than 4 years (Figure 8.7B; P=0.015). However, all girls showed a similar 
HV after commencing EE2 therapy (Figure 8.7). The effects of oxandrolone 
randomisation and duration of GH before commencing E2 at 12 years of age are 
shown in Figure 8.7C.  
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Figure 8.6 – Height velocity of girls treated with EE2 at 12 years (n = 28) 
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Figure 8.7 – Height velocity of girls treated with EE2 at 12 years according to: 
A) Oxandrolone randomisation B) GH duration before EE2 C) Oxandrolone 
randomisation and GH duration before EE2.  
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The growth rate of girls who commenced EE2 therapy at 14 years of age is depicted 
in Figure 8.8. A deceleration in HV was observed from 11-12 years of age which 
increased after the onset of 2 µg per day of EE2 at 14 years of age. A further 
decrease in HV was observed when the daily dose was increased to 4 µg at 15 years 
of age. Subsequent increases of the EE2 dose led to further deceleration in growth. 
Girls who were randomised to oxandrolone treatment had a higher HV than those 
who received placebo until the age of 15 years (Figure 8.9A; P<0.001). Thereafter 
there was no significant difference between the groups (P=0.388). Participants who 
had commenced GH therapy less than 4 years before the initiation of EE2 were 
shown to have a higher HV than those who had been established on GH for longer 
than 4 years until the age of 15 years (Figure 8.9B; P=0.018) thereafter there was no 
significant difference (P=0.292). The effects of oxandrolone randomisation and GH 
duration before commencing EE2 at 14 years of age are shown in Figure 8.9C. 
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Figure 8.8 – Height velocity of girls treated with EE2 at 14 years (n = 47) 
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Figure 8.9 – Height velocity of girls treated with EE2 at 14 years according to: 
A) Oxandrolone randomisation B) GH duration before EE2 C) Oxandrolone 
randomisation and GH duration before EE2.  
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The HV according to age of pubertal induction or daily EE2 dose are demonstrated 
in Figures 8.10 and 8.11 respectively. The growth rate of an untreated cohort of TS 
girls described by Ranke et al shows the constant deceleration in HV that occurs in 
TS in the absence of treatment.
(291)
 The higher HV observed in the girls in the UK 
Turner study prior to EE2 is attributable to GH therapy. When EE2 therapy was 
commenced at 12 years of age, HV appeared to be maintained until the daily EE2 
dose was increased to 4 µg (Figures 8.10, 8.11). However, when EE2 therapy started 
at 14 years of age the natural deceleration in growth was enhanced by the daily EE2 
dose of 2 µg. The height velocities of TS girls who started EE2 at 12 years of age 
differed from those girls who commenced EE2 at 14 years between the ages of 12 to 
17 years (GLM repeated measures P=0.006). 
 
The growth rate of girls with SP who did not require pubertal induction is depicted in 
Figure 8.12. They showed acceleration in HV associated with breast development 
with a mean PHV of 8.5 cm per year. The HV of girls with a spontaneous onset of 
puberty is compared with the HV of girls who required an artificial induction of 
puberty with oral EE2 in Figure 8.13. The height velocities of girls with a 
spontaneous onset of puberty differed from TS girls who commenced E2 at 12 years 
of age (GLM repeated measures P <0.001).  
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Figure 8.10 – Height velocity according to age of pubertal induction compared to 
an untreated historical cohort described by Ranke et al, 1983. 
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Figure 8.11 – Height velocity according to EE2 dose (patient age different between 
the two groups) compared to an untreated historical cohort at a similar age described 
by Ranke et al, 1983.  
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Figure 8.12 – Height velocity of girls with spontaneous puberty (n = 17) 
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Figure 8.13 – Height velocity of girls with spontaneous puberty compared to 
girls who required artificial induction with oral EE2 
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The gain in height during puberty according to its onset, either spontaneous or 
induced at 12 or 14 years, is demonstrated in Figure 8.14. The age at onset of puberty 
was determined as the last age at which Tanner breast stage was recorded as B1 if 
puberty had a spontaneous onset i.e. age at the clinic visit immediately preceding the 
first documentation of pubertal development (Tanner breast stage 2). If puberty was 
artificially induced the age at onset was determined by the age at which oral EE2 was 
commenced which was either 12 or 14 years of age. The amount of height gained 
during puberty was higher in girls who had a spontaneous onset of puberty compared 
to girls who required an artificial induction of puberty at either 12 or 14 years 
(ANOVA: P<0.001, P<0.001 respectively). In addition, girls who commenced oral 
EE2 at 12 years of age grew more during puberty than girls who received oral EE2 
from 14 years (ANOVA: P<0.001). 
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Figure 8.14 – Height gain during puberty of girls with spontaneous puberty 
compared to girls who required artificial induction with oral EE2 at 12 or 14 
years. Post hoc comparisons between groups (Bonferroni corrected) with relative 
significance levels are shown: ***P<0.001 
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8.5.7 Effect of Ethinylestradiol on Bone Maturation 
The bone maturation (change in BA per chronological year) of participants who 
commenced EE2 at 12 or 14 years of age is demonstrated from the age of 11 to 17 
years in Figure 8.15. Using unpaired T-tests a difference in bone maturation was 
observed between the two groups from the age of 14 years onwards, with girls who 
commenced EE2 at 12 years showing faster bone age maturation and earlier growth 
plate fusion (14-15y: P=0.014; 15-16y: P=0.011; 16-17y: P=0.002). It is noteworthy 
that bone maturation in girls who commenced EE2 at 14 years remained less than 1 
per chronological year from 12 to 17 years (Figure 8.15). The bone maturation over 
the 3 year period, from the age of 12 to 15 years, for girls who commenced EE2 at 12 
or 14 years of age is shown in Figure 8.16. There was an increase in bone maturation 
in girls who commenced EE2 at 12 years of age compared to those who started EE2 
at 14 years of age (Figure 8.16; P=0.006). Oxandrolone had no effect on bone 
maturation in either girls who commenced EE2 at 12 years (P=0.33) or at 14 years 
(P=0.36) see Figure 8.17.  
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Figure 8.15 – Bone maturation of girls who started EE2 at 12y (■) or 14y (■) 
from 11-17 years of age: *P <0.05, **P<0.01 
 ** *  * 
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Figure 8.16 – Bone maturation of girls who started EE2 at 12y (■) or 14y (■)  
from 12-15 years of age: **P<0.01 
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Figure 8.17 – Bone maturation of girls who started EE2 at 12y (■) or 14y (■) 
from 12-15 years of age according to Oxandrolone randomisation: **P<0.01 
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8.6 Discussion 
Oxandrolone, the weak anabolic steroid, had a positive effect on FH. Importantly, no 
significant side effects were reported during the study and in particular there were no 
reports of virilisation with the oxandrolone doses used. The growth promotion 
observed with oxandrolone therapy could be due to a systemic effect via the GH-
IGF1 system or a direct action on the androgen receptor in growth plate cartilage. As 
higher GH doses, than that employed in this study, are known to further improve FH 
status
(281)
 it is possible that a further increase in GH could have occurred with 
oxandrolone therapy and account for the height gain. However, oxandrolone 
treatment has been shown to consistently improve HV without an effect on GH 
secretion in girls with TS
(292)
 and in boys with CDGA.
(89;90;293)
 In spite of this, an 
increase in IGF1 concentrations have been observed with oxandrolone in some
(90;292) 
but not all of these studies
(89;293)
. Moreover, other studies have reported that 
oxandrolone does increase GH secretion in boys with CDGA.
(87;294;295)
 Yet, 
hexarelin-induced GH release in short normal boys was not affected by 
oxandrolone.
(296)
 Recently, the effects of oxandrolone at the level of the growth plate 
have been investigated by Chagin et al in the rat metatarsal organ culture model.
(297) 
Oxandrolone and testosterone were both shown to have no effect on linear growth in 
this system even in the presence of charcoal treated serum. It is noteworthy that 
oxandrolone had the least effect on FH in girls with spontaneous puberty who had 
significant residual ovarian function (Figure 8.4; oxandrolone versus placebo delta 
height SD score was 0.2 versus 0.1). The TS girls who required pubertal induction 
may have shown a better response to oxandrolone as they have POI which is also 
associated with a 50% reduction in circulating androgen levels.   
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Delaying pubertal induction with oral EE2 until the age of 14 years was shown to 
increase FH by 3.7 centimetres. A similar increase in FH of 3.4 centimetres was 
reported by Chernausek et al when pubertal induction was delayed from 12 to 15 
years of age.
(278)
 However, this was probably an underestimate as FH was defined by 
the last height performed after the age of 13.5 years. The interaction between 
oxandrolone and delaying EE2 until 14 years of age was negative and close to 
significance suggesting that the their effects on FH are not synergistic but 
antagonistic.  It would seem, therefore, that in girls with POI associated with TS 
treatment with oxandrolone would allow the introduction of oestrogen therapy at 12 
years of age without having a negative impact on FH. An earlier pubertal induction 
would be desirable for psychological, social and physical reasons including uterine 
development, bone and cardiovascular health.  
 
The rate of pubertal progression observed in this cohort of TS girls, according to age 
at Tanner breast stage achieved, was comparable to that of normal unaffected girls. 
The mean age at Tanner breast stage 2, 3 and 4 was similar to that described by van 
Pareren et al who used an alternative low dose oral oestrogen regime to induce 
puberty in TS girls from 12 years of age.
(281)
 The regime consisted of 17β-oestradiol 
(E2): 5 µg/kg/day during the first 2 years, 7.5 µg/kg/day in the third year and 10 
µg/kg/day thereafter until GH was discontinued at which point the E2 dose was 
increased to a dose of 1 mg/day and subsequently to 2 mg/day. As 1 mg of E2 is 
equivalent to 10 µg ethinylestradiol
(298)
 a 40 kg TS girl would have received the 
equivalent of 2 µg EE2 per day in the first 2 years followed by 3 µg per day in the 
third year and 4 µg per day thereafter. In the cohort described by van Pareren et al 
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sixty girls received oral E2 at a mean age of 12.7 years and reached Tanner breast 
stage 2 and 4 at a mean age of 12.9 years and 14.7 years respectively. The pubertal 
development of this cohort was recently described in more detail by Bannink et 
al.
(260)
 A significant delay in achieving Tanner breast stage 5 was observed in these 
girls which may be attributable to the oestrogen regime as the gradual increase in E2 
was sustained up to the fourth year of pubertal induction. At the age of 19 years only 
50% of the TS women had reached breast stage 5 compared to 90% of normal Dutch 
women.
(260)
 In contrast, Chernausek et al employed an oral oestrogen regime using 
conjugated equine oestrogens in the form of Premarin.
(278) 
 The daily oestrogen dose 
for the first six months was 0.3 mg and thereafter 0.625 mg was given which is the 
equivalent of 4.8 µg and 10 µg ethinylestradiol respectively.
(298)
 The dose of 
oestrogen was therefore relatively high and increased fairly rapidly. Not surprisingly 
the pubertal progression was swift with approximately 80% of girls achieving breast 
stage two or greater after 6 months of oestrogen therapy and 90% of girls achieving 
breast stage three or greater after 18 months of which 35% had reached breast stage 
four or five.  
 
Girls with TS who have not received any hormonal treatment show a gradual 
deceleration in HV.
(291)
 The introduction of 2 µg of oral ethinylestradiol at 12 years 
of age led to stabilisation of the downward trend in HV for one year after EE2 
introduction. This is similar to the findings of Chernausek et al where TS girls 
treated with oral 0.3 mg Premarin (equivalent to 4.8 µg EE2) at 12 years of age 
maintained their HV for 1 year after commencing oestrogen and then showed a rapid 
deceleration in HV.
(278)
 By the age of 15-16 years their HV was less than 1 cm per 
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year. van Pareren et al also reported a stabilisation of HV in TS girls who 
commenced 5 µg/kg/day E2 (equivalent to 0.05 µg/kg/day EE2 ≈ 2 µg in 40kg girl) 
at 12 years of age.
(281)
 No further HV data was reported from this cohort. In contrast, 
when pubertal induction was delayed until 14 years of age in the UK Turner study 
the gradual decline in HV continued after EE2 was introduced with no stabilisation 
of HV during the first year of treatment. Whereas, Chernausek et al report a 
stabilisation of HV after oestrogen is introduced at 15 years of age. However, no 
further HV data was provided after 16 years of age from this smaller cohort of TS 
girls (n=16-29).
(278)
  Massa et al reported a deceleration in HV in TS girls established 
on GH therapy when oral ethinylestradiol (0.1 µg/kg/day ≈ 4µg in 40kg girl) was 
introduced. 
 
The sub-group of TS girls with significant residual ovarian function, as evidenced by 
a spontaneous onset of puberty and normal FSH levels, showed a different growth 
pattern during puberty. They had a growth spurt that was of normal timing and 
amplitude compared to unaffected girls. This group of girls all had a mosaic 
karyotype, and so did not include any girls with the classical 45,X karyotype, which 
suggests that the presence of a pubertal growth spurt may be a reflection of a less 
severe underlying skeletal dysplasia. However, at enrolment girls with SP had a 
similar degree of short stature to girls with POI who required EE2 treatment and 
dysmorphology scores were not statistically different between the groups. It is 
therefore more likely that the growth patterns differ because spontaneous puberty is 
more growth enhancing than one which has been artificially induced with oral EE2. 
As it is recognised that the administration of oral EE2 may not be the most 
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physiological method of inducing puberty it is possible that induction with a 
transdermal formulation of a natural oestrogen may improve growth during puberty 
in girls with TS and primary ovarian insufficiency. Although girls with SP did show 
growth acceleration and a greater height gain in puberty a positive effect on FH 
compared to girls who required oral EE2 was not demonstrated.   
 
The introduction of oral EE2 at 12 years of age did not affect bone maturation, as 
compared to those treated at 14 years, during the first two years of EE2 therapy. 
However, after 14 years of age bone maturation was significantly greater in girls who 
commenced EE2 at 12 rather than 14 years of age. Similarly, van Pareren et al 
reported no change in bone maturation in girls treated with low dose E2 during the 
year after E2 initiation as compared to their bone maturation the year before E2.
(281) 
Whereas, Chernausek et al observed a significant increase in bone maturation during 
the year that oestrogen therapy was initiated.
(278) 
These differences observed in bone 
maturation are likely to be related to the dose of oestrogen used.  
 
8.7 Conclusions  
Oxandrolone treatment has an unequivocal positive effect on FH in girls with TS 
when commenced at 9 years of age. Similarly, delaying the onset of EE2 therapy to 
induce puberty until 14 years significantly improves FH outcome in TS girls with 
POI. There is a negative interaction suggesting that there would be little to gain from 
implementing both interventions. It would seem, therefore, that the use of 
oxandrolone would obviate the need to delay pubertal induction until 14 years of age 
in girls with POI associated with TS. The negative interaction does however suggest 
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that there is a finite amount of growth which can be obtained from growth promoting 
therapies in TS and that commencing GH at too early an age for example during 
infancy may not confer an advantage to FH. 
 
The standardised low dose oral EE2 regime induced puberty over a 3 year period 
which corresponds to that observed in normal unaffected girls. Low dose oral EE2 
maintained HV for 1 year when introduced at 12 years of age but led to an immediate 
deceleration at 14 years of age. Thereafter, the natural deceleration in TS girls was 
augmented with subsequent increases in EE2. Girls who received an artificial 
induction of puberty with oral EE2 therefore showed no acceleration of growth 
during puberty. Whereas, TS girls with a spontaneous onset of puberty had a growth 
spurt that was of normal timing and amplitude. The difference in pubertal growth 
pattern may be explained by a less severe underlying skeletal dysplasia or more 
likely, it may be a reflection that puberty with a spontaneous onset is more growth 
enhancing than an artificial puberty with exogenous oestrogen. These findings 
underline the need to examine the effects of more physiological methods of 
oestrogen administration, such as a transdermal formulation, on height velocity as 
well as other markers of pubertal growth and development and would form the basis 
of future studies.  
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9.1 General discussion 
Longitudinal growth in children, which is mainly due to chondrocytic activity at the 
epiphyseal growth plate, is influenced by many hormones and growth factors. Their 
influence is even more complex during the accelerated period of pubertal growth. 
Sex steroids play an essential role in pubertal growth both at the systemic level via 
the GH/IGF1 axis and at the local level of the growth plate. It is now widely accepted 
that oestrogen is the key hormone in controlling acceleration of growth during 
puberty and growth plate fusion. Although abnormalities of growth during puberty 
are very common the mechanisms that control the onset and cessation of pubertal 
growth are not clear. The work within this thesis has endeavoured to increase our 
knowledge of the effects of oestrogen on longitudinal growth through a variety of in 
vitro and in vivo studies involving bench and clinical work.    
 
At the outset it was demonstrated that both of the classical oestrogen receptors, ERα 
and ERβ, were expressed in human and murine chondrocyte cell lines. 
Disappointingly, in the absence of foetal bovine serum, oestradiol had no effect on 
proliferation, differentiation or apoptosis of chondrocyte cells in monolayer culture 
or on linear growth in the foetal murine metatarsal culture system. However, this is 
in accordance with the recent work by Chagin et al.
(129)
 In addition, oestradiol did not 
convey a protective effect to chondrocytes exposed to the pro-inflammatory 
cytokines, TNF-α and IL-1β in monolayer culture. However, endogenous oestrogen 
appears to play an important role in maintaining chondrocyte proliferation in 
monolayer culture of human and murine cells but is not a prerequisite for normal 
linear growth in the foetal murine metatarsals as demonstrated by their respective 
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responses to the non-specific oestrogen antagonist Faslodex. In contrast, Chagin et al 
described a reduction in linear growth in foetal rat metatarsals exposed to 
Faslodex.
(129)
 As the methods and concentrations of Faslodex studied were 
remarkably similar between the experiments the observed difference in metatarsal 
growth after exposure to Faslodex is likely to be due to species differences.  
However, Faslodex did significantly reduce the length of the mineralising zone in 
murine foetal metatarsals suggesting that endogenous oestrogen is important for 
mineralisation. This was supported by the finding that Faslodex-treated metatarsals 
showed a reduction in calcium concentration compared to controls after 14 days 
exposure. As the overall length of the metatarsals was not affected following 
exposure to Faslodex, it suggests that one or more of the other growth plate 
maturational zones must have increased. One possible explanation is that oestrogen’s 
role in mineralisation involves the terminal differentiation of hypertrophic 
chondrocytes and in the absence of endogenous oestrogen the hypertrophic zone 
increases due to a reduction in terminal differentiation. The observed reduction of 
ALP activity in murine ATDC5 chondrocytes after exposure to Faslodex could 
reflect a reduction in chondrocyte differentiation, or alternatively, it could be due to a 
direct effect of Faslodex on ALP activity. Interestingly, the mineralising zone of the 
metatarsals was also reduced after exposure to the selective ERα antagonist, MPP 
suggesting that oestrogen may mediate its effect on mineralisation via ERα.  
 
An interesting finding in both human and murine chondrocytes was the reduction of 
chondrocyte proliferation in the presence of MPP, a selective ERα antagonist, and 
raloxifene, a prototypical selective oestrogen receptor modulator with higher ERβ 
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binding affinity. This was accompanied by an increase in apoptosis of chondrocytes. 
A similar effect was observed in foetal murine metatarsals treated with MPP and 
raloxifene in combination with a marked reduction in linear growth observed after 
five days in culture. A less marked restriction in growth was seen in metatarsals 
treated with MPP in isolation. As MPP is a specific ERα antagonist and raloxifene 
acts mainly as an ERβ agonist it is likely that these effects are mediated by ERβ. 
These findings suggest that the oestrogen receptors in the growth plate may have 
opposing actions with ERβ acting as a brake on chondrocyte proliferation and growth 
and ERα promoting growth. The proliferation and differentiation of growth plate 
chondrocytes are ultimately under the control of cell cycle modulators such as cyclins, 
cyclin-dependent kinases (CDK) and their inhibitors. The levels of some key cell cycle 
proteins from ATDC5 chondrocytes were therefore analysed after exposure to MPP and 
raloxifene in combination. A reduction was found in the cell cycle proteins cyclin E 
and p53 but cyclin D1 and c-Myc were unaltered on Western Blot analysis. Cyclin E 
specifically regulates the G1/S phase transition of the cell cycle. As exposure of 
ATDC5 cells to MPP and raloxifene in combination led to a decrease in cyclin E but 
did not alter cyclin D1 levels it suggests that their effects may be mediated by the 
CDK inhibitors p21 or p27. In the human HCT8 colon cancer cell line over-
expression of ERβ inhibited cell proliferation through regulation of cell cycle 
components with decreased levels of cyclin E and an increase in the CDK inhibitor 
p21. Flow cytometry analysis provided evidence for blocking of the G1/S phase 
progression which was induced by ERβ over-expression.
(200)
 Thus, ER may regulate 
cell proliferation through control of cell cycle modulators and arrest in G1/S phase 
transition in chondrocytes as well as in colonic cells. 
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In the second part of the thesis the results from the clinical studies investigating the 
effect of oral oestrogen on longitudinal growth in girls with POI are presented. POI is 
an uncommon condition in childhood with low prevalence rates in girls aged 16 
years and under. The commonest cause in this cohort of girls is POI associated with 
TS (83.7%). Non-TS associated POI is rare and the leading cause is iatrogenic 
secondary to the effects of total body irradiation for bone marrow transplantation 
(12.8%). A significant proportion of these girls developed POI after full pubertal 
development so few cases were available to investigate the effect of oestrogen on 
linear growth. In addition, previous radiotherapy affected their spinal growth and 
other acquired endocrinopathies such as GH deficiency or hypothyroidism were 
common. The majority of girls with TS had POI but 17.2% had significant ovarian 
reserve and underwent a spontaneous puberty. The actual regime of oral oestrogen 
followed in individual patients with TS was highly variable so it was not possible to 
assess the effects of the oestrogen dose on HV or bone maturation in the context of a 
retrospective study. However, in the second study it was possible to analyse the 
effect of oral oestrogen on HV, bone maturation and FH in girls with TS as a 
standardised regime of oral ethinylestradiol was employed as part of the prospective 
multi-centre UK Turner study. The aims of this randomised, double-blind, placebo-
controlled study of growth promoting treatment in TS was to assess the impact of 
oxandrolone and the age of onset of EE2 at either 12 or 14 years on FH. The effect of 
EE2 on HV was not part of the UK study protocol and additional ethical approval 
was therefore obtained to analyse the raw data. Oxandrolone treatment and delaying 
pubertal induction to 14 years of age both significantly improved FH in girls with TS 
but there was a negative interaction suggesting that the two interventions are likely to 
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be antagonistic. However, oxandrolone therapy would allow the introduction of 
oestrogen at a younger age. The standardised oral EE2 regime employed in the study 
induced puberty over a three year period which corresponds to that observed in 
normal unaffected girls. Low dose EE2 (2 µg/day) maintained HV for one year when 
it was introduced at 12 years of age. Thereafter, the natural deceleration recorded in a 
historical cohort of TS girls
(291)
 was augmented with subsequent increases in EE2. In 
contrast, the same low dose EE2 commenced at 14 years of age led to a reduction in 
HV which increased further with subsequent EE2 dose increases. TS girls who 
received oral E2 to induce pubertal development therefore did not show any growth 
acceleration and peak height velocities were not observed. Girls with preserved 
ovarian function exhibited a different growth pattern during puberty with a mean 
peak HV of 8.5 centimetres/year. This may be explained by a less severe underlying 
skeletal dysplasia or it may be a reflection that puberty with a spontaneous onset is 
more growth enhancing.  
 
During puberty in normal girls, oestradiol levels increase
(299)
 and are significantly 
associated with HV.
(300)
 However, after reaching peak HV the growth rate slows 
despite high circulating levels of E2. Therefore the effect of oestrogen on 
longitudinal growth changes at this point. The laboratory effects of oestradiol found 
in this thesis suggest that ERα may stimulate or maintain growth, and ERβ may 
inhibit growth. The obvious question is how these observations might be involved in 
the complex relationship between puberty, oestrogen and height velocity. This could 
be due to changes of agonist (oestrogen) affinity for the oestrogen receptor, 
differences in receptor expression (absolute number or relative numbers of subtypes),  
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or receptor coupling with second messengers.  
 
Affinity studies show that the half maximal effective concentration (EC50) of 
oestradiol at ERα is achieved at slightly lower concentrations than ERβ.(301) 
Therefore it is conceivable that the ERα effect could predominate at lower systemic 
concentrations of oestradiol and that ERβ could become more important at higher 
concentrations. It is also possible that the expression of ERα reduces or ERβ 
increases in the growth plate after reaching peak HV. Analysis of the ER expression 
in the human growth plate during puberty has not been done in a sequential fashion 
due to the limited availability of growth plate specimens from healthy children. 
Nilsson et al have confirmed the presence of both ERα and ERβ along with the 
androgen receptor in all zones of the growth plate at each pubertal stage. However, 
this was a cross sectional study of children, mainly with leg length inequality.
(115)  
Since the completion of the laboratory component of this thesis the new GPR30 
oestrogen receptor has been reported to be expressed in the human growth plate.
(132)
 
The expression of this receptor declines with pubertal staging. However, its effect on 
the growth plate has yet to be characterised. Obviously if selective agonists and 
antagonists of the oestrogen receptor GPR30 became available it would be of great 
interest to repeat the experiments performed in chapters 3 and 4.   
 
The observations from the Turner study component of this thesis show that the 
introduction of oral EE2 is associated with pubertal development but no acceleration 
in growth in contrast to that claimed by workers using parenteral 
administration.
(302;303)
 These studies which were both performed by Rosenfield et al 
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showed acceleration in growth in TS with the use of systemic E2 in the form of low 
dose monthly depots of oestradiol cypionate.
(302;303)
 However, study numbers were 
small and did not include a control group. This difference observed in growth pattern 
with oral EE2 in contrast to parenteral E2 may reflect its incomplete bioavailability 
due to pre-systemic metabolism and subsequent lower circulating oestrogen levels. 
Also oestrogen levels are more likely to fluctuate with oral administration than 
absorption from a parenteral depot. It is possible that the plasma levels achieved with 
oral EE2 are not consistently high enough to improve HV but still increase bone 
maturation. In addition, direct effects of oral oestrogen on hepatic IGF-1 secretion 
are probably important as several studies have shown decreased IGF-1 
concentrations after administration of oral oestrogen
(304-306)
 compared with 
unchanged IGF-1 levels after transdermal oestrogen.
(304)
 It is difficult to make any 
hypotheses about the role of oestrogen in growth in TS without knowing what 
plasma concentrations were actually achieved with the different treatment routes. 
However, the parental dose employed seems to be higher at 134 µg active oestradiol 
per month (bioavailability of 1) versus 60 µg per month (bioavailability of 0.4-
0.45).
(307)
 
 
Furthermore, in TS there could be a difference in expression of ERα and ERβ 
compared to normal girls. It is quite conceivable the oestrogen deficiency associated 
with POI in early life could influence the expression of ERs.  
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9.2 Future work 
The results presented within the first part of this thesis describe the effect, or rather 
lack of effect, of exogenous E2 at the level of the growth plate and suggest potential 
different roles of the classical oestrogen receptors in the growth plate. However, 
further work is required to clarify the precise mechanisms of action of each ER in the 
growth plate. The growth retardation observed in metatarsals exposed to raloxifene 
and MPP in combination was an interesting finding and suggests that ERβ may have 
an inhibitory effect on linear growth. As growth retardation was also present, but not 
as marked, after exposure to the specific ERα antagonist it suggests that ERα has an 
opposing action to ERβ and promotes growth. The mechanisms leading to growth 
inhibition in murine metatarsals could be examined further by studying the 
expression of the oestrogen receptors along with BMP and VGF. Histology of the 
metatarsals with measurement of zones would be useful, in particular to compare the 
effects of MPP alone and MPP in combination with raloxifene. The reduction of the 
cell cycle regulating proteins cyclin E and p53 in ATDC5 cells exposed to raloxifene 
and MPP in combination suggests that ERβ regulates proliferation through cell cycle 
components. This could occur through the action of CDK inhibitors p21 or p27 and 
further experiments examining these cell cycle regulators could shed further light on 
the precise pathways/molecular mechanisms of action of raloxifene and MPP. 
Further work in primary chondrocytes (murine and/or human) as opposed to a 
transformed cell line would be preferable as this would be more representative of the 
human situation. The role of ERβ in regulating chondrocyte growth could be 
examined further by stable transfection techniques to over-express ERβ or 
alternatively small interfering RNA (siRNA) technology could be utilised to knock 
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down ERβ expression. Alternatively, this could be studied in tissue or cells obtained 
from ERβ knock out mice. 
 
Endogenous oestrogen appears to be important for mineralisation of metatarsals as 
reflected by their response to the non-specific ER antagonist, Faslodex. The role that 
oestrogen plays in mineralisation of the metatarsals could be clarified by further 
experiments incorporating histology and immunohistochemistry/in-situ hybridisation 
to detect zone specific protein and gene expression e.g. collagen type X to assist in 
measurement of the different zones to confirm if there is an increase in the 
hypertrophic zone in metatarsals exposed to Faslodex. A potential further experiment 
would be to compare the effects of Faslodex alone with Faslodex in combination 
with bisphosphonates to investigate if bisphosphonates can ameliorate the effects of 
withdrawal of endogenous oestrogen on mineralisation in this model.  
  
In the clinical component of this thesis it was observed that girls with POI associated 
with TS did not show growth acceleration during pubertal induction with oral 
oestrogen and had sub-optimal uterine development at the end of induction. 
Rosenfield et al showed acceleration in growth in TS with the use of monthly depots 
of oestradiol.
(303)
 Less invasive forms of parenteral oestrogen have been investigated 
and recent studies employing transdermal oestrogen patches or gel to induce puberty 
in hypogonadal girls have shown encouraging results.
(308;309)
 A study comparing a 
transdermal regime of natural oestrogen with the standard oral EE2 regime would be 
a logical next step. In order to recruit a suitably large enough cohort of girls with TS 
it would best be performed as a multicentre study. It would be interesting to know if 
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transdermal oestrogen does improve the amplitude of growth during puberty and 
would therefore allow the introduction of oestrogen at a more appropriate age 
without having a negative impact on FH. The circulating levels of oestrogen obtained 
in the plasma would be useful in comparing the different formulations but may not 
be feasible within a multi-centre setting, but could be performed in a sub-group. 
Analysis of data from the UK Turner study, in which the interaction between 
oxandrolone and late pubertal induction is negative rather than additive,  
points towards there being a finite amount of potential growth that TS girls can 
achieve with growth promoting therapy. It follows from this conclusion that starting 
growth hormone therapy at a particularly early age in TS for example in infancy may 
not confer an advantage in terms of final height, and that the use of oxandrolone 
from 9 years may allow the clinician to begin pubertal induction at a more 
physiological age without having a negative impact on final height.  
 
Much work remains to be done in the field of growth and pubertal induction in 
Turner syndrome. Apart from testing the effect of different protocols of pubertal 
induction on linear growth and pubertal development, their impact on quality of life, 
cardiovascular risk factors, bone health and uterine development needs to be the 
subject of systematic and collaborative study.  
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